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Malaria infects over 200 million individuals and leads to the death of over 600
000 people annually. Currently artemisinin combination therapy treatments
are effective in treating the disease, but resistance has started to emerge in
Cambodia and it is suspected in parts of Vietnam. To maintain the drive to
eradicate malaria globally, a great deal of research is aimed at identifying novel
prevention strategies, vaccines and antimalarial compounds.
Plasmodium falciparum, the most deadly of the malaria parasites, is entirely
dependent on glycolysis for ATP. Several of the enzymes within this pathway
have been proposed as drug targets and studied in isolation, but the pathway
as a whole has not been considered. In this study we employ a bottom up




In this thesis we present the biochemical characterisation each of the glycolytic
enzymes in P. falciparum trophozoites. The kinetic rate equations, which de-
scribed the kinetic behaviour of the individual enzymes, were incorporated
into a kinetic model. The unfitted model was validated in its ability to predict
experimentally measured steady state metabolite concentrations and fluxes as
well as the experimental inhibition of the glucose transporter.
The validated model provided a tool for drug target identification in P. falci-
parum glycolysis. Metabolic control analysis and differential control analysis
identified the glucose transporter, PfHT1, as a drug target based on its high
control of glycolytic flux in the parasite, but low control of flux in the host
erythrocyte. This differential control makes the transporter an attractive drug
target, as even if both the erythrocyte and parasite glucose transporters are
inhibited to the same degree, it is expected that the parasite glycolytic flux
would be inhibited to a much greater degree.
To demonstrate the differential control of the glucose transporter on the flux
and provide further evidence that PfHT1 is an attractive drug target, we in-
vestigated the inhibition of the glucose transporter in isolated trophozoites by
cytochalasin B. We also measured the inhibition of lactate production flux by
cytochalasin B in both isolated P. falciparum trophozoites as well as in ery-
throcytes. Our findings demonstrated that differential control analysis can be
used as a tool for drug target identification and that PfHT1 is an attractive
drug target.
In this study the fields of biochemistry and systems biology were merged to
create a detailed kinetic model of asexual P. falciparum glycolysis and identify
several drug targets in the pathway. The model prediction and experimental
evidence of differential flux control of the glucose transporter in the host and
parasite, has highlighted PfHT1 as a drug target and also demonstrates the
strength of differential control analysis in identifying drug targets within a
system. The kinetic model is a valuable tool for furthering our understanding
of P. falciparum glycolysis and it provides a good foundation for expansion to
identify drug targets in the entire central carbon metabolism of P. falciparum
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Malaria infekteer meer as 200 miljoen mense en veroorsaak jaarliks tot 600 000
sterftes. Tans is die artemisinien-kombinasieterapie effektief in die bestryding
van die siekte, maar weerstandbiedendheid van die parasiet teen die middel
blyk reeds ’n merkbare effek in Kambodja en vermoedelik ook in dele van Vi-
ëtnam te hê. Om ’n wêreldwye bestryding van malaria moontlik te maak, is
’n groot deel van die huidige navorsing gemik op die identifisering van nuwe
voorkomingsstrategieë, entstowwe en malariateenmiddels.
Plasmodium falciparum, die dodelikste van die malaria-parasiete, is geheel
en al afhanklik van glikolise vir ATP vorming. Verskeie van die ensieme in
hierdie metaboliese pad is as teenmiddelteikens voorgestel, en in isolasie be-




ons ’n ’bottom-up’ benadering vir teenmiddel teikenidentifisering in P. falci-
parum glikolise gebruik.
In hierdie tesis bied ons die biochemiese karakterisering van elk van die gli-
kolitiese ensieme in P. falciparum trofozoïete aan. Die kinetiese vergelykings
wat die kinetiese gedrag van die individuele ensieme beskryf, is geintegreer in
’n enkele kinetiese model. Die model waarop geen datapassing toegepas is nie,
is gevalideer om eksperimenteel bepaalde bestendige-toestand metabolietkon-
sentrasies en fluksiewaardes, asook die eksperimentele inhibisie van die glukose
transporter, te voorspel.
Die gevalideerde model verskaf ’n bykomende hulpmiddel om teenmiddeltei-
kens te identifiseer in P. falciparum glikolise. Metaboliese kontrole-analise en
differensiële kontrole-analise het die glukose transporter, PfHT1, as ’n teen-
middelteiken geïdentifiseer, gebaseer op sy hoë kontrole van glikolitiese fluksie
in die parasiet, tesame met ’n lae beheer van die glukose transporter op die
fluksie in die gasheer eritrosiet. Dié differensiële kontrole maak die glukose
transporter ’n aantreklike teenmiddelteiken, want selfs as beide die eritrosiet
en die parasiet glukose transporters tot dieselfde mate geïnhibeer word, sal dit
steeds ’n hoër glikolietiese fluksieinhibisie van die parasiet tot gevolg hê.
Om die differensiële kontrole van die glukose transporter op die fluks te de-
monstreer en verdere bewyse te lewer dat PfHT1 ’n teenmiddelteiken kan wees,
het ons die inhibisie van die glukosetransporter in geïsoleerde trofozoïete deur
sitokalasien B ondersoek. Ons het ook die inhibisie van die laktaatproduksie-
fluksie deur sitokalasien B in beide geïsoleerde P. falciparum trofozoïete sowel
as in eritrosiete ondersoek. Ons bevindings bewys dat differensiële kontrole-
analise as ’n hulpmiddel vir teenmiddelteikenidentifikasie gebruik kan word en
dat PfHT1 ’n aantreklike teenmiddelteiken is.
In hierdie studie is die velde van biochemie en sisteembiologie gekombineer om
’n gedetaileerde kinetiese model van ongeslagtelike P. falciparum glikolise te
konstueer en verskeie teenmiddelteikens in die metaboliese pad te identifiseer.
Die modelvoorspelling sowel as eksperimentele bewyse van die differensiële
flukskontrole van die glukose transporter in die gasheer en parasiet het PfHT1
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uitgelig as ’n teenmiddelteiken en demonstreer ook die krag van differensiële
kontrole analise in die identifisering van teenmiddelteikens binne ’n biologiese
stelsel. Die kinetiese model is ’n waardevolle hulpmiddel vir die bevordering
van ons begrip van P. falciparum glikolise en dit bied ’n goeie basis vir uit-
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Malaria is a disease that infected an estimated 216 million individuals, with
over 655 000 fatalities in 2010 (World Health Organisation (WHO) world
malaria report 2011). The drive to eradicate malaria globally is slowly gaining
ground with five regions being certified malaria free zones and mortality rate
having decreased by 25% globally in the last decade. However, Plasmodium
is gaining resistance to the current artemisinin combination therapies (WHO,
world malaria report 2011) and this necessitates the development of novel ther-
apeutics.
The causative agent, Plasmodium, is transmitted to the human host by the
bite of an infected female Anopheles mosquito. Four species of Plasmodium:,
vivax, malariae, ovale and falciparum are known to use a human host, although
the simian P. knowlesi has also been shown to infect humans43. During the
dual host life cycle of Plasmodium, the parasite has a number of physiologi-
cally different forms. In the human host, the transmitted parasite infects the
liver hepatocytes, multiplies in a series of nuclear divisions followed by cytoki-
nesis (schizogony)213 and releases thousands of invasive merozoites into the
blood stream141. The merozoites subsequently invade the host erythrocytes
and this asexual phase is responsible for the clinical symptoms of malaria. P.
falciparum develops from a merozoite into a young trophozoite (also known as
the ring stage) and then into a mature trophozoite. After undergoing further
schizogony and cellular division, each parasite may produce up to 32 mero-
zoites213. Following erythrocyte lysis, the 48 hour cycle is repeated with the
released merozoites invading new erythrocytes. Some of the merozoites during
the asexual phase form male and female gametocytes. These precursors are
dormant unless ingested by a female Anopheles mosquito during a blood meal,
1
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after which they are activated to produce gametes112. Following fertilisation, a
diploid zygote is formed in the mosquito midgut, which initiates the life cycle
in the mosquito host112.
The asexual bloodstream phase, which is the stage studied in this thesis, has
access to the rich nutrient content of the host cell’s haemoglobin and the host
blood serum. Upon infection by Plasmodium the glucose uptake of the ery-
throcyte has been reported to increase up to 100-fold123. The asexual parasite
does not have any reduced carbohydrate reserves and is largely dependent on
glycolysis for generating ATP. The parasite’s dependence on ATP makes the
glycolytic pathway an attractive drug target and a high degree of inhibition of
an enzyme within the pathway is expected to severely hamper parasite develop-
ment. Several glycolytic enzymes in the P. falciparum have been biochemically
characterised, inhibited in vitro and proposed as potential drug targets. These
studies have been on isolated enzymes and have not considered the glycolytic
pathway as a whole.
Kinetic models of metabolic pathways are useful for analysing systemic be-
haviour and identifying which enzymes are the most important in controlling
the metabolic flux or metabolite concentrations. Kinetic models of yeast205
and Trypanosoma brucei 7 glycolysis constructed from rate equations that de-
scribed each of the glycolytic enzymes could successfully describe systemic
behaviour (e.g. steady state fluxes and metabolite concentrations), enhance
the understanding of the pathways, and, in the case of T. brucei, identified the
pyruvate and glucose transporters as potential drug targets.
Numerous glycolytic enzymes of P. falciparum have been biochemically char-
acterised and further characterisation is simplified by the wide availability of
assay methods. This considered, a bottom up approach (i.e. using individual
enzyme kinetics) to constructing a kinetic model for asexual Plasmodium gly-
colysis is feasible and forms part of this dissertation.
To examine a pathway as a whole, systems biology provides a variety of ana-
lytical methods such as metabolic control analysis (MCA), hierarchical regula-
tion analysis, elementary mode analysis, metabolic flux analysis, flux balance
analysis (these are reviewed by Geenen et al.71) and supply-demand analy-
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sis89. MCA, developed independently by Kascer & Burns107 and Heinrich &
Rapoport168,82, is a theoretical framework that defines coefficients that quan-
tify a) the relative change in steady state systemic properties (e.g. steady
state flux, J, or metabolite concentration, c) due to a small change in a reac-
tion step (i.e. enzyme rate, v). This type of analysis has been utilised as a
tool to improve our understanding of certain diseases (reviewed by Cascante
et al.33), suggest new strategies to treat cancer138 and among others identify
drug targets in African sleeping sickness8 and cancer147.
The MCA approach to drug target identification has generally been to identify
an enzyme or enzymes138 with high flux control. These enzymes are expected
to require a lower degree of inhibition to inhibit the pathway flux compared
to an enzyme with low flux control. By also considering the host metabolic
control profile, one can identify enzyme(s) with a high flux control in the par-
asite, whereas the equivalent reaction in the host has a low flux control8,98.
This differential control approach has been proposed as a tool for drug target
identification8,98, but has yet to be demonstrated in vivo.
The overall goal of this thesis was to create a detailed kinetic model of asex-
ual P. falciparum glycolysis, use it as a tool for drug target identification and
experimentally investigate a drug target predicted by differential control anal-
ysis. In the pursuit of this goal, we also aimed to answer the following broader
questions:
• Does a kinetic model constructed with a bottom up approach describe
network behaviour sufficiently to be used as a heuristic tool for drug
target identification?
• By analysing the glycolytic pathway in its entirety (i.e. using metabolic
control analysis), which of the many enzymes that have been proposed
as drug targets in P. falciparum glycolysis are feasible?
• Is differential control analysis of metabolic networks a relevant approach
for drug target identification in general?
To address these questions the thesis is divided into a series of three research
chapters designed as papers. This format has the advantage that each chapter
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is independent, but I do apologise for the inevitable duplication of introduc-
tory material and materials and methods. Chapter 3 presents i) the detailed
biochemical characterisation of each of the enzymes in asexual P. falciparum
glycolysis, ii) the integration of these enzyme kinetics into a detailed kinetic
model and iii) the steady state prediction of the model.
In Chapter 4 we investigate with validation experiments whether the ki-
netic model, as a function of the underlying biochemical kinetics, gives a fair
representation of systemic behaviour (i.e. steady state fluxes, metabolite con-
centrations). We also use this validated kinetic model and MCA as tools for
drug target identification in P. falciparum glycolysis.
In Chapter 5 we identify drug targets in P. falciparum glycolysis using differ-
ential control analysis and investigate i) experimentally whether the predicted
differential control occurs in the erythrocyte and the parasite and ii) if such
an approach is relevant for drug target identification in general.
In addition to the three research chapters, in Chapter 2 we review what is
currently known about the central carbon metabolism of asexual Plasmodium
spp. with specific focus on the glycolytic enzymes in terms of their kinetics and
how these can be used for constructing a kinetic model. Finally, in Chapter 6
we provide a general discussion of how the work in this dissertation addresses
the general questions stated above.
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Chapter 2
Introduction: Constructing a kinetic model
of the central carbon metabolism of P.
falciparum
2.1 Introduction
Malaria infects over 200 million individuals a year and results in the death
of over 600 000 people (WHO, world malaria report 2011). In an attempt to
eradicate malaria globally there is an internationally concerted effort in terms
of funding, research, and implementation of preventative, diagnostic and treat-
ment measures. The impact of these measures is evident considering the 25%
reduction in mortality rate over the past decade. Artemisinin-based combina-
tion therapy treatment has proven highly effective to date, but of increasing
concern is the development of drug resistance in Cambodia and possibly also
in parts of Myanmar and Vietnam (WHO, world malaria report 2011). The
continued development of novel antimalarial compounds is thus essential for
maintaining the fight against the disease.
During the asexual erythrocyte phase, all Plasmodium spp. are entirely de-
pendent on glycolysis for ATP production193. It is expected that inhibiting
this pathway would severely reduce the growth rate of the parasite and as such
several of the enzymes in the glycolytic pathway have been studied and pro-
posed as drug targets. However, the enzymes have been studied in isolation
5
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and their importance in terms of the entire glycolytic network has not been
considered. Enzymes within the pentose phosphate pathway have also been
proposed as drug targets, since the pathway’s reduction of NADP is essential
for the detoxification of free ferriprotoporphyrin IX (FP) and reactive oxygen
species11.
Identifying drug targets in these pathways is difficult, as many of the gly-
colytic enzymes of Plasmodium spp. share a degree of homology to the host
enzymes. Crystal structures of some of the enzymes (e.g. lactate dehydroge-
nase221,21,34 or triosephosphate isomerase216) aid drug target identification in
this regard by highlighting structural differences between the parasite and host
that may be exploited. What also needs to be considered, however, is the role
of the target enzyme in the pathway as a whole. By examining the kinetics of
the enzymes in isolation it is not possible to identify which enzymes are the
most important for glycolytic flux. The field of systems biology has provided a
number a tools, such as Metabolic Control Analysis (MCA), Hierarchical Reg-
ulation Analysis, Elementary Mode Analysis, Metabolic Flux Analysis, Flux
Balance Analysis (reviewed by71) and supply-demand analysis89 to investigate
the behaviour of a system. MCA is particularly suited to identifying drug tar-
gets within a pathway, as it quantifies the relative importance of each enzyme
in controlling the steady state flux and metabolite concentrations.
Pathway analysis necessitates a model describing the system. For several of
the enzymes in the central carbon metabolism of P. falciparum, kinetic infor-
mation is available, and the construction of a kinetic model is feasible158. To
show how i) the individual enzyme kinetics can be used to construct a kinetic
model of the entire pathway and ii) the relative importance of each enzyme in
controlling the flux and metabolite concentration can be quantified, I describe
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the process for a pathway consisting of two reactions:
Consider the following simple metabolic pathway where a substrate, S, is con-
verted to a product, P, via an intermediate metabolite X (Eq. 2.1.1). In this
pathway the two irreversible reactions (v1 & v2) are catalysed by two enzymes
that follow Michaelis-Menten kinetics (Eq. 2.1.2), where Kx and Ks are the
Michaelis constants for X and S respectively and Vmax1 and Vmax2 are the














Changes in the concentration of X over time, t, can be described by the differ-
ence in its rate of formation, v1 and consumption, v2 (Eq. 2.1.3).
dx
dt
= v1 − v2 (2.1.3)
To calculate the concentration of X at any time, this ordinary differential
equation (ODE) can be integrated over time (Eq. 2.1.3). The results of such
a numerical time integration can be compared to experimentally determined
concentrations of X over time.
All metabolic pathways can be treated as open systems, where there is a
constant influx of substrate and efflux of product. Assuming that the concen-
tration of S remains constant (e.g. glucose in the human blood serum, which
is homoeostatically buffered) and that P remains constant (e.g. immediately
transported out of the cell as soon as it is formed) , the system would relax to
a steady state. During steady state, i) the rate of X formation would be equal
to the rate of X consumption, with this rate defined as the steady state flux,
J, (i.e. v1 = v2=J) and ii) the concentration of X (i.e. steady state concentra-
tion) would be constant over time (i.e. X ′[t] = 0).
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The steady state can be computed by solving for the conditions (i.e. metabo-
lite concentration) where the ODE (which describes the change in metabolite
concentrations over time) is equal to zero. This steady state analysis yields
the steady state metabolite concentration, X, and flux of the pathway,J. This
approach can be scaled-up to a multiple reaction pathway (e.g. glycolysis) by
defining an ODE for each metabolite within the pathway.
A powerful tool for investigating the systemic properties (i.e. steady state
fluxes and metabolite concentrations) of a pathway in terms of the local prop-
erties (i.e. enzyme rates and kinetic parameters) is Metabolic Control Analysis
(MCA). MCA defines elasticity coefficients, control coefficients and response
coefficients, which quantify the degree to which a change in a local property
(e.g. enzyme rate, or an effector of enzyme activity) alters the systemic prop-
erty of the pathway (i.e. metabolic fluxes and metabolite concentrations).
To demonstrate how these coefficients describe the local and systemic prop-
erties, consider a pathway of which a parameter, p, (e.g. an activator of an
enzyme) is perturbed:
The small change in the parameter concentration (e.g. an activator) would
lead to a change in the local enzyme activity, v. This change can be quantified




The change in the individual enzyme rate (due to the parameter perturbation)
would result in the system reaching a new steady state (a systemic property).
The change in the systemic properties can be quantified by control coefficients,
which describe the percentage change in fluxes or metabolite concentrations
(flux and concentration control coefficients, CJv & Cxv ) due to a small change
in the local rate, v. Mathematically they can be formulated as:
CJv =
d ln J





The change in the parameter, p, induced a change in the local enzyme rate, v,
which in turn resulted in a new steady state. The combined response of the
system (i.e. change in flux or metabolite concentration) to a change in the
parameter, p, is defined as a response coefficient, RJp . The response coefficient
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can also be expressed as the product of the control and elasticity coefficient:
RJp =
d ln J
d ln p = C
J
v · εvp & Rxp =
d ln x
d ln p = C
x
v · εvp (2.1.4)
In summary, i) elasticity can be defined as the percentage change in a local
enzyme rate, v, due to a 1% change in a local parameter, p ii) control is de-
fined as the percentage change in a systemic property such as steady state flux
or metabolite concentrations due to a 1% change in the local enzyme rate, v
and lastly iii) The response is defined as the percentage change in a systemic
property such as steady state flux or metabolite concentrations due to a 1%
change in a parameter, p.
Although not discussed here, it should be noted that the control coefficients
can be expressed in terms of the elasticity coefficients using connectivity and
summation theorems64,87. Using these theorems and the coefficients discussed
one can, among others, quantify i) the influence of parameters (e.g. kinetic
parameters) on the steady state flux (i.e. response coefficients) and ii) the
control each enzyme has on the steady state metabolite and flux concentra-
tions. MCA thus allows the systemic properties to be understood in terms of
the local properties.
The theory of MCA was developed independently by Kascer & Burns107 and
Heinrich & Rapoport168,82 and further developed by others. For further detail
on MCA and its mathematical formulation refer to Fell et al 64 and Hofmeyr87.
It is relatively straightforward to calculate these coefficients computationally
if a kinetic model for the system is available by making a small perturbation
to an enzyme activity and analysing the effect on the steady state. However,
experimentally measuring a control coefficient is difficult.
One method to measure a control coefficient is via a so-called inhibitor titration
experiment. In this type of experiment the elasticity and response coefficient
are measured, and the control coefficient is calculated from the ratio of the
response coefficient and the elasticity (see Eq. 2.1.4).
To measure the elasticity, one could use an inhibitor that specifically inhibits
a reaction step (e.g. glucose transporter) or enzyme (e.g. hexokinase). By
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 2. INTRODUCTION: MODELLING THE CENTRAL CARBON
METABOLISM 10
measuring the percentage decrease in enzyme rate, v, over a range of inhibitor
concentrations and, one can calculate the elasticity (i.e. decrease in glucose
transporter rate, v, due to a small increase in inhibitor concentration). In
practice this elasticity is calculated as the slope on a ln (v) vs. ln ([inhibitor])
plot at zero inhibitor concentration.
In a separate experiment, the response on steady state flux could be measured.
This could be determined by incubating cells in the presence of an inhibitor
and determining the decrease in the steady state flux. From these data one can
calculate the response coefficient (i.e. decrease in steady state flux due to a
small increase in inhibitor concentration). Emphasis is placed on the difference
between inhibiting the pathway flux (a global property) and the inhibition of
the enzyme rate (a local property).
The flux control coefficients are particularly useful for identifying drug targets
within a pathway. An ideal target would have a high flux control coefficient,
which would mean that inhibition of this step would lead to a high degree of
inhibition of the pathway flux.
Above we have described the process of creating a kinetic model on the basis
of the enzyme kinetics and how the system can be analysed over time or in
steady state. A number of the enzymes in the central carbon metabolism and
especially glycolysis, of asexual P. falciparum have been biochemically char-
acterised. An aim of this dissertation is to construct a detailed kinetic model
of P. falciparum glycolysis and use the model as a tool to evaluate which of
the proposed drug targets in the pathway are the most promising and also to
identify new drug targets within the pathway. These aims required i) a broad
knowledge of the network topology (i.e. which enzymes were present), ii) a
number of kinetic parameters and iii) knowledge of which enzymes have been
targeted or proposed as drug targets. The aim of the following review is to pro-
vide a detailed description of what is currently known about each enzyme in P.
falciparum glycolysis, the pentose phosphate pathway and tricarboxylic acid
cycle with particular focus on the biochemical characterisation of the enzymes.
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2.2 Glycolysis
Plasmodium spp. infected erythrocytes rapidly utilise glucose from the host
serum156,190 and upon infection glucose uptake may increase as much as 100
fold123. Asexual parasites require glucose or fructose for growth222,119 and are
unable to utilise ribose, mannose or galactose as a carbohydrate source123
Plasmodium spp. has a classical Embden-Meyerhof pathway (Fig. 2.1) and
nearly all glucose passes through the anaerobic glycolytic pathway, with a net
yield of approximately two moles ATP and two moles lactate per mole glu-
cose190. The almost complete conversion of glucose to lactate was initially
thought to indicate that the pentose phosphate pathway (PPP) was inactive,
although it is now known that there is a low flux (relative to glycolysis) through
the PPP, as well as through a glycerol producing branch and a carbon dioxide
fixating branch.
The considerable increase in glucose uptake rate and rapid production of lac-
tate necessitates an efficient transport system. Sufficient glucose needs to be
obtained from the host serum to support the rapidly multiplying parasite and
since excessive lactate build-up in the cell is toxic, the parasite has an ef-
ficient monocarboxylate export system. Although, strictly speaking, hexose
and lactate transport would not fall under the central carbon metabolism,
these transport steps are an integral part of glycolysis and thus warrant their
inclusion.
We broadly review the current knowledge of the Plasmodium spp. glycolytic
enzymes - hexokinase (HK), phosphoglucoisomerase (PGI), phosphofructoki-
nase (PFK), aldolase, triose phosphate isomerase (TIM), glyceraldehyde-phosphate
dehydrogenase (G3PDH), phosphoglycerate kinase (PGK), phosphoglycerate
mutase (PGM), enolase, pyruvate kinase (PK), lactate dehydrogenase (LDH)
as well as the glucose and lactate transporters. Selected published kinetic
parameters are tabulated at the end of the enzyme subsections in Table 2.1.
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Figure 2.1: Overview of asexual P. falciparum central carbon metabolism. Asex-
ual P. falciparum, which resides within the host erythrocyte, has a classic glycolytic
pathway, a pentose phosphate pathway, a glycerol producing branch and a carbon
dioxide fixation branch. Enzyme names are shown in italics and the metabolites
and cofactors in bold. Red circles indicate enzymes that have been proposed in sci-
entific literature as drug targets. Finely dashed reaction arrows (GK and PEPCK)
represent reactions that do not occur during the asexual phase. The dashed re-
action arrows with a question mark (inside a white circle), represent reactions
that are thought to occur, but the enzymes that catalyse the reactions are cur-
rently unknown. HK, hexokinase, PGI, phosphoglucoisomerase, PFK, phosphofruc-
tokinase, ALD, aldolase, TIM, triosephosphate isomerase, G3PDH, glyceraldehyde-
3-phosphate dehydrogenase, PGK, phosphoglycerate kinase, PGM, phosphoglycerate
mutase, ENO, enolase, PK, pyruvate kinase, LDH, lactate dehydrogenase, GluPho,
Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase, R3PE, Ribulose-3-
phosphate epimerase, GlrDH, glycerol-3-phosphate dehydrogenase, GK, glycerol ki-
nase, AspTA, aspartate transaminase, MDH, malate dehydrogenase, PEPC, PEP
carboxylase, PEPCK, PEP carboxy kinase, AQP, Aquaglyceroporin
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2.2.0.1 Hexose transport
Asexual Plasmodium spp. reside within the host erythrocyte and hexose trans-
port from the serum to the parasite is obtained i) directly via ’new permeation
pathways’ induced by the parasite115 and ii) by transporting glucose across the
parasite plasma membrane via a hexose transporter, PHT1222.
Within the erythrocyte, glucose and fructose cross the parasitophorous vac-
uolar membrane via high-capacity non-selective channels49 and are then trans-
ported across the parasite plasma membrane via a hexose transporter, PHT1222.
This passive transporter has been expressed in Xenopus oocytes and shown to
be a saturable, sodium-independent, and a stereospecific transporter of both
glucose and fructose223. The P. vivax and P. falciparum transporters, PvHT1
and PfHT1 respectively, have been kinetically characterised100,101,222,223 as well
as those from P. knowlesi (simian) and P. yoelii (murine)102. Immunofluores-
cence microscopy studies have shown that PfHT1 resides in the parasite plasma
membrane and not in the erythrocyte membrane223 and it has been established
that PfHt1 is a single copy gene with no close homologues223. Expression of
the single PfHt1 transcript varies throughout the P. falciparum life cycle with
mRNA levels peaking 8-hour post invasion of the erythrocytes.223.
Inhibition of PfHT1 immediately leads to a decrease in ATP levels179. This
has prompted a great deal of research (reviewed by Patel et al.155) focussed
on inhibiting the transporter, which has been found to kill asexual parasites
as well as vector (mosquito) and liver stage parasites102,179,100,101,198.
2.2.0.2 Lactate Transport
The parasite transports lactate and pyruvate across the parasite plasma mem-
brane with a lactate-proton cotransporter44,57. This saturable transporter that
shares many characteristics of the monocarboxylate transporter (MCT) family
and also transports pyruvate57. The transport of lactate and pyruvate is pro-
ton linked with a 1:1 stoichiometry and has been biochemically characterised
for P. falciparum in terms of its Vmax, affinity for both pyruvate and lactate,
which compete for the same binding site44,57.
In uninfected erythrocytes, lactate is removed to the blood stream via three
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major pathways: (i) a specific H+ monocarboxylate transporter, (ii) the band
3 anion exchanger, and (iii) by diffusion of the protonated form across the lipid
bilayer115. The capacity of these transport systems is considered to be insuffi-
cient for the removal of the lactate produced by Plasmodium spp. glycolysis in
parasitised erythrocytes109,115. When these transport pathways are inhibited,
however, there is still a high lactate flux across the erythrocyte membrane and
this has been attributed to anion-selective diffusion pathways in the erythro-
cyte membrane44,109,115.
2.2.0.3 Hexokinase
Hexokinase (HK), the first reaction in glycolysis, phosphorylates glucose in an
ATP dependent reaction, producing glucose 6-phosphate (G6P) and ADP. In
P. falciparum the 47 kDa hexokinase protein is coded by a gene on chromosome
8 that is only 26% homologous to human HK121,143,190. The total HK activity
in P. berghei and P. falciparum infected erythrocytes is more than 25-fold
greater than in uninfected erythrocytes121,175. The P. berghei enzyme has
been biochemically characterised in terms of its affinity for ATP (Km 2 mM)
and glucose (Km 0.431 mM). The enzyme has not been characterised in terms
of its products, which may be relevant from a systems biology perspective as
G6P is known to have feedback inhibition in mammalian cells207 and act as
an activator in the filarial roundworm, Brugia malayi 195.
2.2.0.4 Phosphoglucoisomerase
Phosphoglucoisomerase (PGI) catalyses the isomerisation of G6P to fructose-
6-phosphate (F6P). Interestingly, P. falciparum has been reported to possess
three or four PGI isozymes202 with an apparent size of 66 kDa, but it is not
known if these are expressed at different stages or differ in terms of their ki-
netics. A P. falciparum gene coding for PGI has been mapped to chromosome
14 and cloned and expressed in Escherichia coli 111. The deduced amino acid
sequence has a 34% identity to the human equivalent with the highest degree
of similarity in the proposed active sites111.
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2.2.0.5 Phosphofructokinase
Phosphofructokinase (PFK) catalyses the ATP dependent phosphorylation of
F6P to form fructose 1, 6-bisphosphate (F1,6BP) and ADP. In P. berghei,
PFK activity has been found to be fairly insensitive to pH changes, com-
pared to the host erythrocyte PFK which would indicate structural and ki-
netic differences182. Classically, PFK is highly regulated and is potentially
inhibited by ATP, phosphoenolpyruvate (PEP), 2,3-bisphosphoglycerate, cit-
rate and activated by AMP, F6P, ADP, F1,6BP and fructose 2,6-bisphosphate
(F 2,6BP)211,22. Buckwitz et al. reported that P. berghei PFK is strongly
inhibited by ATP and Mg2+ ions and is activated by PEP, F6P and inor-
ganic phosphate22,23,24,25. Buckwitz et al. characterised the murine P. berghei
enzyme extensively and could describe the kinetic behaviour with a Monod-
Wyman-Changeaux type equation. In P. falciparum, Mony et al. identified
putative genes coding for PFK on chromosome 9 and 11, although only the
protein from chromosome 9, when expressed in E. coli exhibited the appro-
priate catalytic features137. This enzyme has domains that are homologous
to a pyrophosphate dependent PFK found in plants. As in P. berghei, the P.
falciparum enzyme is not activated by citrate or F2,6BP, but is insensitive to
PEP137.
2.2.0.6 Aldolase
Aldolase catalyses the aldol-cleavage of F1,6BP into dihydroxyacetone phos-
phate (DHAP) and glyceraldehyde-3-phosphate (GAP). In contrast to humans
which have three aldolase isozymes, Plasmodium spp. only has a single gene
coding for aldolase which is 50% homologous to its human equivalent.39,117.
The P. berghei and P. falciparum genes have been cloned, sequenced and ex-
pressed in E. coli 51,136. The homotetrameric enzyme has a molecular mass of
160 kDa113 and has been kinetically characterised for its substrate F1,6BP51.
Aldolase activity, which also correlated to mRNA expression levels, varies
during the asexual phase, reaching peak activity between 32 and 36 hours
(mature trophozoite stage)99,142,143,219. Aldolase has been the focus of some
drug target discovery studies. Wanidworanun et al. reported 50% inhibition
of parasitemia in the presence of nanomolar concentrations of phosphorothioate
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antisense oligodeoxynucleotides that targeted several sites on the P. falciparum
aldolase gene219. The crystal structure of P. falciparum aldolase113 revealed
two distinct differences between the parasite and human enzyme. i) A highly
variable tail in the C-terminal region156, which is essential for enzymatic catal-
ysis99,52 and i) the so called 290’s loop, which forms part of the binding pocket
in conjunction with two nearby loops156. There may be an interaction between
the C-terminal tail and the binding pocket as they are located close together
prompting Kim et al. to propose that small hydrophobic inhibitors that bind
to the binding pocket, and interact with the lysine residues in the C-terminal
tail may selectively inhibit the parasite enzyme113. The low genetic variation
in Plasmodium spp. aldolase has been utilised in monoclonal antibody rapid
diagnostic kits114.
2.2.0.7 Triosephosphate isomerase
Triosephosphate isomerase (TIM) catalyses the isomerisation of DHAP to
GAP. A single gene coding for TIM is located on chromosome 14. The coding
region of the gene is 42 - 45% homologous to TIM genes from other sources,
and has been cloned and expressed in E. coli 167. In P. falciparum the gene
codes for a 28 kDa protein, which has been crystallised and the crystal struc-
ture resolved to 2.2 Å 216 and at 1.1 Å in complex with 2-phosphoglycerate154.
The crystal structures revealed several structural differences to the human en-
zyme and, for drug target identification, focus was placed on specific amino
acid substitutions on the dimer interface216. Peptides designed to bind to
the dimer interface have been shown to inhibit the enzyme at sub-micromolar
concentrations196 and anionic sulfonated dyes targeting this region have been
shown to inhibit the enzyme at concentrations below 100 mM106. More de-
tail of the strategies employed to inhibit this enzyme are reviewed in169 and156.
2.2.0.8 Glyceraldehyde-3-phosphate dehydrogenase
Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) catalyses the conversion
of GAP, Pi and NAD to 1,3-bisphosphoglycerate (1,3BPG) and NADH. In P.
falciparum G3PDH has been cloned and expressed in E. coli 47. The estimated
36.6 kDa protein has 63.5% identity to the erythrocyte G3PDH47. Typically
G3PDH exists as a tetramer and is composed of four identical polypeptide
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chains26,47 and for P. falciparum the tetrameric enzyme has been crystallised
and the crystal structure, with NAD+ bound to each subunit, resolved to 2.5
Å 184 and 2.25 Å 171. The asexual malaria parasite degrades haemoglobin dur-
ing its development, which produces free ferriprotoporphyrin IX (FP) as a toxic
product. Certain antimalarials such as chloroquine prevent FP detoxification
and it was reported that free FP strongly inhibits P. falciparum G3PDH in
vitro (Ki 0.2 µM)29. This finding indicated that in addition to other oxida-
tive damage, metabolism itself may be halted by targeting FP detoxification
mechanisms. Plasmodium spp. G3PDH has not been extensively biochemically
characterised, although its affinity for GAP has been determined29.
2.2.0.9 Phosphoglycerate Kinase
Phosphoglycerate kinase (PGK) is the first ATP producing enzyme in glycol-
ysis and converts 1,3BPG and ADP to 3-phosphoglycerate (3PGA) and ATP.
P. falciparum has two 45 kDa PGK isozymes that are distinct from the host
enzyme with differing kinetic properties (i.e. Km, Vmax), isoelectric points and
immunologic epitopes75. The gene coding for PGK is 60% homologous to other
eukaryotic enzymes and is located on chromosome 9190. The enzyme has been
biochemically characterised in terms of its substrates75,148. Crystal structures
of the P. falciparum enzyme have been resolved to 3 Å 148 and in two different
conformations at 3 Å and 2.7 Å respectively199. Some inhibitory studies have
been performed and suramin was found to inhibit PGK expressed in E. coli
with an IC50 of 7 µM148.
2.2.0.10 Phosphoglycerate Mutase
Phosphoglycerate mutase (PGM) catalyses the conversion of 3PGA to 2-phosphoglycerate
(2PGA). Two putative genes coding for PGM have been identified in P. fal-
ciparum and Hills et al. crystallised and characterised one of them, PGM285.
Interestingly the enzyme could not only utilise 3PGA as a substrate, but could
also act as a phosphatase on F6P, F1,6BP, PEP, 3PGA, 2,3-bisphosphoglycerate
(2,3BPG) and a number of amino acids85.
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2.2.0.11 Enolase
Enolase catalyses the inter-conversion of 2-phosphoglycerate and phospho-
enolpyruvate. The enolase gene has been isolated, characterised and mapped
to chromosome 10151,170. The gene is 60-70% homologous to other eukaryotic
enolase enzymes170. The enzyme is a homodimer, with a molecular size of
100 kDa151. For activity, P. falciparum enolase requires the binding of two
divalent cations (Mg2+ in vivo), per subunit151. The binding at site I leads to
a conformational change within the enzyme, whereas binding at site II is es-
sential for catalysis62. At high concentrations, bivalent cations inhibit enzyme
activity151. P. falciparum enolase is strongly activated by Mg2+, slightly by
K+ and inhibited by Na+ 151. The enzyme has been dissociated into catalyti-
cally functional, but inefficient, monomers with distinct differences compared
to the dimer in terms of kinetic behaviour and thermal stability.149. It was
suggested that the monomeric form may play a role in moonlighting functions.
Plasmodium spp. enolase, as in many organisms153, appears to play a role in
more than just metabolism. In P. yoelii enolase was found to be associated
with nuclei, cell membranes and cytoskeletal elements152 and in P. falciparum
the enzyme was found localised to the merozoite cell surface150. The exact role
of the moonlighting functions is unknown in Plasmodium spp., but in other
organisms it has been reported, among other functions, to act as a cell surface
receptor for plasminogen, act as a heat-shock protein and also as a hypoxic
stress protein (see153 for a review).
2.2.0.12 Pyruvate Kinase
Pyruvate kinase catalyses the substrate level phosphorylation of ADP, us-
ing phosphoenolpyruvate and producing pyruvate and ATP. Pyruvate kinase
activity was identified in the P. falciparum infected human erythrocytes173
and P. berghei infected mice erythrocytes22. The enzyme activity appears to
increase over 11-fold upon infection173 and is highly regulated in protozoan
parasites, such as Toxoplasma gondii, Trypanosoma brucei and Leishmania
mexicana 58,59,131 and Plasmodium spp.35.
P. falciparum has two PK isozymes (PK1 & PK2) and both are expressed dur-
ing the asexual phase36. The isozymes differ in size (56 and 87 kDa), have low
amino sequence identity (20%) and PK2 is unique to the Apicomplexans36.
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PK1 expression is continually high during the asexual phase as is thought to
be part of the glycolytic pathway. PK2 expression levels peak at 20h post
invasion, which coincides with lipid synthesis genes36. PK2 and lipid synthesis
have been localised to the apicoplast155,130. P. falciparum PK has been cloned,
isolated, kinetically characterised35. It is competitively inhibited by ATP with
respect to PEP and non-competitively inhibited by citrate35. Pyruvate kinase
appears not to be activated by F1,6BP35, which is a common activator in other
species212.
2.2.0.13 Lactate dehydrogenase
Lactate dehydrogenase (LDH) is responsible for the recycling of NAD+ from
NADH by reducing the keto group of pyruvate to a hydroxyl group (lactate).
The 33 kDa P. falciparum LDH is coded by a single gene on chromosome 1328.
A wealth of structural and kinetic information is available for human and Plas-
modium spp. LDH and differences between the enzymes have been highlighted
as potential drug targets. The enzyme has been extensively biochemically
characterised21,34,194,221 and proposed to follow an ordered bi-bi mechanism
with the coenzyme binding first194.
The crystal structures of P. berghei, P. vivax (in complex with NADH and
3-acetylpyridine adenine dinucleotide (APADH)), P. brucei and P. falciparum
LDH have all been determined221,21,34. The structures are all highly similar
and it is thus likely that inhibitors targeting malarial LDH would be effective
across the Plasmodia genus34. Structural differences between human and Plas-
modium spp. LDH are few, but key differences are a shift in the positioning of
the NADH cofactor and a larger active site due to a five amino acid extension
of the substrate-binding loop20,54,135.
Inhibition of LDH has been shown to kill the parasite176 and numerous studies
have focussed on inhibiting this enzyme. The cofactor binding site has been
largely targeted. Gossypol, a polyphenolic binaphthyl disequiterpene found in
cottonseed, binds competitively to LDH with respect to NADH and inhibits
LDH in vitro at submicromolar (0.7 µM) levels176 and displays anti-malarial
activity in vitro 73, with an IC50 of 10 µM20. Napthoic acid based compounds,
such as 2,6-dicarboxy naphthalene, have been shown to span across the LDH
active site and NADH binding pocket20. Docking studies of compounds struc-
turally similar to NADH, identified posaconazole as a potential drug, and it
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inhibited P. falciparum in vitro and P. berghei in vivo 159.
2.2.0.14 Kinetic Parameters Present in Scientific Literature
Many of the glycolytic enzymes for Plasmodium spp. have been fully or par-
tially characterised and the published kinetic parameters that were obtained
during the scientific literature study are summarised below in Table 2.1.
Table 2.1: Summary of kinetic parameters present in scientific literature for the
glycolytic enzymes of Plasmodium spp..
Enzyme Metabolite Km (mM) Reference
Hexokinase Glucose 1 0.43 ATP 2.0 143,175
Phosphoglucoisomerase F6P 2 0.26 - 202
Phosphofructokinase F6P 0.032 ATP 0.72 24,23,22
Aldolase F1,6BP 0.020 - 51
Triosephosphate Isomerase GAP 0.35 - 196
Triosephosphate Isomerase GAP 0.39 - 70
Triosephosphate Isomerase DHAP 0.59 - 196
Glyceraldehyde 3 PDH GAP 1.0 - 29
Phosphoglycerate Kinase 3PGA 1.9 75
Phosphoglycerate Kinase ADP 0.30 BPG 0.013 148,174
Phosphoglycerate Kinase ATP 0.63 3PGA 0.52 148,174
Phosphoglycerate Mutase 3PGA 0.85 2,3BPG 4.2 85
Enolase 2PGA 0.041 PEP 0.25 151
Pyruvate Kinase PEP 0.34 ADP 0.15 35
Lactate Dehydrogenase PYR 0.030 NAD 0.086 73
Lactate Dehydrogenase LAC 12 NADH 0.0070 73
Lactate Dehydrogenase PYR 0.055 NAD 0.18 194
Lactate Dehydrogenase LAC 47 NADH 0.011 194
Glucose Transporter, PfHT1 GLC 0.48 GLC 1.0 223,222,102
Monocarboxylate Transporter LAC 3.8 PYR 16 57
1 Binding constant determined from lysed malaria parasite-infected erythrocytes and is a function
of both Plasmodium and erythrocyte enzyme binding.
2 Average value of three isozymes shown. Standard deviation of the mean is 0.026
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2.2.1 Tricarboxylic Acid Cycle
The classic TCA cycle occurs in the mitochondrion under aerobic conditions
and utilises acetyl-CoA derived from glycolytic pyruvate. Acetyl-CoA com-
bines with oxaloacetate, to produce citrate, which is subsequently catabolised
in several reactions to produce CO2, NADH, FADH2, GTP, and ultimately
regenerate oxaloacetate. NADH and FADH2 are used as electron donors in
the electron transport chain (ETC) to generate ATP. Experimentation and
analysis of the Plasmodium spp. genome has revealed all classic or equivalent
TCA enzymes (reviewed in214). However, in asexual Plasmodium spp. the
cycle does not function in a typical fashion as there is not a direct link be-
tween glycolysis and the TCA cycle via the pyruvate dehydrogenase complex
(PDH). Typically the PDH complex supplies the TCA cycle with acetyl-CoA
derived from pyruvate, but in Plasmodium spp. the complex is located in the
apicoplast67. This has been confirmed by reports that radioactive glucose fed
to P. falciparum infected erythrocytes is converted predominantly to lactate
with minimal conversion to TCA intermediates or acetyl-CoA9,27,145. The PDH
complex in the apicoplast prevents the supply of acetyl-CoA to the TCA cycle
and is thought to play a role in lipid biosynthesis67 and acetylation of amino
sugars145. Another possible source of acetyl-CoA is from the β-oxidation of
fatty acids, but this does not appear to occur in Plasmodium spp.214.
The architecture of the pathway appears to be unique in that it is branched
rather than cyclic with a reductive (produces NADH) and an oxidative branch
(produces NADPH). In P. falciparum it appears that several enzymes function
in reverse to produce the large majority of acetyl-CoA from the amino acids
glutamate and glutamine, which are deaminated to yield α-ketoglutarate145.
A small fraction of acetyl-CoA is derived from glucose and is used to acety-
late amino sugars145,146. This latter reaction occurs in the apicoplast where
glycolytic PEP is converted to acetyl-CoA via PK2 and the PDH complex. In
labelled uptake experiments that majority of acetyl-CoA was used for histone
acetylation145.
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Figure 2.2: Overview of asexual P. falciparum tricarboxylic acid cycle. Asexual
P. falciparum has a branched TCA cycle and obtains the carbon required for acetyl-
CoA from glutamine and glutamate. Question marks inside a white circle represent
reactions that are thought to occur, but it is not certain which enzymes catalyse
them.
2.2.2 Pentose Phosphate Pathway
During the asexual phase, Plasmodium spp. is engaged in intensive nucleotide
synthesis and is subjected to endogenously produced oxidative radicals, which
necessitates the reducing potential of NADPH18. The pentose phosphate path-
way (Fig. 2.1.) is essential for the production of NADPH, nucleotides and for
the NADP dependent detoxification of oxidative radicals. The pathway can
be divided into an oxidative and non-oxidative branch:
2.2.2.1 Oxidative Branch
The oxidative branch, which is the first part of the pathway, utilises G6P from
glycolysis and produces two molecules of NADPH and ribulose-5-phosphate.
Isomerisation of the latter, by ribose phosphate isomerase or ribulose-phosphate-
3-epimerase, yields ribose-5-phosphate and xylulose-5-phosphate, respectively.
The typical branch consists of three enzymes: glucose-6-phosphate-dehydrogenase
(G6PD), 6-phosphogluconolactononase (6PGL) and 6-phosphogluconate de-
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hydrogenase18, but in P. falciparum the first two enzymes are combined in a
single bifunctional G6PD-6PGL (GluPho) enzyme38.
2.2.2.2 Non-oxidative Branch
The non-oxidative branch of PPP is primarily for the production of 3, 5 and
7-carbon sugars, that can be used for biosynthetic purposes, or form part
of glycolysis for ATP production. Transketolase catalyses the first reaction
of the non-oxidation branch, which is the conjunction of ribose-5-phosphate
and a 2-carbon fragment from xylulose-5-phosphate. This reaction yields
sedoheptulose-7-phosphate and GAP18. The second reaction, catalysed by
transaldolase, involves the transfer of three carbons from sedoheptulose-7-
phosphate to GAP, yielding erythrose-4-phosphate and fructose-6-phosphate18.
Transketolase catalyses a further reaction where another molecule of xylulose-
5-phosphate donates two carbon atoms to erythrose-4-phosphate, yielding an
additional molecule of GAP and F6P.
The non-oxidative pathway can function in reverse, utilising GAP and F6P
from the glycolytic pathway to produce ribose-5-phosphate (R5P) and this
has been shown to occur in G6PD-deficient parasites by measuring the incor-
poration of [1-14C] glucose into nucleotides6.
2.2.2.3 Link to the Oxidative Defence
The PPP, and more specifically the production of NADPH, is essential for the
parasite defence mechanisms against reactive oxygen species (ROS). During
the asexual phase, haemoglobin is degraded, providing amino acids and suffi-
cient space for parasite growth11. The degradation of haemoglobin occurs in
the acidic food vacuole and produces a toxic free oxidised haem (ferri / ferro-
protoporphyrin IX; FP) as well as ROS. The acidic environment oxidises the
FP from the Fe (II) to Fe (III) state, which results in production of superox-
ide that dismutates to hydrogen peroxide and oxygen11. Both FP and H2O2
required detoxification and for FP this is facilitated by biomineralisation, a
process where FP is converted into a crystalline form, known as haemozoin.
Glutathione (GSH) and thioredoxin-dependent proteins play an integral role
in the detoxification of peroxides. These proteins are oxidised by peroxides,
which are converted to H2O and O2 in the process. The oxidised proteins are
reduced again by NADPH, thus producing a continuous detoxification mech-
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anism, as long as the PPP provides sufficient NADPH.
Despite the importance of the PPP for the survival of the parasite, research
aimed at inhibiting enzymes in the pathway is limited and in comparison to
the vast amount of information existing for the glycolytic pathway, structural
and kinetic data for the PPP is sparse.
2.2.3 Pentose Phosphate Pathway Enzymes
2.2.3.1 Glucose-6-phosphate
dehydrogenase-6-phospho-glucono-lactonase
Early reports suggested that asexual malaria parasites did not possess a glu-
cose 6-phosphate dehydrogenase (G6PD) and that they depended on the host
erythrocyte for NADPH. However, G6PD was found in P. berghei and the par-
asite enzyme was found to account for 5% of the total G6DP present in infected
cells25. Yoshida and Roth partially purified and biochemically characterised P.
falciparum in G6PD deficient erythrocytes226 and the enzyme was also later
purified by others122,127. The P. falciparum gene coding for G6PD, located
on chromosome 14, was cloned and expressed140,189. The enzyme with an esti-
mated molecular mass of 450 kDA140 exists as a homodimer or homotetramer9.
Compared with the human enzyme, the N-terminal region of the parasite
protein has an additional 286 to 310 amino acid extension, which is rich in
hydrophilic and charged residues38. This extension had no homology to other
G6PD enzymes, but was homologous to a protein that is encoded near to the
G6PD gene in Haemophilus influenzae, which suggested that it might encode
an alternative PPP enzyme23,187. The homologous human cDNA was shown to
encode for 6-phospho-glucono-lactonase (6PGL) activity40, which led Clarke
et al.38 to test for 6PGL. It was shown in P. berghei that the N-terminal has
6PGL activity, while the C-terminal region has G6PD activity38.
The bifunctional enzyme is unique and the G6PD-6PGL (GluPho) enzyme
oxidises the first carbon of G6P to a lactone, which is linked to the reduction
of NADP+ to NADPH. The resulting glucono-1,5-lactone-6 is converted to
6-phospho-gluconate by the PGL activity of the N-terminal. The 6-phospho-
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gluconate is decarboxylated and oxidised by G6PD, yielding R5P, a molecule
of CO2 and NADPH. Jortzik et al.104 cloned, overexpressed and kinetically
characterised the G6PD and 6PGL activity of the complete purified enzyme
in detail. The bifunctional enzyme was reported to follow a random order bi-bi
mechanism104.
GluPho presents a favourable drug target, as its inhibition would prevent the
production of NADPH, which is expected to induce severe oxidative stress
in the parasite166. It has been shown that RNA mediated silencing of the
GluPho gene arrested the parasite in the trophozoite stage and promoted the
formation of gametocytes46. Preuss et al.162,161 specifically targeted GluPho
in a high throughput approach and tested over 34 000 compounds in vitro.
A lead compound162,161 was identified that achieved submicromolar inhibition
and also has good drug-like qualities in terms of solubility and stability.
2.2.3.2 6-Phosphogluconate dehydrogenase
6-Phosphogluconate dehydrogenase (6PGDH) catalyses the decarboxylation
and oxidation of 6-phospho-gluconate, yielding R5P, a molecule of CO2 and
NADPH. The activity of 6PGDH has been detected indirectly and presumed
to be present in Plasmodium spp.66,206. A putative gene coding for the enzyme
was identified in P. falciparum 18, and it was shown that chloroquine induced
accumulation of FP inhibits the enzyme63.
2.2.3.3 Transketolase
Transketolase catalyses two reactions, i) where xylulose 5-phosphate donates
2 carbon atoms to erythrose-4-phosphate, yielding GAP and F6P and ii)
where xylulose-5-phosphate and ribulose-5-phosphate are converted to GAP
and sedoheptulose-7-phosphate. The gene coding for transketolase has been
identified in P. falciparum 18 and the enzyme has been expressed, purified and
biochemically characterised105. The hexameric enzyme has low homology to
the host enzyme and consists of subunits with a molecular mass of approx-
imately 70 kDa. Confocal microscopy results indicate that the enzyme is
located in both the cytoplasm and nucleus of the asexual parasite105. The en-
zyme can utilise both F6P and hydroxypyruvate as substrates and is strongly
inhibited by p-hydroxyphenylpyruvate.
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2.2.3.4 Transaldolase
Typically the transaldolase reaction involves the transfer of 3 carbons from
sedoheptulose-7-phosphate to GAP, yielding erythrose-4-phosphate and F6P.
Surprisingly, the gene that codes for transaldolase could not be found in the
genome of any Plasmodium spp. species, although biochemical evidence sug-
gests the presence of a functional non-oxidative branch18. It may be possible
that a novel enzyme performs the same function or as Joshi et al. suggested,
perhaps transketolase produces erythrose 4-phosphate alone or in conjunction
with another enzyme .
2.2.3.5 Ribose-phosphate isomerase
Ribose-phosphate isomerase catalyses the interconversion of ribose-5-phosphate
and ribulose-5-phosphate. The gene coding for ribose phosphate isomerase has
been identified in P. falciparum 18 and the enzyme has a low (35%) sequence
identity to the human enzyme. The crystallised enzyme suggested a dimer,
although in eukaryotes it exists as a tetramer92. The enzyme has not been
biochemically characterised.
2.2.3.6 Ribulose-phosphate 3-epimerase
Ribulose-phosphate-3-epimerase catalyses the isomerisation of ribulose-5-phosphate
and xylulose-5-phosphate. In P. falciparum the ribulose-phosphate 3-epimerase
gene18 codes for a dimeric protein with a classic TIM-barrel fold32. The P.
falciparum enzyme has been crystallised and the crystal structure with a co-
ordinated Zn2+ and sulphate ion bound in the active site was resolved to 2
Å 32.
2.2.4 Ancillary pathways
The malarial parasite has several supplementary pathways, such as glycerol
production, carbon dioxide fixation and purine salvage pathways. The role
of glycerol production and carbon fixation is unclear at present, but they are
essential for parasite survival. The purine salvage pathways supply free amino
acids, keto acids and organic acids to the parasite, but are not discussed in
this review.
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2.2.4.1 Glycerol Production
The production of glycerol by asexual P. falciparum was discovered by Lian et
al.125, indicating the presence of a glycerol producing pathway where presum-
ably glycerol is produced from DHAP. Lian et al. suggested the existence of a
shuttle consisting of a cytosolic glycerol-3- phosphate dehydrogenase and mi-
tochondrial glycerol-3-phosphate:ubiquinone oxidoreductase, which would con-
vert DHAP to glycerol 3-phosphate (G3P) and in the process oxidise NADH.
It is not known, however, how glycerol is produced from G3P. In P. falciparum
glycerol kinase is expressed, but not during the asexual stage; disruption of
this gene does not inhibit growth and development of the asexual parasite186.
Furthermore, no putative genes for glycerol 3- phosphatase have been identi-
fied in the P. falciparum genome69. The ability of the P. falciparum PGM
isozyme to act as a phosphatase (discussed previously) on a wide variety of
substrates may provide an alternative enzyme85 to produce glycerol. The role
of glycerol in asexual Plasmodium spp. is unclear, but what has not been
considered previously is that asexual Plasmodium spp. glycolysis is not redox
neutral. Both lactate and more importantly pyruvate are transported out of
the parasite via the same monocarboxylate transporter57. The loss of pyruvate,
prevents the oxidation of NADH via lactate dehydrogenase and consequently
the parasite requires an alternative pathway such as the production of glycerol
and consequent oxidation of NADH to maintain redox balance.
2.2.4.2 Carbon dioxide fixation
P. lophurae 208,191, P. knowlesi 192, P. falciparum 188 and P. berghei 139 have
all been shown to incorporate 14CO2 into oxaloacetate, α-ketoglutarate, gluta-
mate, aspartate, malate and citrate. Phosphoenolpyruvate carboxylase (PEPC)
and PEP carboxy kinase (PEPCK) are present in P. berghei 197.
PEPCK is normally involved in gluconeogenesis and converts oxaloacetate
and ATP to PEP and ADP. Compared to asexual stages, the enzyme has
been shown to be highly expressed in gametocytes and zygotes, suggesting
that during these stages gluconeogenesis is initiated in preparation for condi-
tions experienced in the mosquito host81. Further evidence that the enzyme
is not active during the asexual phase is provided by the observation that
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parasites supplied with 13C labelled aspartate do not produce labelled PEP,
pyruvate or lactate146,145.
Activity of PEPC, which carboxylates PEP to form oxaloacetate and inor-
ganic phosphate results in the loss of 1 mol ATP per mol glucose incorporated
into glycolysis. This enzyme is active during the asexual phase as evidenced
by the incorporation of 14CO2 into a variety of amino and keto-acids146,145. A
280 kDa PEPC has been purified and characterised for P. berghei in terms of
its affinity for PEP (Km 2.6 mM), bicarbonate (Km 2.0 mM) and Mg2+ (Km
1.3 mM)134.
The role of carboxylation in Plasmodium spp. central carbon metabolism is
unclear. It does utilise some of the glycolytic intermediates (i.e. PEP) and
cost 1 mol ATP per mol carbon dioxide fixated. However, the finding of an
almost 2:1 ratio of mol lactate190 produced to mol glucose consumed indicates
that the flux through the pathway is low and probably does not have much
influence on the energy metabolism, but may be important for anabolism.
2.3 Summary
This review has summarised what is currently known in the scientific litera-
ture about the central carbon metabolism in asexual Plasmodium spp. with
specific focus on i) network topology and information that may be useful in
constructing a kinetic model of the central carbon metabolism and ii) studies
focussed on the inhibition of the individual enzymes.
The network structure of the central carbon metabolism of Plasmodium spp.
is different from many organisms in that, although gylcolysis and the TCA cy-
cle are present, the TCA cycle does not contribute towards ATP production.
The localisation of the PDH complex to the apicoplast prevents the formation
of acetyl-CoA derived from glycolytic pyruvate. Consequently the parasite is
entirely dependent on glycolysis for ATP and makes the pathway an attractive
drug target. The TCA cycle instead follows a branched structure and utilises
amino acids (glutamine and glutamate) to generate acetyl-CoA. The pentose
phosphate pathway is similar to the structure found in other organisms, al-
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though the enzyme that catalyses the transaldolase reaction is unknown. The
role of the glycerol production branch is unknown, although we hypothesise it
to be essential for balancing the redox imbalance produced by the transport of
pyruvate out of the parasite. The reason why the carbon dioxide fixation path-
way is essential for the asexual parasite is unclear, as it does not contribute
much to the TCA cycle and the majority of carbon channelled from glycolysis
through this pathway is exported in the form of malate146,145.
The distinct separation of glycolysis and the TCA cycle would suggest that
a kinetic model aimed at identifying drug targets in the parasite energy (i.e.
ATP) metabolism would not need to include the TCA cycle or carbon dioxide
fixation branch, although the integration of each of these pathways may pro-
vide insight into the function of the TCA cycle.
Many of the glycolytic enzymes have been biochemically characterised in part
(i.e. for one substrate or product), but apart from PFK, which has been
extensively biochemically characterised in P. berghei in terms of its allosteric
regulation, none of the glycolytic enzymes have been characterised in detail for
allosteric regulation. The incomplete kinetic data set for glycolysis is a starting
point for the construction of a kinetic model and could be supplemented with
kinetic data obtained for enzymes in other organisms. For a kinetic model,
constructed as a tool for analysing pathway behaviour in vivo, the enzyme
parameter values should reflect those found in the parasite (i.e. kinetic pa-
rameters should have been determined under conditions similar to those found
in the parasite). In the scientific literature, however, most of the enzymes
were biochemically characterised in the presence of contaminating erythrocyte
enzymes, or in a purified form under ideal conditions (e.g. pH, ionic strength).
Thus it was decided that for the study presented in this thesis, kinetic param-
eters (and assay methods) in scientific literature for P. falciparum glycolysis
would be used as reference values for further experimental characterisation.
By following the approach of van Eunen et al.215 who characterised each of
the glycolytic enzymes in yeast lysates under the same conditions (set to re-
flect intracellular conditions in vivo), a more complete set of kinetic data for
P. falciparum can be obtained. In Chapter 3 we describe the kinetic charac-
terisation of the glycolytic enzymes and integrate the kinetic rate equations
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into a kinetic model for P. falciparum glycolysis.
Many of the glycolytic and some of the PPP enzymes have been proposed
as drug targets. A kinetic model constructed from some of the kinetic data
obtained from this scientific literature study as well as from additional exper-
imental characterisation studies, may provide insight into which of these drug
targets are the most favourable.
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Chapter 3
Construction of a detailed kinetic model
of asexual Plasmodium falciparum glycolysis,
Part 1: Enzyme Kinetics & Construction
Penkler, G.P1., Rautenbach, M., Snoep, J.L.
3.1 Introduction
The central carbon metabolism of Plasmodium has been intensely studied to
understand the metabolic link between host and parasite and to discover po-
tential drug targets. P. falciparum is dependent on glycolysis for ATP193 and
the parasite does not store any reduced carbon reserves156,190. Because of
the essential role of ATP in the energy metabolism, glycolysis and numerous
enzymes within it have been suggested as targets for novel antimalarials. How-
ever, the enzymes have been studied and examined in isolation, not taking into
account the metabolic pathway as a whole.
One may think that it is not important which of the glycolytic enzymes is
inhibited, because as long as the enzyme is inhibited strongly enough it will
block glycolysis effectively. However, for such an inhibitor to be a good drug
it is important that it does not significantly inhibit the host’s glycolysis. As
such it would be important to identify reaction steps in the parasite whose
inhibition leads to a drastic decrease in glycolysis (i.e. enzymes with a high
flux control). Additionally, if the homologous step in the host has a low flux
control it would be possible to selectively inhibit the parasite’s glycolysis, even
if the drug does not differentiate between the parasite and host target enzyme.
1Part of the biochemical characterisation of the glycolytic enzymes was presented in my
M.Sc. thesis.158. Here we present a full characterisation, which includes completely new
analysis of HK, PFK, TPI, G3PDH and PGK.
31
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To identify which of the enzymes in glycolysis have a high flux control it is
necessary to analyse the system as a whole. In this study we outline the con-
struction of a detailed kinetic model of P. falciparum glycolysis, which would
enable the analysis of the entire system.
The central carbon metabolism of Plasmodium falciparum consists of glycoly-
sis, the pentose phosphate pathway and a glycerol production pathway. The
tricarboxylic acid cycle is not directly linked to glycolysis as the pyruvate
dehydrogenase complex is localised in the apicoplast and does not contribute
much acetyl-coA to the tricarboxylic acid cycle. Instead the TCA cycle utilises
primarily glutamine and glutamate as carbon sources145. Although a modi-
fied form of the TCA cycle exists, it is not considered as part of the central
carbon metabolism. It was initially thought that P. falciparum glycolysis was
homolactic, which supported the finding of an almost 2:1 ratio of mole lac-
tate produced per mole glucose190. However, this is inconsistent with several
findings, such as pyruvate being transported out of the cell57, which prevents
the recycling of NADH to NAD+. The production of glycerol by asexual P.
falciparum was reported by Lian et al.125, which indicates the presence of a
glycerol producing pathway. The presence of this oxidative pathway could
counter the redox imbalance caused by pyruvate excretion. The pentose phos-
phate pathway flux is low in asexual P. falciparum, although it is thought to
play an essential role in the oxidative defence system190,11.
Some of the glycolytic enzymes have been kinetically characterised for a va-
riety of Plasmodium species, with many characterised as pure enzymes (after
cloning, expression and isolation) under optimal conditions. Ideally, all of the
kinetic parameters should be determined under physiologically relevant con-
ditions. In order to examine the glycolytic pathway as a whole, we employed
the bottom up approach of van Eunen et al.215 in yeast, where each of the gly-
colytic enzymes were characterised under conditions (e.g. pH, ionic strength,
temperature) which mimicked those found in the yeast cytosol.
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Figure 3.1: Overview of asexual P. falciparum glycolysis. The asexual parasite
has a classic glycolytic pathway as well as a glycerol producing branch. The enzyme
names are in italics and the metabolites shown in bold font. Red circles indicate
enzymes that have been proposed as drug targets in scientific literature. It is not cer-
tain which enzyme produces glycerol during the asexual phase and this is indicated
by a question mark.
In this study we test if our biochemical knowledge (i.e. enzyme kinetics)
of P. falciparum glycolysis can describe the pathway in terms of fluxes and
metabolite concentrations found in the parasite. We follow an approach that
is similar to a study on yeast by Teusink et al 205. Firstly we present the bio-
chemical characterisation of each of the glycolytic enzymes and describe the
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kinetic behaviour with a mechanistic kinetic equation. Each of these equations
is integrated into an ordinary differential equation (ODE) based model. The
steady state (i.e. fluxes and metabolite concentrations) of the kinetic model
is analysed. This systematic bottom up approach to modelling a metabolic
pathway provides a strong foundation for constructing a kinetic model to im-
prove our understanding the pathway and for drug target identification. We
also present the model on an open source database (JWS Online144,201), which
allows users to analyse the model and have access to the kinetic datasets and
rate equations.
3.2 Methods
3.2.1 Culturing and synchronisation of P. falciparum
Packed human erythrocytes (A+, obtained from the Western Province Blood
Bank, South Africa) were infected with P. falciparum D10 and incubated with
3% oxygen, 4% carbon dioxide and 93% nitrogen at 37 ◦C in RPMI 1640 cul-
ture medium supplemented with 0.5% m/v Albumax II (R), 22 mM glucose, 25
mM HEPES, 3 mM hypoxanthine, 25 mM sodium bicarbonate and 50 µg/mL
gentamycin sulphate as described elsewhere45,209.
Parasite cultures were synchronised by suspending pelleted infected erythro-
cytes (750 × g, 3 min), in a 5% m/v sorbitol solution and incubating the
suspension at 37◦C for 5 min as described by Hoppe at al.97. Following fur-
ther centrifugation the infected erythrocytes were cultured as described above.
Sorbitol treatment leaves the erythrocytes intact, but destroys all but ring
stage parasites. After sorbitol treatment, the suspensions were centrifuged
and cultured as described above.
3.2.2 Trophozoite Isolation and Lysate Preparation
Trophozoites (36 - 40 hours post invasion) were isolated from the erythrocyte
using a saponin lysis protocol178. Saponin permeabilises the erythrocyte and
parasitophorous vacuolar membranes by interacting with cholesterol found in
these membranes3,4, but leaves the parasite plasma membrane intact and able
to maintain a transmembrane ion gradient and a substantial membrane po-
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tential178,177. Greater than 95% of parasites ,isolated in this manner, maintain
the ability to exclude 0.04% v/v trypan blue177.
After washing isolated trophozoites twice in assay buffer, lysates were prepared
by three freeze - thaw cycles between liquid nitrogen and room temperature.
The lysis protocol was optimised by the inclusion of a 30 second sonication
step between freeze-thaw cycles. After centrifugation (10 000 ×g , 10 min), the
supernatant was retained and used for kinetic determinations. Lysates were
prepared before enzyme kinetic assays and kept on ice.
3.2.3 Enzyme Characterisation
For reference each of the enzyme abbreviations are defined as follows: HK,
hexokinase; PGI, phosphoglucoisomerase; PFK, phosphofructokinase; ALD, al-
dolase; TIM, triosephosphate isomerase; G3PDH, glyceraldehyde 3-phosphate
dehydrogenase; PGK, phosphoglycerate kinase; PGM phosphoglycerate mutase;
ENO, enolase; PK, pyruvate kinase; LDH, lactate dehydrogenase; αGlyPDH,
glycerol 3-phosphate dehydrogenase; G6PDH, glucose 6-phosphate dehydroge-
nase
Each of the metabolites is abbreviated as follows: G6P, glucose 6-phosphate;
F6P, fructose 6-phosphate; F1,6BP fructose 1,6-bisphosphate; DHAP, dihy-
droxy acetone phosphate; GAP, glyceraldehyde 3-phosphate; B1,3PG, bis 1,3-
phosphoglycerate; 3PGA, 3-phosphoglycerate; 2PGA, 2-phosphoglycerate; PEP,
phosphoenolpyruvate; PYRpyruvate; LAClactate; GLCglucose
Each of the glycolytic enzymes were characterised in cell lysates in terms of
their maximal specific activity (Vmax) and affinity for each substrate and prod-
uct. The NADH/NAD+/NADP+ linked enzyme assays used were adapted
from Teusink et al.205. These oxidation/reduction assays were measured at
340 nm in 96-well plates (Greiner bio-one Flat Bottom microplate) on a spec-
trophotometer (VarioSkan microplate reader, Thermo Electron Corporation ).
The assay buffer, 20 mM HEPES, 20 mM MgCl, 10 mM KCl and 20 mM
NaCl, included a high magnesium concentration to ensure that ATP was pre-
dominantly in the active MgATP form. The pH of the assay buffer was set
to 7.17, matching the cytosolic pH of P. falciparum D10224. All of the link-
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ing enzymes were used at a final concentration of 5 U/mL. For each assay
a control was used to ensure that the linking reactions were not rate limit-
ing. For bisubstrate reactions, saturating concentrations of one substrate was
maintained while varying the concentration of the other in the presence or ab-
sence of product. All reagents and enzymes were obtained from Sigma-Aldrich.
HEXOKINASE (HK): The enzyme was characterised in the forward direc-
tion in terms of glucose (0 -10 mM) and ATP (0 - 10 mM) and inhibition
by ADP (0 - 20 mM) by linking the production of G6P to the reduction of
NADP+ (0.8 mM) via G6PDH. Product inhibition by G6P (0 - 30 mM) was
characterised by linking the production of ADP to the oxidation of NADH (0.8
mM) via LDH and PK in the presence of PEP (2 mM).
PHOSPHOGLUCOISOMERASE (PGI): The conversion of G6P (0 - 35 mM)
to F6P was linked to the oxidation of NADH (0.8 mM) via αGlyPDH, ALD,
TPI, PFK in the presence of ATP (2 mM). The reverse isomerisation of F6P
(0 - 2.5 mM) to G6P was linked to reduction of NADP+ (0.8 mM) via G6PDH.
PHOSPHOFRUCTOKINASE (PFK): The phosphorylation of F6P (0 - 30
mM) by ATP (0 - 10 mM) as well as inhibition by ADP (0 - 5 mM) was linked
to the oxidation of NADH (0.8 mM) via αGlyPDH, ALD, TPI. Product inhi-
bition by F1,6BP (0 - 60 mM) was assayed by linking the production of ADP
to the oxidation of NADH (0.8 mM) via LDH, PK in the presence of PEP (2
mM). Since PFK exhibited substrate inhibition, the enzyme rates could not be
normalised to maximal specific activity at saturating substrate concentrations.
A control rate was determined at 1.25 mM ATP and 1 mM F6P.
ALDOLASE (ALD): The reaction was characterised in terms of its substrate
F1,6BP (0 - 0.8 mM) by linking the production of DHAP to the oxidation of
NADH (0.8 mM) via αGlyPDH in the presence of excess TPI.
TRIOSEPHOSPHATE ISOMERASE (TPI): The isomerase reaction was as-
sayed in both directions via αGlyPDH or G3PDH in the presence of NADH
(0.8 mM) and GAP (0 - 1.2 mM ) or NAD+ (0.8 mM), KH2PO4 (10 mM) and
DHAP (0 - 15 mM ) respectively.
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GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (G3PDH): The
forward assay included NAD+ (0 - 2.5 mM), GAP (0 - 5 mM) and KH2PO4
(10 mM) and the reverse reaction included NADH (0 - 0.8 mM) and 3PGA
(0 - 2.5 mM). Since the product B1,3PG is chemically unstable with a short
half-life and not commercially available, 3-phosphoglycerate was used together
with PGK and ADP to produce B1,3PG. Complete and immediate conversion
by PGK is assumed to validate the B1,3PG concentration.
PHOSHOGLYCERATE KINASE (PGK): The kinase reaction was assayed
in the reverse direction by linking the production of B1,3PG from ATP (0 -
5 mM) and 3PGA (0 - 10 mM) in the presence of ADP (0 - 10 mM) to the
oxidation of NADH (0.8 mM) via G3PDH.
PHOSHOGLYCERATE MUTASE (PGM): The conversion of 3PGA (0 - 10
mM) to 2PGA was linked to the oxidation of NADH (0.8 mM) via LDH, PK,
ATP (2 mM) and ENO. The reverse reaction (2PGA 0 - 20 mM ) was linked
to NADH (0.8 mM) oxidation by G3PDH via PGK and ATP (2 mM).
ENOLASE (ENO): The forward conversion of 2PGA (0 - 5 mM ) to PEP
was linked to NADH oxidation by LDH via PK and ADP (2mM) and reverse
conversion of PEP (0 - 12 mM) to 2PGA was linked to NADH (0.8 mM) oxi-
dation by G3PDH via PGM, PGK and ATP (2 mM).
PYRUVATE KINASE (PK): The phosphorylation of ADP (0 - 5 mM) by
PEP (0 - 5 mM) was characterised in the presence of ATP (0 - 5 mM) by link-
ing the reaction to NADH oxidation by LDH and in the presence of pyruvate
(0 - 100 mM) by linking the production of ATP to the reduction of NADP+
(0.8 mM) via G6PDH, HK and glucose (10 mM). Since PK exhibited substrate
inhibition, the enzyme rates could not be normalised to maximal specific ac-
tivity at saturating substrate concentrations. A control rate was determined
at 1.25 mM PEP and 0.625 mM ADP.
LACTATE DEHYDROGENASE (LDH): The enzyme was characterised for
the forward oxidation of NADH (0 - 0.8 mM) by pyruvate (0 - 2.5 mM) and
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the reverse reduction of NAD+ ( 0 - 2 mM) by lactate (0 - 80 mM).
3.2.4 Glucose transport characterisation
The rate of glucose uptake over 2 s was measured using a modification of the
method by Walsh et al.217,218, which was based on a method by Bisson and
Fraenkel12. Isolated trophozoites were washed and suspended in glucose free
incubation modified Ringer buffer (25 mM HEPES, 1 mM MgCl2, 10 mM
KCl, 120 mM NaCl, pH 7.1) similar to that described by Wünsch et al.224 and
stored on ice before the assay. In this buffer the parasites were able to exclude
0.04% v/v trypan blue. An aliquot of this suspension was incubated at 37◦C
in a petri dish. Glucose solutions (1 - 20 mM, specific radioactivity 700 to
10 Bq nmol−1) were incubated separately in a water bath. An equal volume
of radiolabelled D-[1-14C] glucose was mixed with the incubated trophozoites
and incubated for 2 s. Uptake was halted by quenching with 10 mL of quench
buffer (500 mM Glucose, 25 mM HEPES, 1 mM MgCl2, 10 mM KCl, 120 mM
NaCl, pH 7.1), maintained at -5◦C on a salt-ice mixture. The trophozoites
were immediately transferred to a filter (covered with a thin layer of filter aid
Celite 545, Sigma-Aldrich, to prevent clogging) and washed with 10 mL of ice-
cold quenching solution. Filters were transferred immediately to scintillation
vials containing 5 mL scintillation fluid.
For uptake rates under 2 s, a simple programmable quench-flow device was
utilised (see Appendix B for a detailed description of the device design, con-
struction and calibration). The apparatus used the same method as above,
where glucose and trophozoites were loaded into temperature controlled sample
chambers and allowed to reach 37◦C. Upon triggering the device, the samples
were injected through a mixing chamber into a collection vial and at the pre-
programmed quench time, pre-chilled quenching solution was injected. The
cells were washed as described above. The control in each method was the
addition of the quench fluid prior to the addition of labelled glucose.
3.2.5 Fitting rate equations
For each glycolytic enzyme we wanted to describe the complete experimental
data set with a single rate equation. For this the independent kinetic data
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(i.e. for all substrate and product concentrations) were normalised to their re-
spective Vmax values and combined into a single data array for fitting. Fitting
of the entire combined multidimensional dataset was achieved usingWolfram
Mathematica 8.0® and its NonlinearModelFit function. For PFK and PK, in-
dependent data were normalised to enzymes rates measured under standard-
ised substrate concentrations as described in their respective enzyme assay
methods. Subsequently the rate equations were fitted to the combination of
these normalised datasets, with the difference that the Vmax was also fitted and
not set to 1. This fitted Vmax was used to scale the apparent Vmax accordingly.
3.2.6 Computational Modelling
The kinetic model was constructed using Wolfram Mathematica 8.0®. The
set of ordinary differential equations was solved using the NDSolve function.
Steady state was calculated using the FindRoot function. The mathematical
model was also constructed in Copasi96.
3.3 Results and Discussion
3.3.1 Kinetic Characterisation
3.3.1.1 Hexokinase
Hexokinase, the first step in glycolysis, phosphorylates glucose using ATP to
form glucose 6-phosphate (G6P) and ADP. The enzyme was characterised in
terms of both its substrates (glucose and ATP) and products (G6P and ADP)
as shown in Figure 3.2. The saturation curve for glucose shows a classical
Michaelis-Menten type curve and product inhibition of G6P and ADP showed
simple monotonous behaviour, but ATP exhibits inhibitory behaviour at con-
centrations above 3 mM. Mg2+ concentrations were maintained at least twice
the concentration of ATP at all times, so inhibition is attributed to the ac-
tivated Mg-ATP complex. For simplicity, in this study, ATP refers to the
complexed Mg-ATP form. Inhibition was not competitive with respect to glu-
cose (data not shown). The inhibitory effect of ATP is not expected to play
an important role in vivo due to the relatively high concentration at which it
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occurs.
vHK =

























Figure 3.2: Biochemical characterisation ofP. falciparum hexokinase. HK catal-
yses the ATP-dependent phosphorylation of glucose to form G6P and ADP. Sat-
uration of the enzyme with glucose (A) and ATP (B) is shown in addition to the
inhibition of ADP (C) and G6P (D). Equation 3.3.1 was tted to the entire nor-
malised dataset and describes the data well (adjusted R2 = 0.97). The tted lines
(adjusted R2 = 0.96) are shown in the gures above and the parameters values ob-
tained from the tting are presented in Table 3.1. The error bars represent SEM,
where n = 3 (C), n = 2 (D), n = 3 (A) and n = 4 (B) independent experiments.
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Table 3.1: Summary of the kinetic parameters for P. falciparum hexokinase. The
combined hexokinase kinetic data were normalised to Vmax (Fig. 3.2) and fitted
simultaneously to Eq. 3.3.1. The fitted parameters (± asymptotic standard error)
are compared to the affinities determined for infected erythrocyte lysate (i.e. kinetics
are the combination of erythrocyte and parasite HK). The maximal specific activity,
VHK was determined independently (see Table 3.15 and Section 3.3.2 for discussion).
Parameter Fitted Value Literature Value Reference
KGlc (mM) 0.076 ± 0.019 0.43 ± 0.0211 175
KATP (mM) 0.75 ± 0.030 3.1 ± 1.41 175
KADP (mM) 1.1 ± 0.22 - -
KG6P (mM) 0.021 ± 0.0064 - -
KiATP (mM) 1.2 ± 0.087 - -
VHK (µmol·min−1·mg−1) 0.34 ± 0.058 -
Keq 1310 17
1 Determined in P. falciparum infected erythrocyte lysates and includes the affinity of the
native erythrocyte enzymes (see text for discussion).
Erythrocyte hexokinase: KATP (mM) = 2.5 ± 1.0175 and KGlc (mM) = 0.098 ± 0.0010175
Equation 3.3.1 was derived assuming a rapid equilibrium random ordered bi-bi
mechanism. The inhibitory mechanism of ATP is not known and we assumed
a non-competitive mechanism where up to four ATP molecules can bind to
the enzyme. This equation could describe the kinetics quite well (Fig. 3.2)
although the Michaelis constants for glucose and ATP are lower than those
determined by Roth et al.175. However, their Michaelis constants were de-
termined in infected erythrocyte lysates and these parameters are thus the
combination of parasite and erythrocyte HK kinetics175.
3.3.1.2 Phosphoglucoisomerase
Phosphoglucoisomerase catalyses the conversion of glucose 6-phosphate to
fructose 6-phosphate. Srivastava et al. identified and characterised three
PGI isoenzymes from P. falciparum each with a similar Km for fructose 6-
phosphate202.
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The expression profile of the three isozymes during the asexual development
phase of the P. falciparum life cycle is not known and in this work we charac-
terised the average of the three isozymes during the asexual phase. The data
of five independent experiments (two for the forward reaction and three for
the reverse) were normalised to their respective maximal activities (Vmax) and
combined, followed by fitting to a reversible Michaelis-Menten equation (Eq.
3.3.2), which described the data well (Fig. 3.3). Fitted parameter values are












Figure 3.3: Biochemical characterisation ofP. falciparum phosphoglucoisomerase.
P. falciparum PGI was characterised in terms of its substrate, glucose 6-phosphate
(A) and product fructose 6-phosphate (B). The tted curve of a reversible Michaelis-
Menten equation, which was used to determine the Michaelis constants is shown
(adjusted R2 = 0.99). The forward reaction is a combination of two independent
experiments and the reverse reaction is a combination of three independent exper-
iments, each normalised to their maximal activity. Error bars represent SEM (n 
3).
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Table 3.2: Summary of the average kinetic parameters for the three P. falciparum
PGI isozymes. The kinetic data were fitted to a reversible Michaelis-Menten equa-
tion (Eq. 3.3.2). The fitted curves are shown in Fig. 3.3 and the fitted parameters
are indicated with asymptotic standard error. The forward and reverse maximal
specific activities (VfPGI and VrPGI , respectively) were determined in separate ex-
periments (Table 3.15, Fig. 3.15).
Parameter Fitted Value Literature Value Reference
KG6P (mM) 1.0 ± 0.056 - -
KF6P (mM) 0.097 ± 0.0053 0.26 ± 0.0261 202
VfPGI (µmol·min−1·mg−1) 3.7 ± 0.37 - -
VrPGI (µmol·min−1·mg−1) 1.4 ± 0.26 - -
Keq 0.17 - 0.382 0.33 203,72
1 Average value of three P. falciparum isoenzymes with SEM.
2 Lower and upper range determined from the Haldane relationship and error on the fitted parameters.
3.3.1.3 Phosphofructokinase
PFK catalyses the ATP-dependent phosphorylation of F6P to form F1,6BP
and ADP. In this work we characterised PFK in terms of its substrates and
products, and also tested for its regulation by PEP and F1,6BP found in P.
berghei 22,23,24,25. We found substrate inhibition by ATP, product inhibition by
both ADP and F1,6BP and a classical Michaelis-Menten saturation curve for
F6P (Fig. 3.4). To describe the kinetic data (Fig. 3.4) and regulatory effects
of ATP, a variety of equations were tried. Neither competitive, noncompetitive
nor uncompetitive models of substrate inhibition, as described by124 were suf-
ficient in describing the inhibition exhibited by ATP. Furthermore, a reversible
Hill equation90 with ATP as an independent modifier, could also not describe
the data (results not shown).
A Monod-Wyman-Changeux (MWC) equation for bisubstrate reactions (Eq.
3.3.3) as derived by Hess and Pletter84 was successfully used to describe the
kinetic behaviour after making certain assumptions (see below).
Equation 3.3.3 describes a bi-substrate reaction describing tense (T) and re-
laxed (R) enzymatic states, with j number of allosteric effectors. Vmaxr and
Vmaxt describe the maximal rate of the R and T state respectively. Further-
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more, gr and gt are affinity coefficients for two substrates at the R and T state
in absence of modifiers. Modifier behaviour is determined by cij which is de-
fined as ratio of modifier binding to the R and T state. Thus if cij > 1, γ acts
as an inhibitor and if 0 < cij < 1, γ is an activator. Lo describes the equilib-
rium ratio between the R and the T state. c1 and c2 are binding coefficients
for the two substrates and defined as the ratio of the Michaelis constants for
each substrate in the R and the T state. Binding of an inhibitor results in the




Vmaxr · gr · α1 · α2 ·R(n−1) + Vmaxt · L · gt · c1 · α1 · c2 · α2 · T (n−1)
)
(Rn + L · T n)
(3.3.3)
















R = (1 + α1 + α2 + gr · α1 · α2)
T = (1 + c1 · α1 + c2 · α2 + gt · c1 · α1 · c2 · α2)
The following assumptions were made with regards to P. falciparum PFK:
• Fructose 6-phosphate does not bind to the T-state, such that c2 = 0
• ATP, F1,6BP and ADP are modelled as allosteric inhibitors and regulate
the ratio of the R to T state.
• The reaction was assumed to be irreversible at physiological concentra-
tions of substrate and product, due to the high equilibrium constant (Keq
= 229079) of the PFK catalysed reaction.
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Using these assumptions, Eq. 3.3.3 reduces to Eq. 3.3.4, where Vmaxr is the
maximal rate of the R-state,Katpr andKf6pr are dissociation constants for ATP
and F6P and Kiatp, Kifbp, Kiadp are inhibitory constants for ATP, F1,6BP
and ADP, respectively. The ratios of the dissociation constants for the R and
T-states for ATP, F1,6BP and ADP are given by catp, cfbp and cadp respectively.
vPFK =






























 n1 + cfbp·fbpKifbp
1 + fbpKifbp
 n1 + cadp·adpKiadp
1 + adpKiadp
 n
Figure 3.4: Biochemical characterisation of P. falciparum phosphofructokinase.
The enzyme was characterised in terms of its substrates, ATP and F6P as well as its
products ADP and F1,6BP. A MWC equation (Eq. 3.3.4) was tted simultaneously
to all the data and the equation gives a good description the data (adjusted R2 =
0.95). Parameter values obtained from the tting are shown in Table 3.3. The data
are a combination of 8 independent experiments and error bars represent SEM (n
>3).
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Table 3.3: Summary of kinetic parameter values for P. falciparum phosphofruc-
tokinase. The parameters were obtained by simultaneously fitting Eq. 3.3.4 to the
kinetic data (Fig. 3.4). The parameters are listed below ± asymptotic standard
error.
Parameter Fitted Value
Vmaxr (µmol·min−1·mg−1) 0.68 ± 0.13
Katpr (mM) 1.0 ± 3.7
Kf6pr (mM) 0.11 ± 0.72
Kiatp (mM) 7.0 ± 8.8
Kifbp (mM) 25 ± 18
Kiadp (mM) 3.0 ± 5.0
gr 1.9 ± 6.6
c1 4.9 ± 5.8
catp 60 ± 0.12
cfbp 16 ± 9.2
cadp 5.0 ± 7.7
n 1.0 ± 0.19
Lo 0.58 ± 6.8
Buckwitz et al.22,23,24,25 characterised PFK from P. berghei in detail and showed
it to be inhibited by ATP, and Mg2+ ions and activated by PEP, F6P and in-
organic phosphate. P. falciparum PFK is similar to P. berghei PFK in terms
of inhibition by ATP. However, in this study and others137, it is not activated
by F1,6BP or PEP
The MWC equation described the combined datasets fairly well (Fig. 3.4), and
could also account for kinetic behaviour at both saturating and non-saturating
concentrations of substrates and products. Interestingly the equation fitted
best when n = 1. This is consistent with the results shown by Money et al.137,
which indicated the existence of an α and β subunit, fused into a single protein
200kDa protein, where the β subunit contains the catalytic domain with the
alpha subunit showing almost no enzymatic activity.
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3.3.1.4 Aldolase
Aldolase catalyses the aldol cleavage of F,16BP into GAP and DHAP. The for-
ward reaction for P. falciparum aldolase was characterised in terms of its sub-
strate, F1,6BP (Fig 3.5). The kinetic data were described by a random order
uni-bi rapid equilibrium rate equation (Eq. 3.3.5), and the fitted parameters
are summarised in Table 3.4. In lysate the presence of triosephosphate iso-
merase prevents the characterisation of product inhibition by its products GAP
and DHAP. Characterising the reaction in reverse via glucose 6-phosphate de-
hydrogenase was also not possible as phosphofructokinase has a high Keq.
The Michaelis constants for the products, KGAP and KDHAP were estimated
by averaging the Michaelis constants found for T. brucei, Lactococcus lactis
and human erythrocytes83,86,93 (Table 3.4).
vALD =














Figure 3.5: Kinetic characterisation of P. falciparum aldolase. The enzyme was
assayed to determine its anity for F1,6BP. The tted curve (adjusted R 2 = 0.98)
was obtain using a uni - bi rate equation (Eq. 3.3.5) and the tted parameters are
shown in Table 3.4. The data are a combination of two independent experiments,
normalised to their respectiveVmax values. Error bars represent SEM (n 3).
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Table 3.4: Summary of kinetic parameters for P. falciparum aldolase, The enzyme
was characterised in terms of its affinity for its substrate, F1,6BP and maximal
specific activity VALD (Fig. 3.5). The data were fitted to a uni-bi rate equation
(Eq. 3.3.5) and the fitted parameter values are summarised below. The product
affinities could not be determined in lysates and these parameters were estimated
by averaging the values of the affinities determined for L. lactis, T. brucei and human
erythrocytes. The data are the combination of two independent experiments with
each point measured in triplicate.
Parameter Fitted Value Literature Value Reference
VALD (µmol·min−1·mg−1) 0.27 ± 0.049 -
KF1,6BP (mM) 0.067 ± 0.0046 0.025 ± 0.0060 51
KGAP (mM) - 0.046 ± 0.0191 83,86,93
KDHAP (mM) - 0.11 ± 0.0891 83,86,93
Keq (mM−1 - 0.090 128
1 Estimated by averaging value of affinities in Trypanosoma brucei, Lactococcus lactis &
human erythrocytes (Mean ± SEM).
3.3.1.5 Triosephosphate Isomerase
Triosephosphate isomerase (TIM) catalyses the isomerisation of DHAP and
GAP and was characterised in terms of it substrate (DHAP) and product
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Figure 3.6: Kinetic characterisation of P. falciparum triosephosphate isomerase.
P. falciparum triosephosphate isomerase exhibits Michaelis-Menten kinetics with
regard to b oth its substrate (DHAP) and pro duct (GAP), as well as b eing inhibited
comp etitively by PEP. The data shown was combined and tted simultaneously
to a reversible Michaelis-Menten equation with a comp etitive inhibitor term (Eq.
3.3.6). The equation d es crib es th e data well (adjusted R 2 = 0.93) and the tted
parameters are displayed in Table 3.5. Each saturation curve is the combination of
two indep endent exp eriments and error bars represent SEM (n = 6)
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The data were described by a reversible Michaelis-Menten equation, with PEP
as a competitive inhibitor (Eq. 3.3.6), where VTIM is the maximal rate, Kgap
and Kdhap are the Michaelis constant for GAP and DHAP, and KiPEP is the
Michaelis inhibition constant for the competitive inhibitor, PEP. Keq is the
equilibrium constant of the reaction. The fitted parameters for the equation
are shown in Table 3.5.
Table 3.5: Summary of Kinetic parameters for P. falciparum triosephosphate iso-
merase. The kinetic behaviour of triosephosphate isomerase was characterised in
terms of its substrate, product and inhibition by PEP (Fig. 3.6). The combined
data were fitted to a reversible Michaelis-Menten equation with a competitive in-
hibitor (Eq. 3.3.6) and the parameters obtained for the fit are displayed below
with asymptotic standard error. The forward (VfTIM ) and reverse (VrTIM ) maximal
specific activities were determined separately (see Fig. 3.15 and text for discussion.)
Parameter Fitted Value Literature Value Reference
VfTIM (µmol·min−1·mg−1) 7.0 ± 1.0 - -
VrTIM (µmol·min−1·mg−1) 15 ± 0.74 - -
KGAP (mM) 0.34 ± 0.039 0.35 ± 0.16 196,132
KDHAP (mM) 2.0 ± 0.33 0.59 196
KiPEP (mM) 0.47 ± 0.053 - -
Keq 0.050 - 0.131 0.046 13
1 Lower and upper range as determined from the Haldane relationship within the error range
of the parameters.
TIM is generally viewed as a near equilibrium reaction and was not thought
to contribute to the regulation of glycolysis. However, TIM was proposed to
have a regulatory role in yeast when PEP was discovered as an inhibitor of the
enzyme in yeast and rabbit muscle77. In P. falciparum TPI is strongly inhib-
ited by PEP (see Fig 3.6) and is almost entirely inhibited at concentrations >
5 mM, which may have implications regarding the regulation of flux towards
glycerol (see discussion).
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3.3.1.6 Glyceraldehyde 3- Phosphate Dehydrogenase
Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) catalyses the conversion
of GAP, Pi and NAD+ to 1,3 -bisphosphoglycerate and NADH. G3PDH has not
been previously characterised for P. falciparum. For the forward reactions, the
phosphate concentration was fixed at 10 mM and either GAP or NAD+ varied
at saturating concentrations of the other (Fig. 3.7). The reverse reaction was
also characterised by varying either B1,3PG (indirectly via 3PGA and PGK)


















A random order bi-bi equilibrium binding equation (Eq. 3.3.7) was fitted to all
of the normalised kinetic data simultaneously (Fig. 3.7). The fitted parameters
are summarised in Table 3.6.
Figure 3.7: Biochemical characterisation of P. falciparum glyceraldehyde 3-
phosphate dehydrogenase. The enzyme was characterised in the forward (NAD+ ,
GAP) and the reverse (NADH, B1,3PG) direction. The rates were normalised to
maximal specic activity and the combined data are well described by Eq. 3.3.7
(adjusted R2 = 0.96). The tted parameter values are summarised in Table 3.6.
Each saturation curve is the combination of two independent experiments and data
points represent the mean SEM, n  3.
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Table 3.6: Summary of kinetic parameters for P. falciparum glyceraldehyde 3-
phosphate dehydrogenase. G3PDH was characterised in terms of GAP and NAD+
under high phosphate concentrations as well as for NADH and B1,3PG (Fig. 3.7).
The normalised data were fitted simultaneously to a random order bi-bi equilibrium
equation (Eq. 3.3.7) and the fitted parameters are displayed below with asymptotic
standard error. The maximal forward and reverse specific activities were determined
independently (See Fig 3.15 and text for discussion).
Parameter Fitted Value Literature Value Reference
VfG3PDH (µmol·min−1·mg−1) 1.2 ± 0.25 - -
VrG3PDH (µmol·min−1·mg−1) 3.1 ± 0.23 - -
KGAP (mM) 0.92 ± 0.11 1.0 29
KNAD (mM) 0.54 ± 0.058 - -
KNADH (mM) 0.029 ± 0.0038 - -
KB1,3PG (mM) 1.1 ± 0.094 - -
It should be noted that KB1,3PG obtained from the fitted G3PDH curve (Fig.
3.7) is in all likelihood an overestimation. Since 1,3 BPG is chemically unstable
with a short half-life, 3PGA is used together with PGK and ADP to produce
B1,3PG. Complete conversion is assumed for the calculation of the B1,3PG
concentration, although this is unlikely, especially as the Keq for PGK is rela-
tively high. The apparent sigmoidality seen in the saturation curve (Fig. 3.7)
is attributed to the assay method. The method is not expected to result in a
linear correlation between the concentrations of B1,3PG produced at high and
low concentrations of 3PGA. Due to the assumption of complete conversion,
it is expected that the Michaelis constant is overestimated.
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3.3.1.7 Phosphoglycerate kinase
PGK is the first ATP producing reaction of glycolysis and converts B1,3PG and
ADP to 3PGA and ATP. P. falciparum phosphoglycerate kinase was charac-
terised in the reverse direction with ATP and 3-phosphoglycerate as substrates
as well for the product inhibition of the reverse reaction by ADP (Fig. 3.8). As
stated before, determining a Michaelis constant for B1,3PG was not possible,
as it is chemically unstable and not commercially available. The kinetic data
(Fig. 3.8) was described by a random order bi-bi rapid equilibrium equation
(Eq. 3.3.8) and the fitted parameters are displayed in Table 3.7. The Michaelis





















Equation 3.3.8 is not in the standard Haldane relationship form, as the maxi-
mal forward rate (defined as the ATP forming direction) is unknown. By using
the Haldane relationship the forward maximal rate, VfPGK can be defined in
terms of the Michaelis constants, Keq and VrPGK . Substituting this into the
standard Haldane relationship form of the equation, gives Eq. 3.3.8 and de-
scribes the forward rate as a function of the reverse maximal specific activity.
Two isoenzymes of PGK have been isolated from P. falciparum 190, but the
role of these isoenzymes and, whether they are expressed during the differ-
ent life stages is not known. The kinetic parameters determined here would
therefore be apparent Michaelis constants representing both isoenzymes.
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Figure 3.8: Biochemical characterisation of P. falciparum phosphoglycerate kinase.
PGK was assayed for its products and one of its substrates, ADP. The reaction was
characterised in the reverse direction, hence ADP inhibiting the reaction and ATP
and 3-phosphoglycerate increasing the reaction rate. The tted curves (adjusted R 2
= 0.99) were obtained using a random order bi-bi equation (Eq. 3.3.8) and the tted
parameters are presented in Table 3.7. Each saturation curve is the combination of
two independent experiments where error bars represent SEM (n  3).
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Table 3.7: A summary of kinetic parameters for P. falciparum phosphoglycerate
kinase. PGK was biochemically characterised in the reverse direction for ATP,
ADP and 3PGA and the combined data fitted (Fig. 3.8 to a random order bi-bi
rate equation (Eq. 3.3.8). Michaelis constants are shown ± asymptotic standard
error.
Parameter Fitted Value Literature Value Reference
VrPGK (µmol·min−1·mg−1) 1.7 ± 0.36 -
VfPGK (µmol·min−1·mg−1) 301 -
KADP (mM) 0.15 ± 0.0095 0.302 174
KATP (mM) 0.78 ± 0.027 0.682, 0.633 174,148
K3PGA (mM) 0.27 ± 0.013 0.172, 0.523 174,148
KB13PG (mM) - 0.0132 174
Keq - 1890 61
1 Calculated using the Haldane relationship.
2 Determined for PGK-deficient erythrocytes infected with P. falciparum.
3 Determined for recombinant P. falciparum PGK.
3.3.1.8 Phosphoglycerate Mutase
Phosphoglycerate mutase (PGM) converts 3PGA to 2PGA. In this work P.
falciparum PGM was biochemically characterised in both the forward and
reverse directions. The saturation curves (Fig. 3.9) were fitted to a reversible
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Figure 3.9: Bio chemical characterisation of P. falciparum phosphoglycerate mu-
tase. The enzyme was characterised in terms of its substrate, 3PGA and pro duct,
2PGA. The combined and normalised data were tted (adjusted R 2 = 0.99) to a
Michaelis-Menten equation (Eq. 3.3.8) and the tted parameters are shown in Table
3.7. For 2PGA, the rate b ecomes negative and denotes the en zyme functioning in
reverse. Each saturation curve is the combination of three indep endent exp eriments
and error bars represent S EM (n  3).
Table 3.8: Summary of kinetic p arameters for P. falciparum phosphoglycerate
mutase. PGM was bio chemically characterised in the forward (3PGA) and reverse
(2PGA) direction and the combined data tted (Fig. 3.9) to a Michaelis-Menten
equation (Eq. 3.3.9). The  tted parameters are displayed b elow  asymptotic
standard error.
Parameter Fitted Value Literature Value Reference
Vf P GM (molmin  1 mg 1 ) 0.87  0.072 - -
Vr P GM (molmin  1 mg 1 ) 0.22  0.050 - -
K 3P GA (mM) 1.7  0.091 0.85 85
K 2P GA (mM) 0.32  0.016 0.041 85
K eq 0.14 - 0.451 0.10 128
1 Lower and upper range as determined from the Haldane relationship and error on the parameters.
CHAPTER 3. ENZYME KINETICS AND MODEL CONSTRUCTION 57
3.3.1.9 Enolase
Enolase catalyses production of PEP from 2PGA and was kinetically char-
acterised in both the forward and reverse direction (Fig 3.10). The forward
and reverse reactions follow classical Michaelis-Menten kinetics and are well
described by a reversible Michaelis-Menten equation (Eq. 3.3.10). The fitted














Figure 3.10: Biochemical characterisation ofP. falciparum enolase. The enzyme
was characterised in the forward (2PGA) and reverse (PEP) direction. The curve
(adjusted R2 = 0.96) is the description of the data by Eq. 3.3.10 and the tted
parameters are summarised in Table 3.9. The data are the combination of two
independent experiments. Error bars represent SEM (n 3).
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Table 3.9: Summary of the kinetic parameters of P. falciparum enolase. The
enzyme was assayed in the forward and reverse direction (Fig. 3.10) and the data
were fitted to a reversible Michaelis-Menten equation (Eq. 3.3.10). Values are listed
as the mean ± asymptotic standard error.
Parameter Fitted Value Literature Value Reference
VfENO (µmol·min−1·mg−1) 1.3 ± 0.41 - -
VrENO (µmol·min−1·mg−1) 0.94 ± 0.44 - -
K2PGA (mM) 0.53 ± 0.055 0.041 ± 0.00402 151
KPEP (mM) 1.3 ± 0.13 0.25 ± 0.0302 151
Keq 1.8 - 9.61 4.6 128
1 Lower and upper range as determined from the Haldane relationship and the error on the parameters.
2 P. falciparum enolase expressed in E. coli and characterised in its purified form.
The affinities for PEP and 2PGA determined in this work are between 6 and
10 fold weaker than determined by Pal-Bhowmick et al.151, but these were
determined for a cloned and purified enzyme, at optimal pH (Table 3.9).
3.3.1.10 Pyruvate Kinase
Pyruvate kinase catalyses the substrate level phosphorylation of ADP, using
phosphoenolpyruvate and producing pyruvate and ATP. P. falciparum PK was
characterised in the forward direction for substrates, PEP and ADP and prod-
uct inhibition by ATP and pyruvate (Fig. 3.11). From the saturation curves
(Fig. 3.11) it is apparent that the PK is under kinetic regulation, inhibited by
both of its substrates at higher concentrations and inhibited cooperatively by
its product ATP. The enzyme is fairly insensitive to pyruvate and inhibition
is only observed at more than 20 mM.
A variety of rate equations were evaluated in an attempt to capture the overall
kinetic behaviour in a single equation. Reversible Hill equations, with PEP
and ADP as allosteric inhibitors could not describe the bi-substrate inhibition,
although it did describe the cooperative inhibition by ADP (data not shown).
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Figure 3.11: Kinetic characterisation of P. falciparum pyruvate kinase. PK was
characterised in terms of its subs trates (ADP and PEP) and pro ducts (ATP and
pyruvate). A) Indicates the allosteric inhibition of the enzyme by ADP. B,C&
D) PEP inhibition at varying concentrations of ADP. E,F & G) Strong co op erative
inhibition shown by ATP. F) Slight pro duct inhibition by pyruvate. The −tted curve
(adjusted R 2 = 0.97) through each of the datasets was obtained by simultaneously
−tting all the kinetic data to Equation 3.3.12. Parameter values are shown in Table
3.10. The data are representative of seven ind ep endent exp eriments and errors bars
represent S EM (n  3).
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An MWC equation, which assumes an irreversible reaction, rapid equilibrium
binding and independent binding of substrates (Eq. 3.3.11) and described by
Buckwitz et al.24 was used to describe the observed kinetic behaviour. The
equation describes the reaction rate as a function of two substrates (S1 & S2),
where KS1 and KS2 are Michaelis constants for the first and second substrate,
Lo describes the equilibrium constant between the R and the T-state, n is the
number of subunits and Ki is the inhibition constant of an inhibitor, i.
v =







 · ( 11 + L
)
(3.3.11)





Using Eq. 3.3.11 for PK with the additional assumption that only a tetrameric
form (n = 4) is active (1 + ( i
Ki
)n) with atp, pep, adp and PYRacting as
inhibitors yields (Eq. 3.3.12). This equation could describe the bi-substrate
inhibition, the cooperativity of ATP and the inhibition by pyruvate in a single
rate equation (Fig. 3.11) and the fitted parameters are shown in Table 3.10.
vPK =






































Plasmodium possesses two homotetrameric pyruvate kinases (PK1 and PK2).
Both are expressed during the asexual phase36, but PK1 expression is constant
and continually high throughout the asexual phase and thought to be part of
glycolysis, whereas PK2 correlates with the expression of lipid synthesis genes.
Since the enzyme characterisation is in trophozoite lysates, both isozymes
would be present and the characterisation would represent the combined be-
haviour and kinetics. The interpretation of this data thus has to consider the
relative contribution of the two enzymes. In this work, it is assumed that the
relative contribution of the apicoplast PK2 compared to PK1 is minimal. This
assumption is based on i) that cDNA levels are far higher for PK136 and ii) the
reasoning that rate of lipid synthesis would be far less than the glycolytic rate
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Table 3.10: Summary of kinetic parameters for P. falciparum pyruvate kinase. PK
is inhibited by both of its substrates, as well as cooperatively by ATP and inhibited
at high concentrations of pyruvate. The kinetic data shown in Figure 3.11, were
fitted simultaneously to a MWC type equation (Eq. 3.3.12). The fitted parameters
and the respective asymptotic standard error for each parameter are indicated below.
Parameter Fitted Value Literature Reference
VfPK (µmol·min−1·mg−1) 2.3
KADP (mM) 0.30 ± 0.050 0.13 ± 0.043 36
KPEP (mM) 0.39 ± 0.047 0.19 ± 0.028 36
KiPyr (mM) 69 ± 6.7 - -
KiATP (mM) 1.4 ± 0.12 - -
KiADP (mM) 1.9 ± 0.15 - -
KiPEP (mM) 2.8 ± 0.24 - -
Lo 0.198 ± 0.0877 - -
n 4
and with the small apicoplast volume, not much enzyme would be required to
fulfil the flux requirement. It is also assumed that the regulation of the two
enzymes is the same, although this may not be the case.
3.3.1.11 Lactate Dehydrogenase
P. falciparum lactate dehydrogenase (LDH) is essential for maintaining the
redox balance of the cell by recycling NAD+ from NADH by reducing the keto
group of pyruvate to a hydroxyl group (lactate). In this work, the enzyme
was characterised in the forward and reverse directions (Fig. 3.11). Pyruvate
has been shown to inhibit the enzyme as high concentrations with a Ki of
140 mM194, but this inhibition is negligible at physiological concentrations
of pyruvate and thus excluded. The combined kinetic data were described
successfully (Fig. 3.11) with a random order bi-bi rapid equilibrium equation

















CHAPTER 3. ENZYME KINETICS AND MODEL CONSTRUCTION 62
Figure 3.12: Kinetic characterisation of P. falciparum lactate dehydrogenase. LDH
was assayed in both the forward (NADH & pyruvate) and reverse directions (NAD +
& lactate). The curve (adjusted R 2 = 0.97) shows the t obtained for a random
order bi-bi equation (Eq. 3.3.13). The tted parameters are displayed in Table
3.12. Each saturation curve is the combination of three biological repeats with n 
3 technical repeats. Error bars indicate SEM.
Table 3.11: Summary of kinetic parameters determined for P. falciparum lactate
dehydrogenase. LDH was biochemically characterised for asexual P. falciparum (Fig.
3.11) and the kinetic data tted simultaneously to Eq. 3.3.13 to obtain the below
parameters ( asymptotic standard error).
Parameter Fitted Value Literature Value Reference
Vf LDH (molmin  1 mg 1 ) 2.5  0.23 - -
Vr LDH (molmin  1 mg 1 ) 1.4  0.18 - -
K P yr (mM) 0.13  0.0080 0.030, 0.055 73,194
K NADH (mM) 0.046 0.0031 0.0070, 0.011 73,194
K Lac (mM) 3.6  0.30 12, 47 73,194
K NAD (mM) 0.23  0.020 0.086, 0.18 73,194
K eq 150 - 4301 227 - 7194 165,48
1 Lower and upper range as determined using the Haldane relationship and error in the parameters.
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3.3.1.12 Glycerol Production and Transport
The experimental finding of a 2:1 ratio of lactate produced per mole glucose
consumed supported the hypothesis that P. falciparum glycolysis was homo-
lactic190. However, this is inconsistent with several findings, such as pyruvate
being transported out of the cell57, which would prevent the recycling of NADH
to NAD+ . The production of glycerol by asexual P. falciparum was discov-
ered by Lian et al.125, which indicates the presence of a glycerol shunt pathway
where presumably glycerol is produced from DHAP combined with the impor-
tant oxidation of NADH to balance pyruvate excretion. The enzyme(s) used
to produce glycerol in P. falciparum during the asexual phase have yet to be
identified. We measured glycerol 3-phosphate dehydrogenase activity (con-
verts DHAP to G3P combined with the oxidation of NADH to form NAD+)
in trophozoite lysates (results not shown). However, the reaction that converts
G3P to glycerol (if this is the pathway for glycerol production in asexual P.
falciparum) is unknown. In P. falciparum studies have shown the existence of
a gene that codes for glycerol kinase, but it is not expressed during the asex-
ual stage and disruption of this gene does not inhibit growth and development
of the parasite186. Furthermore, no putative genes for glycerol-3-phosphatase
have been identified in the P. falciparum genome69. There is however, a PGM
isozyme, PGM285, which has phosphatase activity and it may be able to utilise
G3P as a substrate to produce glycerol.
Since the pathway for glycerol production is not clear, a single rate equa-
tion (Eq. 3.3.14) was used to describe the production of glycerol, NAD+
and orthophosphate from DHAP combined with the oxidation of NADH. The
orthophosphate concentration was not included in the rate equation. For sim-
plicity it was also assumed that all glycerol produced is transported out of the
trophozoite. The parameters for the reaction (assumed to be the same as for

























CHAPTER 3. ENZYME KINETICS AND MODEL CONSTRUCTION 64
Table 3.12: Summary of the kinetic parameters obtained for the glycerol producing
enzyme. The enzymatic pathway for the production of glycerol in P. falciparum has
yet to be identified. The production of glycerol was described by a single rate
equation (Eq. 3.3.14). The first step in the pathway is assumed to be glycerol-
3-phosphate dehydrogenase and parameters for this enzyme were obtained from
the Brenda Enzyme database185 for a number of organisms. The maximal specific
activity, VfGlr , was fitted to obtain experimentally measured flux rates.
Parameter Literature Value Reference
VfGlr (µmol·min−1·mg−1) 0.0201 Fitted (This work)
KDHAP (mM) 0.23 ± 0.162 185
KNADH (mM) 0.023 ± 0.0253 185
KGlycerol (mM) 5.0 4 -
KNAD (mM) 0.25 ± 0.195 185
Keq 326006 227
1 Fitted to obtain experimentally measured flux.
2 Mean ± SD of 18 independent values for Gly3PDH across 13 different organisms)
3 Mean ± SD of 22 independent values for Gly3PDH across 18 different organisms)
4 Assumed to be fairly insensitive to external glycerol.
5 Mean ± SD of 17 independent values for Gly3PDH across 13 different organisms)
6 Keq for Gly3PDH reaction.
3.3.1.13 Glucose Transporter, PfHT1
Asexual Plasmodium relies on the erythrocyte GLUT1 and GLUT5 enzymes
for glucose and fructose transport respectively. The rapid transport facilitated
by these enzymes far exceeds the demands of the parasite115 and uptake of
both glucose and fructose into the parasite has been shown to be a passive pro-
cess116. Glucose and fructose are thought to first cross the parasitophorous vac-
uolar membrane via high-capacity non-selective channels116,74,119 after which
they are transported across the parasite plasma membrane via a specialised sat-
urable, sodium-independent and stereo-specific hexose transporter223,222. The
P. vivax and P. falciparum hexose transporters (PvHT1 and PfHT1 respec-
tively) as well as those for P. knowlesi and P. yoelli have been biochemically
characterised223,222,100,101,102. The potential of PfHT1 as a drug target has been
examined with inhibitors in several studies100,101,102,179 and reviewed by Patel
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et al.155.
During this study the glucose transporter, PfHT1 was characterised using
14C labelled D-glucose uptake experiments (Fig. 3.14) in isolated P. falci-
parum trophozoites. Many studies have looked at uptake rates of glucose
derivatives or L-glucose by the transporter when expressed in Xenopus laevis
oocytes223,102,133, but this does not reflect the expression of the transporter in
vivo. It is also difficult to obtain the specific activity of the parasite glucose
transporter from data describing the uptake of labelled glucose in infected ery-
throcytes116,74. In isolated parasites Saliba et al.179 investigated the uptake of
2-deoxy-D-glucose(2DOG), at times greater than 20 seconds, which may not
reflect zero-trans influx kinetics. Goodyer et al.74 estimated that the Vmax of
the parasite transporter was a factor of 2 to 4 less than the RBC transporter
rate, which is in agreement with the observations that uptake for 2DOG into
P. falciparum was extremely rapid116,179. In erythrocytes, it has recently been
shown that unless uptake is measured in less than 30 ms, the rate is underes-
timated and does not reflect zero-trans influx kinetics15.
To determine the maximal uptake rate of glucose into the parasite, we inves-
tigated the uptake of 14C D-glucose into isolated trophozoites with a simple
quench flow device (Appendix B). This device enabled us to observe uptake
rates within 0.25 s, which was essential for measuring zero-trans flux kinet-
ics. Knowing the concentration of internal 14C label after a specific sample
time makes it possible to determine the uptake rate (i.e. change in internal
glucose per time). However, the sampling time has a large influence on the
perceived uptake rate. It is expected that at sufficiently short sampling times,
the change in internal label is expected to reflect only an increase in internal
glucose and not metabolised glucose (i.e. labelled intermediate metabolites).
The transport rate determined under these short sampling times would repre-
sent a zero-trans flux rate. At longer sampling times, as glucose is metabolised,
the change in 14C label concentration would include labelled glycolytic metabo-
lites. Uptake rates calculated at these longer time intervals would consequently
be lower than the zero-trans uptake rate. To ascertain the sampling time re-
quired to measure zero-trans uptake in P. falciparum trophozoites, we deter-
mined the glucose uptake rate within a range (0.2 - 60 s) of sampling times.
The calculated uptake rates were normalised to total protein and are shown in
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semi-logarithmic space (Fig. 3.13). The uptake rate increases almost exponen-
tially (linear region within semi-logarithmic plot) as the sample time decreases
below 5.1 s (Fig. 3.13). To obtain the y-intercept value, which represents the
transporter maximal carrying capacity, v, (v = Vmax·s
s+Ks ) a linear regression was
performed on the data between 0.25 and 5.1 s. This time range was selected
as it falls within the linear region on the semi-logarithmic plot. The two data
points below this time were excluded from the regression as they were deter-
mined near the dead time of the quench flow device, and are expected to have
a larger degree of error. The data points above 5.1 s were excluded as the
uptake rate is no longer reflecting zero-trans uptake. During the assay, the
substrate concentration,s, is 5 mM and the Ks is 1.8 mM (Table 3.13). By
taking the antilogarithm of the fitted y-intercept value (-0.819 ± 0.157), v, and
substituting the aforementioned parameters into the equation, the Vmax value
is determined to be 0.207 (0.143, 0.296) µmol·min−1·mg−1 with the lower and
upper limits indicated in parentheses. The lower and upper limits were ob-
tained by taking into account the standard error of the linear regression when
solving for Vmax. The uptake rates determined below 0.25 s are expected to
have a high degree of experimental error, but do indicate that the maximal
uptake rate may indeed by higher than determined from the linear regression.
To ensure that this does not bias model predictions, the model simulations
(e.g. steady fluxes) in this thesis include an upper and lower boundary value
obtained by also performing the simulations with the glucose transporter Vmax
set to 1.0 and 0.1 µmol·min−1·mg−1, respectively.
It should be noted that Kirk et al.116 found that for P. falciparum infected
erythrocytes, the internal and external concentrations of "non-metabolisable"
2-deoxy D-glucose (2DOG) equilibrated within a minute. In our studies where
the labelled glucose is metabolised by hexokinase and subsequent enzymatic
reactions, it is not expected that internal and external glucose concentrations
would equilibrate. In our assays, the internal concentration of label (i.e sum
of a labelled metabolites) attained 1.6 mM over a period of 10 min, compared
to the 5 mM external glucose concentration.
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Figure 3.13: The specic activity of the glucose transporter PfHT1 as a function
of quench time. A simple quench ow device allowed the study of labelled D-glucose
uptake into isolated trophozoites. The rate of uptake (change in internal14C label
concentration per time and normalised to total protein) was determined at sampling
times ranging between 0.2 and 60 s and presented in a semi-logarithmic form. To
calculate the carrying capacity of the glucose transporter a linear regression was
performed on the data between 0.25 and 5.1 s and the y-intercept value was used
to determine the Vmax (see text for details). The data are the combination of
four biological repeats. Individual data points that are shown were determined in
singleton. Error bars represent the mean SEM (n >2).
Due to error in measuring the uptake rate at low quench times, theK m of
the transporter was determined by assaying the change in rate as a function of
external glucose at a 2 second sampling time (Fig. 3.14). The kinetic data were
tted to a reversible Michaelis-Menten equation (Eq. 3.3.15) and binding was
assumed to be symmetrical, where the Michaelis constant for external glucose
(K Glcext ) is the same as for internal glucose (K Glc int ). The K m of 1.8 mM 
0.99 mM is higher than determined by others, but comparable considering the
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Table 3.13: Summary of the kinetic parameters for P. falciparum hexose transport.
The P. falciparum hexose transporter was been characterised in terms of its maximal
specific activity and affinity for glucose. VGlcTr is calculated from Fig. 3.13 (see text
for details) and displayed with the lower and upper limit in parentheses.
Parameter Fitted Value Literature Value Reference
KGlcext (mM) 1.8 ± 0.99 0.48, 1.0, 0.97 223,222,102
VGlcTr (µmol·min−1·mg−1) 0.21 (0.14 - 0.30) - -














Figure 3.14: Kinetic characterisation of P. falciparum PfHT1. The glucose trans-
porter was biochemically characterised for glucose uptake in isolated trophozoites.
Individual data points are presented for the rate of glucose transport determined in
two independent experiments (sampled at 2 s) each normalised to their respective
Vmax values. The data follows Michaelis-Menten kinetics with a Km of 1.8 ± 0.99
mM.
3.3.1.14 Lactate and pyruvate transporters
Human erythrocytes facilitate the removal of internal lactate into the blood
stream via i) a specific H+ monocarboxylate transporter, ii) the band 3 an-
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ion exchanger, and iii) by diffusion of the protonated form across the lipid
bilayer115. The capacity of these pathways, however, is calculated to be in-
sufficient for the increased production of lactate by Plasmodium during infec-
tion109,115. Lactate is transported from the parasite into the host cytosol via
a pyruvate/lactate-proton cotransporter, which shares many characteristics of
the monocarboxylate transporter (MCT) family57. The transport of pyruvate
or lactate is H+ linked with a 1:1 stoichiometry and saturable57.
Elliot et al.57 characterised the P. falciparum transporter in terms of both
lactate and pyruvate influx and to a lesser degree, efflux. The transport kinet-
ics are summarised in Table 3.14. They fitted the transporter kinetics to Eq.
3.3.17, where monocarboxylate refers to the concentration of either lactate or
pyruvate, Km is the Michaelis constant, Vmax is the maximal specific activity
and Kd was included as a linear component to fit their data.
The Vmax is in the units (mmol H+min−1 ·L cell water−1). Using the conver-
sion factor of 4.67 µL cytosol·mg total protein−1 determined in this work, the
Vmax for lactate and pyruvate influx become 0.44 ± 0.028 and 0.16 ± 0.037
(µmol·min−1 · mg−1 respectively. These rates were determined at an assay
temperature of 4 ◦C, and as such the rates are expected to be substantially
faster at 37 ◦C. The Vmax rates were assumed to be 8 fold greater, based on
the rule of thumb that the rate doubles for every increase of 10 ◦C. This rough
rule is based on the Arrhenius equation (Eq. 3.3.16), where k is the rate con-
stant, EA is the activation energy, R is the universal gas constant, T is the
temperature in kelvin and A is the pre-exponential factor. If one assumes that
A and EA remain constant with temperature and that the activation energy
is between 10 and 50 kJ/mol, the rate would increase between 2 and 10 fold
respectively for a 33 ◦C change in temperature.
k = A · e
EA
R·T (3.3.16)
To model the reversible transport of pyruvate and lactate, Eq. 3.3.17 extended
to a reversible random order bi-bi equation with the addition of the mass action
linear component (Eq. 3.3.18). The affinity of protons for the transporter has
not been determined and for simplicity it is assumed that they have an almost
infinite affinity, which reduces Eq. 3.3.18 to the simpler form of Eq. 3.3.19.
Although the kinetic component of protons is removed from the equation, the
thermodynamic component of the pH gradient is still taken into account by
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the disequilibrium ration, Γ. The intracellular pH of P. falciparum strains has
been shown to vary between 7.17 and 7.4178,224,16,80,225. The average pH was
taken as 7.2 and the erythrocyte cytosolic pH set to 6.9. The erythrocyte pH is
generally considered to be 7.1224,16,225, but it has been shown that immediately
adjacent to the parasite, the pH is a fraction lower at 6.980. The ratio of
extracellular to intracellular proton concentration is thus two and incorporated
into the disequilibrium ratio. Lactate and pyruvate bind competitively to the
monocarboxylate transporter and Cranmer et al.44 showed that the transport
rate was inhibited by 44 ± 10% (mean ± SEM, n = 4) at 0.5 mM lactate and
2.5 mM pyruvate. To incorporate this into the rate equation, two competitive
inhibition terms are included into Eq. 3.3.19, yielding Eq. 3.3.20. Binding of
protons, lactate and pyruvate was assumed to symmetrical and the inhibition
constants for pyruvate and lactate, Kilac and Kipyr, were fitted (Table 3.14),
such that equations 3.3.20 & 3.3.21) are inhibited by 44% at 0.5 mM lactate
and 2.5 mM pyruvate.
H+influx = Vmax · [monocarboxylate]
Km + [monocarboxylate]
























) + kd · (Lacint − Lacext) (3.3.18)
Assuming KH+intand KH+int → 0,
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) + kd · (Lacint − Lacext) (3.3.19)
Where Γ = H
+ext · Lacext
H+int · Lacint
and H+ = 10−pH

































) + kdPyr · (Pyrint − Pyrext) (3.3.21)
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Table 3.14: Summary of kinetic parameters for P. falciparum lactate and pyruvate
transport obtained from scientific literature. In P. falciparum lactate and pyruvate
are transported by the same monocarboxylate transporter, which has been biochem-
ically characterised by Cranmer et al.44 and Elliot et al.57. Eqs. 3.3.20 & 3.3.21
are used to describe the reversible transport and competitive inhibition between
pyruvate and lactate. The parameters for these equations are tabulated below.
Symmetrical binding (internal/external) is assumed for pyruvate and lactate as de-
noted by the int/ext subscript. The inhibition constants were obtained by fitting
these equations to data reported by Cranmer et al.44.
Parameter Parameter Value Reference
VLacTr (mmol H+min−1L cell water−1) 94 ± 6.01 57
VPyrTr (mmol H+min−1L cell water−1) 34 ± 8.01 57
KPyrint/ext (mM) 16 ± 3.3 57
KLacint/ext (mM) 3.8 ± 0.80 57
kdPyr (min−1) 0.11 ± 0.010 57





1 In the model these rates are normalised to µmol·mg−1·mg−1 total protein using a conversion
factor of 4.67 µL cytosol·mg total protein−1 .
2 Eqs. 3.3.20 & 3.3.21 were fitted to obtain 44% inhibition at 0.5 mM lactate and 2.5 mM
pyruvate as determined by Cranmer et al.44.
3.3.1.15 ATPase
P. falciparum utilises the nett ATP produced during glycolysis in a variety of
biosynthetic and homeostatic processes. This rate of ATP consumption, how-
ever, cannot be measured experimentally, since ATP is used for a variety of
biosynthetic and homeostatic reactions. For simplicity we define a single ’AT-
Pase’ reaction, which includes all of the cellular ATP demand. In the model
this ATP demand is described by simple mass action kinetics (Eq. 3.3.22),
where VATPase is the reaction rate constant. The intracellular ATP:ADP
has been experimentally measured to be between 1 (glucose starved) and
5.7178,37,68,204. To obtain an ATPase rate for the model (see Model Descrip-
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tion), we fitted the VATPase (0.035 min−1) to obtain a steady state ATP:ADP
ratio of 3.
vATPase = VATPase · atp (3.3.22)
3.3.2 Maximal Specific Activities
Asexual Plasmodium develops over 48 hours, with glycolytic flux peaking dur-
ing the trophozoite stage. When Plasmodium is isolated from the infected
erythrocyte, the degree of synchrony and the exact point in the developmental
cycle is expected to vary between isolates. This would alter total protein, and
if the enzymes are expressed to different degrees, it would have an impact on
the Vmax2 determinations. In order to counter this variation, specific activi-
ties were determined for a large number of different trophozoite isolations at
saturating or near saturating concentrations of substrate. Total protein was
determined using the method of Bradford19 and bovine serum albumin as a
standard. These specific activities were adjusted to Vmax by substituting the
substrate concentrations into the fitted rate equations and dividing the specific
activity by corresponding v
Vmax
ratio. The Vmax values for each of the enzymes
characterised in this work are shown in Table 3.15 and Figure 3.15.
2The Vmax values presented in this study were determined in trophozoite lysates and
are normalised to mg total protein. These are thus not true Vmax values, which are instead
normalised to mg pure enzyme protein.
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Figure 3.15: Comparison of the Vmax values of the P. falciparum glycolytic en-
zymes. The maximal specific activities for each of the glycolytic enzymes of P.
falciparum were determined from numerous trophozoite isolations to ensure a good
representation of the enzyme activities at this stage of parasite development. Each
Vmax includes the values obtained during the biochemical characterisation (satura-
tion curves). In addition, the enzymes were assayed in several independent isolations
(n displayed in figure) at near saturating concentrations of substrate and these were
adjusted to represent Vmax. The error bars represent SEM, where n is displayed
for each enzyme. The subscript fwd and rev, refer to the forward and reverse rates
respectively.
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Table 3.15: Maximal specific activity for each of the glycolytic enzymes in P. fal-
ciparum as measured in this study. Both the forward and reverse reaction activities
are indicated. Error is given as SEM, n is displayed below.
Enzyme Maximal Specific Activity (µmol·min−1·mg−1)
Forward n Reverse n
HK 0.32 ± 0.076 15 - -
PGI 3.7 ± 0.37 17 1.4 ± 0.26 14
PFK 0.42 ± 0.084 17 - -
ALD 0.70 ± 0.049 25 - -
TIM 7.0 ± 1.0 13 15 ± 0.74 3
G3PDH 4.0 ± 0.23 4 1.2 ± 0.25 23
PGK - - 1.7 ± 0.36 24
PGM 0.87 ± 0.072 22 0.35 ± 0.14 3
ENO 1.3 ± 0.41 24 0.94 ± 0.44 2
PK 1.1 ± 0.16 24 - -
LDH 2.5 ± 0.23 32 1.4 ± 0.18 7





vGlcTr 0.21 (0.14 - 0.30)3 4
1 Obtained from57. See Section 3.3.1.14 for details.
2 Fitted to the glycerol flux. See Section 3.3.1.12.
3 Lower - Upper Limit
3.3.3 Model Description
3.3.3.1 Rate Equations, Moieties and Parameters Values
The model consists of eighteen reaction steps (Fig. 3.1), which describe the
glycolytic conversion of glucose to its end products, lactate, pyruvate and glyc-
erol with the concomitant production of ATP, as well as the transport of these
metabolites in and out of the P. falciparum trophozoite. In the above results,
each reaction step has been described by a kinetic rate equation obtained by
fitting to experimental data or from scientific literature in the case of monocar-
boxylate transport (pyruvate and lactate). Only two reactions were fitted, the
first being the ATPase rate as it cannot be measured experimentally and the
second reaction being the Vmax for the GlrDH enzyme in the glycerol pathway
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 3. ENZYME KINETICS AND MODEL CONSTRUCTION 75
as this pathway has yet to be elucidated.
The transport rates of glucose, pyruvate and lactate are described by vGlcTr,
vPyrTr and vLacTr respectively (Eqs. 3.3.23,3.3.37 & 3.3.38). Glycerol pro-
duction and transport is described by vGlrDH (Eq. 3.3.35). The glycolytic
enzyme rates are described by vHK (hexokinase, Eq. 3.3.24), vPGI (phos-
phoglucoisomerase, Eq. 3.3.25), vPFK (phosphofructokinase, Eq. 3.3.26),
vALD (aldolase, Eq. 3.3.27), vTIM (triosephosphate isomerase, Eq. 3.3.28),
vG3PDH (glyceraldehyde 3-phosphate dehydrogenase, Eq. 3.3.29), vPGK
(phosphoglycerate kinase, Eq. 3.3.30), vPGM (phosphoglycerate mutase, Eq.
3.3.31), vENO (enolase, Eq. 3.3.32), vPK (pyruvate kinase, Eq. 3.3.33) and
vLDH (lactate dehydrogenase, Eq. 3.3.34). ATP consumption is described by
vATPase (Eq. 3.3.36). The parameter values obtained for each rate equation
are described above and are summarised in Tables 3.15 & 3.16.
Asexual P. falciparum resides within the erythrocyte and to model the P. fal-
ciparum "compartment", two changes were made to the rate equations. Firstly,
the Vmax values were in the units µmol·min−1 · mg−1 total protein and these
were changed to mmol·min−1 · L cytosol−1 by multiplying each Vmax by the
parasite volume and by the factor α (4.67 µL cytosol·mg−1 total protein, which
was determined assuming a trophozoite cytosolic volume of 28 fL). The second
change to the rate equations was to explicitly include the compartment volume
for each metabolite. Thus in each rate equation, the P. falciparum metabolites
are divided by the P. falciparum trophozoite cytosolic volume (VPf ) and for
the external metabolites (i.e. in the erythrocyte), are divided by the external
volume (VRBC). The volume of the trophozoite has been measured to be be-
tween 21 and 30 fL2 and in this study, is assumed to be 28 fL. These changes
were made in order to model in terms of mole quantity and not concentration
(e.g. mM) and has the advantage that the model can easily be integrated
as a separate compartment into a model of erythrocyte glycolysis. The ex-
ternal concentrations (subscript ext in the rate equations) of glucose, lactate,
pyruvate and glycerol were fixed (Table 3.17) for steady state analysis. The
remaining metabolites were always variables as a function of time, denoted in
the rate equations by metabolite[t].
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The model has two conserved moieties, where the concentration of NAD+ +
NADH and ATP + ADP remains constant (Eqs. 3.3.39 & 3.3.40). The total
concentration of the adenosine phosphate moiety was set to 3.0 mM and the
NAD+ moiety set to 3 mM (Table 3.17). The total ATP + ADP moiety con-
centration has been measured experimentally to be between 3 and 4 mM178,204,
although Choi and Mikkelsen37 reported a value of 0.9 mM. For the model we
use the value of 3 mM, which is in agreement with the aforementioned studies.
Typically the cytosolic concentration of unbound NAD+ greatly exceeds that
of NADH65, and for instance in rat liver cytoplasm, an NAD+:NADH ratio of
approximately 700 has been measured220. In P. falciparum NAD+ has been
measured to be approximately 3 mM204, and assuming a high NAD+:NADH
ratio, this concentration is representative of the total moiety concentration
and is used as such.
NAD+ + NADH = [Total NADH Moiety] (3.3.39)
ADP + ATP = [Total ATP Moiety] (3.3.40)
3.3.3.2 Ordinary Differential Equations and Starting Conditions
The model consists of 18 ODEs (Eqs. 3.3.41 - 3.3.56), which describe the
change in concentration of external metabolites (glucoseexternal, lactateexternal,
pyruvateexternal and glycerolexternal (Eqs. 3.3.41, 3.3.56-3.3.58) and as well as
each of the internal metabolites (Eqs. 3.3.42-3.3.53) and ADP (Eq. 3.3.54)
and NAD+ (Eq. 3.3.55) as a function of time and enzyme rates. ATP and
NADH are not modelled explicitly, as they form part of moiety conserved
cycles (Eqs. 3.3.39 & 3.3.40). As such, the concentration of ATP and NADH
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can be calculated from the total moiety sum.
Glucoseexternal′[t] = −vGlcTr (3.3.41)
Glucoseinternal′[t] = vGlcTr− vHK (3.3.42)
G6P′[t] = vHK− vPGI (3.3.43)
F6P′[t] = vPGI− vPFK (3.3.44)
F1,6BP′[t] = vPFK− vALD (3.3.45)
DHAP′[t] = vALD− vTIM− vGlrDH (3.3.46)
GAP′[t] = vALD + vTIM− vG3PDH (3.3.47)
B1,3PG′[t] = vG3PDH− vPGK (3.3.48)
PGA3′[t] = vPGK− vPGM (3.3.49)
PGA2′[t] = vPGM− vENO (3.3.50)
PEP′[t] = vENO− vPK (3.3.51)
Pyrinternal′[t] = vPK− vLDH− vPyrTr (3.3.52)
Lacinternal′[t] = vLDH− vLacTr (3.3.53)
ADP′[t] = vHK + vPFK− vPGK− vPK + vATPase (3.3.54)
NAD′[t] = vLDH− vG3PDH + vGlrDH (3.3.55)
Glyexternal′[t] = vGlrDH (3.3.56)
Pyrexternal′[t] = vPyrTr (3.3.57)
Lacexternal′[t] = vLacTr (3.3.58)
The presence of new permeation pathways and increased permeability of the
parasitised erythrocytes to a variety of solutes115 led to the assumption that
the concentrations of glucose, lactate, pyruvate and glycerol experienced by
the intracellular parasite, would be similar to those found in the human blood
plasma. On this basis, the concentrations glucose, lactate, pyruvate and glyc-
erol in the model were fixed at concentrations found in the blood plasma of
healthy and mildly infected patients (Table 3.17).
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Table 3.17: External metabolite concentrations and moiety concentrations. In the
model the external metabolite concentrations were fixed at concentrations similar to
those found in the blood plasma of healthy to mildly infected malaria patients. The
total moiety concentrations of ATP:ADP and NADH:NAD+ were set to represent
concentrations measured in scientific literature.
Concentration (mM)
Fixed Parameter Model Literature Reference
Glucose external 5.0 4.0 - 6.0 1,60
Lactateexternal 2.0 2.0 - 5.0 210,118
Pyruvateexternal 0.20 0.13 - 0.35 118
Glycerolexternal 0.15 0.10 - 0.20 163,78
ATP + ADP moiety 4.0 0.90 - 4.4 37,178,204
NADH + NAD+ moiety 3.0 2.9 ± 0.50 204
3.3.3.3 Steady state analysis
The initial concentrations of each of the variable metabolites were set to ap-
proximately their steady state concentrations (Table 3.18). These conditions
could be varied (as long as total moiety concentrations remained the same),
without impacting the steady state fluxes and concentrations. The model at-
tains steady state under the conditions described above and the resulting fluxes
and metabolite concentrations are given in Table 3.18.
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Table 3.18: Kinetic model initial conditions and steady state predictions. The
starting concentrations and the steady state metabolite concentrations and fluxes
as described by the model of P. falciparum glycolysis are summarised below. The
external metabolites were clamped at concentrations that are found in mildly malaria
infected patients (Table. 3.17).
Metabolite Concentration (mM) Flux Rate
Initial Steady State (µmol·min−1 ·mg−1)
Glucose 3.0 2.8 JGlcTr 0.0486
G6P 3.0 2.5 JLacTr 0.0920
F6P 1.0 0.8 JGlyTr 0.00512













The steady state glycolytic flux is remarkably similar to that found for another
human parasite, T. brucei (0.07 vs. 0.05 µmol·min−1 ·mg−1protein) and the 1:1
ratio of glycerol and pyruvate flux is as expected to balance the loss of NADH
reduction due to pyruvate export. The steady state metabolite concentrations
look physiologically feasible, with no concentrations being abnormally high or
low.
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3.4 General Discussion
In this study we have followed a bottom up approach for constructing a model
of P. falciparum glycolysis. Bakker et al.7 (T. brucei) and Teusink et al.
(yeast)205 used bottom up approaches similar to the approach in this study to
try to understand glycolysis on the basis of the pathway kinetics alone. The
lack of kinetic parameters available in the scientific literature for P. falciparum
prevented the method of Bakker et al, who utilised numerous parameters from
scientific literature, and necessitated an approach similar to van Eunen et al.215
and Teusink et al.205 who characterised a number of enzymes.
We have presented the thorough biochemical characterisation of each P. falci-
parum glycolytic enzyme and incorporated the resulting rate equations into a
detailed kinetic model. In this study, most of the kinetic data were fitted to
simple reversible Michaelis-Menten (uni-uni reactions) or random order rapid
equilibrium (bi-bi reactions) "convenience" equations126,41. It is not expected
that all of the bi-bi reactions have random binding order, but the kinetic be-
haviour is well described by these equations. For the purposes of this work,
the exact enzyme mechanism is not essential as the aim of the work was not to
understand the underlying mechanism of each glycolytic enzyme, but rather
to see if the combined kinetics can describe glycolysis. As such, exact enzy-
matic mechanisms were not determined, as long as a mechanism based rate
equation (e.g. random order bi-bi) could describe the kinetic behaviour over
the physiological concentrations ranges of respective substrate, product and
allosteric effectors.
This discussion does raise the matter of using phenomenological versus mecha-
nistic rate equations. In systems biology it is not a necessity that a reaction be
described by a mechanistic equation, since a model consisting of phenomeno-
logical equations (that describe kinetic behaviour of each enzyme adequately)
would have similar global predictions of flux and metabolite concentrations
when compared to a mechanism based model. Mechanistic based equations
have the advantage that the parameters are clearly defined (e.g. half saturation
constants), which also provides a standard for the comparison of parameters.
The latter point is of paramount importance when utilising parameters from
databases or scientific literature. Detailed mechanism based equations (e.g.
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 3. ENZYME KINETICS AND MODEL CONSTRUCTION 84
ping pong, random order equations), however, are cumbersome as they con-
tain numerous kinetic parameters, which require a substantial amount of ex-
perimental data for fitting the parameters41,172. Somewhere in between purely
phenomenological and detailed mechanism based equations are so-called gen-
eralised equations such as presented by Hanekom et al.172, Liebermeister et
al.126 and Cornish-Bowden et al.41. These generalised equations have well
defined constants, incorporate thermodynamic principles, can describe a wide
variety of enzymatic behaviour, but consist of fewer parameters than a detailed
equation, which can thus be readily determined experimentally.
This work builds on the work of others and increases our knowledge of P.
falciparum glycolysis at a biochemical level. At an enzyme level we found
few allosteric regulators, but this work has highlighted PEP, ADP and ATP
as being important for the regulation of PFK, PK and TIM activity. The
regulation of TIM and PK by PEP has recently been proposed to play a role
in controlling the redox metabolism in yeast77. The regulation of the same
enzymes in P. falciparum by PEP may thus serve a similar purpose.
The model, as well as all of the kinetic data, is available for viewing, in-
terrogation or download on JWS online (http://jjj.biochem.sun.ac.za). The
online version has the advantage that a user can analyse and interrogate the
model without specialised software or skills. The availability of the kinetic
data are provided for two purposes i) a user can see the description of the
kinetic data and ii) it allows a user to fit custom equations to the data, which
is of particular interest to someone incorporating the data into a larger dataset
and fitting the combination of the data to more detailed or simplified equation.
The compilation of the kinetic model described in this work provides a good
tool for understanding glycolysis in terms of the underlying kinetics as well
as for identifying potential drug targets. In the work by Bakker et al. and
Teusink et al., the fluxes and metabolites concentrations could be described
by models composed of glycolytic enzyme kinetics and it appears it may do
so for P. falciparum. The current model reaches steady state with physiolog-
ically feasible steady state metabolite concentrations and fluxes and provides
the foundation for further investigating and analysis. To investigate if the
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kinetics can describe glycolysis in P. falciparum the model predictions will
be compared to metabolic fluxes and metabolite concentrations in vivo in the
next chapter. A model validated in this manner promises to be an important
heuristic tool for drug discovery in P. falciparum glycolysis.
3.5 Conclusion
We have described a systematic approach to modelling the glycolytic pathway
of asexual P. falciparum. Each of the enzymes was biochemically characterised
and its kinetic behaviour described by a mechanistic rate equation. The in-
tegration of all the rate equations into a kinetic model has yielded a tool to
analyse the behaviour of the system as a whole. The model predicts phys-
iologically relevant steady state fluxes as well as metabolite concentrations.
The individual kinetics indicate the importance of ATP, ADP and PEP as
modulators of enzyme activity and suggest that they may be important for
the regulation of P. falciparum glycolysis. Further analysis of the model is
expected to yield insight into the regulation of the system, as well as identify
the enzymes that are most important in controlling Plasmodium glycolysis.




Construction of a detailed kinetic model
of asexual Plasmodium falciparum glycolysis,
Part 2: Model validation and analysis
Penkler, G.P1, Adams, W.P.2, Rautenbach, M., Snoep, J.L.
4.1 Introduction
Malaria infection results in the death of millions of people annually, most of
who are children under the age of 5 (WHO, Annual Report 2011). Wide
spread drug resistance to most frontline antimalarials has promoted initia-
tives to combat Plasmodium spp. at many levels ranging from combating the
mosquito vector, to targeting various stages of the parasite life cycle within
the human host. In the asexual phase, Plasmodium spp. derives most of its
ATP from glycolysis and as such, this pathway has been investigated as a
potential drug target. Phosphoglucoisomerase202, aldolase219, triosephosphate
isomerase216,106, phosphoglycerate kinase148 and lactate dehydrogenase34,73,20
have been proposed as drug targets and inhibited in vitro. These enzymes
have been investigated in isolation, but to date, the role of these enzymes in
the pathway as a whole has not been considered.
To examine a pathway as a whole, the field of systems biology provides a
1Is responsible for all of sample generation, and all analysis of experimental and theoret-
ical data presented in this chapter. The data from two unlabelled-glucose flux experiments
presented in my M.Sc. thesis were incorporated with experimental fluxes determined with
14C labelled glucose and further unlabelled-glucose flux experiments (Section 4.3.1).
2Adams, W., was responsible for the HPLC analysis of the 14C external metabolite
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variety of frameworks such as Metabolic Control Analysis (MCA), Hierarchi-
cal Regulation Analysis, Elementary Mode Analysis, Metabolic Flux Analysis,
Flux Balance Analysis (these methods are reviewed by Geenen et al.71) and
supply-demand analysis89.
MCA, developed independently by Kascer & Burns107 and Heinrich & Rapoport168,82,
is a theoretical framework that defines coefficients that quantify i) the rela-
tive change in steady state systemic properties (e.g. steady state flux, J, or
metabolite concentration, c) due to a small change in a reaction step (i.e. en-
zyme rate, v), defined as flux or concentration control coefficients (CJv = d ln Jd ln v
and Ccv = d ln cd ln v respectively) and ii) the relative change in a local property such
as an enzyme rate (v) due to a small change in an effector or substrate concen-
tration, as elasticity coefficients (εvs = ∂ ln v∂ ln s ). The systemic control coefficients
can be expressed in terms of local elasticity coefficients via connectivity and
summation theorems88.
As such MCA makes it possible to quantitatively understand the systemic
properties in terms of the properties of each reaction step. For more detail on
MCA and its formulation, refer to reviews by Fell et al.64 and Hofmeyr87.
The summation theorem for the flux control coefficients is useful at it means
that the control of flux and metabolites may be distributed across the enzymes
in the pathway and moves away from the idea of a ’rate limiting’ step. This
has important implications for drug target identification within a metabolic
network.
As previously stated, the glycolytic enzymes of Plasmodium spp. have been
studied in isolation and proposed as drug targets without taking into consid-
eration the pathway as a whole. Targeting an enzyme, which has a low control
of the flux, would require a high degree of inhibition and this has repercus-
sions in terms of toxicity for the host unless it is highly specific. Targeting a
flux-controlling enzyme or better yet, a number of flux-controlling reactions138
would be preferable. Targeting the enzymes of Plasmodium spp. glycolysis is
challenging as there is often a high degree of homology between the human
and parasite glycolytic enzymes (Chapter 2). Obtaining drug specificity is
thus crucial. Or is it? Consider a reaction step that has a high flux control
in the parasite, but the same reaction has low control in the host. Inhibition
of such a step would have a much greater effect on the parasite than on the
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host, even if the drug would inhibit parasite and host enzyme to the same
degree. Applying such a differential control approach has been proposed as a
tool for drug target identification8,98 and has been utilised by Bakker et al.8 to
identify the Trypanosoma brucei glucose transporter as a potential drug target.
A detailed mathematical model in combination with MCA could be impor-
tant tools for drug target identification. The strength of such an approach
is largely dependent on the accuracy of the model. This can be assessed via
model validation. A typical method of validating models is to compare model
predictions to independent experimental datasets (i.e. data not used for model
construction).
A more substantial form of validation would be to compare model predictions
to experiments where specific perturbations are made to the system. These
perturbations could include inhibiting a single step or multiple reactions, in-
creasing an enzyme activity (i.e. by over expressing a particular enzyme), or
deleting a step (i.e. knockout strain). However, these perturbations are often
complex to perform experimentally and it is also difficult to ascertain if a per-
turbation of a certain step is not also perturbing a variety of other reactions.
What then can be considered a good validation and perhaps even more im-
portantly, a sufficient validation?
A perfect model would include the entire system and accurately describe the
response of the system to a wide range of perturbations. This is perhaps the
holy grail of systems biology - the silicon cell - a model that is able to describe
every reaction, pathway and interaction at a macromolecular level200. Sys-
tems biology models are tools to further our understanding of a system, and
validation should give i) a measure of confidence using the model as a tool to
investigate the system and ii) support for predictions and hypotheses derived
from model analysis.
Evaluating the responses of a model to parameter perturbations is another
important part of validation. Such an assessment is made in a sensitivity
analysis, and is a useful means of critically examining whether a parameter or
set of parameters is unduly influencing the model output. A method of sensi-
tivity analysis that is often used, is to vary each parameter value by a small
degree and quantify the relative increase or decrease in a systemic property
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(i.e. flux or metabolite concentrations). These effects can be quantified as
response coefficients 108 and are useful in identifying parameters that severely
influence model output. Ideally, parameters that substantially influence the
model should be determined as accurately as possible. More comprehensive
global sensitivity analysis methods (see Saltelli et al.180 for review) simultane-
ously vary all parameters within a given range (compared to a small change in
the case of response coefficients). These methods quantify the relative contri-
bution of each parameter (first order) or combination of parameters (multiple
order) to the variation observed in the model output. Such methods are com-
putationally expensive and more technical to implement, but do provide a
more comprehensive examination of the parameter set.
In the previous chapter (Chapter 3) we constructed and described a detailed
kinetic model of asexual P. falciparum glycolysis during the trophozoite phase.
In this chapter we examine if the model, on the basis of the enzyme kinetics
alone can describe the glycolytic flux and metabolite concentrations in vivo.
Following this validation, we analyse the model with a sensitivity analysis and
MCA, and compare the results with drug targets suggested in the scientific
literature. The validated model provides a useful heuristic tool for improving
our current understanding of P. falciparum glycolysis.
4.2 Methods
For reference each of the enzyme abbreviations are defined as follows: HK,
hexokinase; PGI, phosphoglucoisomerase; PFK, phosphofructokinase; ALD, al-
dolase; TIM, triosephosphate isomerase; G3PDH, glyceraldehyde 3-phosphate
dehydrogenase; PGK, phosphoglycerate kinase; PGM phosphoglycerate mutase;
ENO, enolase; PK, pyruvate kinase; LDH, lactate dehydrogenase; αGlyPDH,
glycerol 3-phosphate dehydrogenase; G6PDH, glucose 6-phosphate dehydroge-
nase
Each of the metabolites used in this work are abbreviated as follows: G6P, glu-
cose 6-phosphate; F6P, fructose 6-phosphate; F1,6BP fructose 1,6-bisphosphate;
DHAP, dihydroxy acetone phosphate; GAP, glyceraldehyde 3-phosphate; B1,3PG,
bis 1,3-phosphoglycerate; 3PGA, 3-phosphoglycerate; 2PGA, 2-phosphoglycerate;
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PEP, phosphoenolpyruvate.
Reagents were obtained from Sigma Aldrich, unless otherwise stated.
4.2.1 Culturing and isolation of P. falciparum
P. falciparum D10 was routinely cultured in A+ erythrocytes (obtained from
the Western Province blood bank, South Africa) at 3 - 4% v/v haematocrit
in culture medium consisting of RPMI 1640, 0.5% m/v Albumax II®, 22 mM
glucose, 25 mM HEPES, 3 mM hypoxanthine and 50 µg/mL gentamicin sul-
phate, under 3% oxygen, 4% carbon dioxide and 93% nitrogen at 37 ° C as
described elsewhere (36, 146). Synchronisation of the cultures was maintained
by centrifuging the infected erythrocytes (750 × g, 3 min) and suspending
the pellet in 5% m/v sorbitol97. Following 5 min incubation at 37 ° C and
centrifugation (750 × g, 3 min), the pellet was suspended in culture media
and cultured as described above. Sorbitol destroys all but the ring stage par-
asites97, ensuring that they are kept in phase. Isolation of trophozoites was
achieved using a saponin lysis protocol178, which permeabilises the erythro-
cyte and parasitophorous vacuolar membrane by interacting with the choles-
terol found in these membranes3,4. More than 95% of parasites isolated in
this manner can maintain a transmembrane potential and exclude 0.04% v/v
trypan blue177. Saponin (0.05% m/v and 0.005% w/w active component sa-
pogenin) was added to infected erythrocytes suspended in culture medium
(typically 5% v/v haematocrit). After mixing by inversion, the suspension
was centrifuged (1800 × g, 7 min). Upon removal of the supernatant, the
parasites were washed twice in culture medium or a buffer of choice.
4.2.2 Flux and Internal Metabolite Experiments
For the glycolytic flux and metabolite determination experiments, trophozoites
were isolated, washed twice and suspended in incubation a modified Ringer
buffer (5 or 10 mM glucose, 50 mM HEPES, 1 mM MgCl2, 10 mM KCL, 120
mM NaCl, pH 7.1) similar to that described by Wünsch et al.224. In this buffer
the parasites were able to exclude 0.04% v/v trypan blue. Immediately after
suspension, two aliquots were taken for cell counting (Improved Neubauer
Haemocytometer) and total protein determinations (method of Bradford et
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al.19). External metabolites were determined in two ways i) enzymatically
and ii) using a radiolabelled HPLC method with 14C labelled glucose (1:80 ra-
tio) as substrate. For both methods, time point samples of the incubation were
centrifuged (5000 × g, 1 min) and the supernatant i) retained for enzymatic
determinations or ii) added to acetonitrile (70% v/v final) for HPLC deter-
mination (see below). For the determination of internal metabolites at spe-
cific time intervals, aliquots of the cell suspension were taken and metabolism
halted by the addition of 70% m/v perchloric acid (12% m/v final concentra-
tion). Following 1 min sonication and centrifugation (10 min, 20 000xg, 4 °C),
the supernatant was retained for the enzymatic determination of the glycolytic
metabolites. The supernatant was neutralised with 10 M KOH. Samples were
stored at -80°C until analysis.
4.2.3 Enzymatic Glucose, Lactate, Pyruvate and
Glycerol determinations
Extracellular D-glucose was assayed by linking it to NADP reduction via HK
and G6PDH. Samples and standards were incubated at room temperature in
HEPES buffer (50 mM, pH 7.5) containing HK (5 U/mL), ATP (0.2 mM),
G6PDH (10 U/mL) and NADP (0.5 mM). After a 15 minute incubation pe-
riod the absorbance at 340 nm was measured. Extracellular L-lactate was
assayed by using an LDH and NAD+ linked assay. After a 20 min incubation
period at room temperature in HEPES buffer (50 mM, pH 7.5) containing
LDH (10 U/ml), NAD+ (0.2 mM) and hydrazine (16 µL/ml), samples and
standards were measured at 340 nm. Hydrazine binds to pyruvate and thus
thermodynamically drives the unfavourable LDH reaction (reverse) to com-
pletion. Glycerol was measured using the method developed by Eggstein and
Kuhlmann55. Glycerol samples and standards were incubated in assay buffer
(150 mM HEPES (150 mM), MgSO4 (15 mM), pH 7.5) with glycerol kinase
(8.4 U/ mL), PEP (1 mM), NADH (0. 4 mM), ATP (1 mM), pyruvate kinase
(3 U/mL) and lactate dehydrogenase (3.6 U/ mL) and the oxidation of NADH
after 10 min was measured at 340 nm. Pyruvate samples and standards were
incubated in HEPES buffer (50 mM, pH 7.5) containing LDH (10 U/mL) and
NADH (0.1 mM) and the absorbance after 10 minutes measured at 340 nm.
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4.2.4 Enzymatic Determination of Metabolites
The intermediates of upper glycolysis (G6P, F6P, F1,6BP, DHAP and GAP)
were all assayed within a single sample (180 µL) by linking the metabolite
assays to the reduction of NADP via G6PDH or oxidation of NADH via
α-glycerolPDH. G6P was determined by adding G6PDH (1U/mL final) and
NADP (5mM final). Total change in absorbance at 340 nm was determined
upon completion of the reaction. A spike of G6P (20 µM) was added and
change in absorbance determined once the reaction was complete. To the same
sample, PGI (1U/mL final) was added for assaying F6P and again the total
change in absorbance determined. After completion, a 20 µM F6P spike was
added to the mixture. In a similar stepwise (sample/spike) manner, DHAP,
GAP and FBP were determined via NADH (0.8 mM final) and α-glycerolPDH
(1U/mL final, TPI (1U/mL) and aldolase (1U/ml) respectively. Under these
experimental conditions there is a linear dependency between absorbance (340
nm) and metabolite (G6P, F6P and F1,6BP) concentration (2 - 200 µM). The
change in absorbance for the 20 µM intermediate spike was thus used as an
internal standard to determine the concentration of each intermediate within
the sample. The intermediates of lower glycolysis could not be determined
due to high concentrations of lactate and pyruvate in the samples. This pre-
vented the linked determination of PEP and the phosphoglycerates via LDH
and NADH.
Trophozoite counts (Improved Neubauer Haemocytometer) and the assump-
tion of a trophozoite cytosolic volume of 28 fL2 were used to calculate the
intracellular concentration of each metabolites.
4.2.5 Glucose, Lactate, Pyruvate and Glycerol HPLC
Determinations
The method of Antonio et al.5 was employed to determine the concentrations
of the radiolabelled extracellular glucose, lactate, pyruvate and glycerol. An-
tonio et al.5 did not detect glycerol as it ionises poorly in an ESI (electro-spray
ionisation) source. Glucose, lactate, pyruvate and glycerol eluted at 13.4, 6.5,
10.1 and 10.4 min respectively. We confirmed that the eluent at 10.4 min was
glycerol using enzyme determination assays. Briefly, separation occurred on
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a ZIC®-HILIC column (150×7.5mm, 5 µm, 200 Å, SeQuant™, Merck, Darm-
stadt, Germany) fitted with a guard column (20×2.1mm, 5 µm, SeQuant™,
Merck, Darmstadt, Germany) on a HPLC system. The system consists of a
SpectraSYSTEM P4000 pump (Thermo Separation™ products, San Jose, CA,
USA), a SpectraSYSTEM AS3000 autosampler (Thermo Separation™ prod-
ucts, San Jose, CA, USA) and a Flo-One liquid scintillation spectrophotometer
(Radiomatic, Tampa, FL, USA). A flow rate of 1.0 mL/min and an injection
volume of 100 µL were used. Separation occurred at room temperature (25°C).
Mobile phase A consisted of acetonitrile (0.1% m/v formic acid) and mobile
phase B of 5 mM ammonium acetate, pH 4 (0.1% m/v formic acid). The
method was slightly modified by pumping 90% v/v A through the system for
1 min, prior to the initiation of the gradient elution profile. The analogue
intensity (V) data were integrated and analysed with Mathematica 8.0®.
4.2.6 Model Simulations and Analysis
Most of the model simulations presented in this thesis were performed using
Wolfram Mathematica 8.0®. The kinetic model of P. falciparum glycolysis
is available on JWS Online (jjj.biochem.sun.ac.za)201,144 for interrogation or
download in various standard formats. Steady state analysis and metabolic
control analysis was performed both in Wolfram Mathematica 8.0®, JWS On-
line and Copasi96. Parameter sensitivity analysis of the model was performed
using Copasi96.
4.3 Results
In the preceding chapter we reported the construction of a detailed kinetic
model of P. falciparum glycolysis, which consists of mechanistic rate equa-
tions that were obtained from the biochemical characterisation of each of the
glycolytic enzymes. Upon integration of the model, steady state was obtained
and here we aim to validate the model by comparison of the model prediction
to the steady state glycolytic data obtained with isolated trophozoite incuba-
tions. As such we test whether our knowledge of the isolated enzyme kinetics
can describe the glycolytic behaviour of intact trophozoites.
For the model validation we needed to adapt the model minimally by i) setting
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the ATPase rate and ii) adding kinetics to the glycerol branch. P. falciparum
utilises the nett production of ATP during glycolysis in a variety of biosyn-
thetic and homeostatic processes. This rate of ATP consumption, however,
cannot be measured experimentally and had to be fitted. In the model , the
ATPase rate determines the ATP:ADP ratio to some extent and the ATPase
rate was fitted to obtain an ATP:ADP ratio of 3. This is in agreement with
experimentally determined ratios, which vary between 1 (glucose starved) and
5.737,68,178,204.
In asexual P. falciparum the enzymes involved in the production of glycerol
are not yet known and in the model the glycerol 3-phosphate dehydrogenase
is assumed to produce glycerol.
4.3.1 External metabolite fluxes
The complete conversion of 14C glucose to lactate, pyruvate and glycerol was
measured over 90 min in isolated trophozoites (Figs. 4.2 & 4.2). The external
metabolite concentrations were quantified with an HPLC / scintillation counter
method (see methods), which successfully separated each external metabolite
(Fig. 4.1). Glucose, lactate, pyruvate and glycerol eluted at 13.4, 6.5, 10.1
and 10.4 min respectively. Pyruvate and glycerol eluted in quick succession
from the HPLC column. In most of the samples the two peaks could be sepa-
rated and a pyruvate: glycerol ratio of 0.92 ± 0.23 (SD, n = 7) was obtained.
When the two peaks could not be separated, a 1:1 ratio was assumed. To
our knowledge this is the first report of the combined production of pyruvate
and glycerol in Plasmodium spp.. Glycerol production has been observed125,
and pyruvate has been shown to be transported by a proton coupled monocar-
boxylate transporter57, but has not been measured extracellularly. We show
a production ratio of 1:1, which would lead to a closed redox balance, i.e.
the glycerol production balances the excess NADH produced due to pyruvate
excretion. This is not a unique for Apicomplexans, as T. brucei also trans-
ports pyruvate across the plasma membrane and utilises glycerol production
to maintain redox balance7.
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Figure 4.1: HPLC chromatograms of 14C labelled external metabolites produced
by isolated P. falciparum trophozoites. Isolated P. falciparum trophozoites were
incubated in a labelled glucose containing buer. Samples taken over time were
analysed for extracellular glucose (GLC), pyruvate (PYR), glycerol (GLR) and lac-
tate (LAC). Shown are chromatograms of samples taken at 0, 45 and 135 min,
which indicate the consumption of glucose and production of extracellular metabo-
lites. The combined results of these labelled glucose incubation experiments are
presented in Fig. 4.2.
The pathway uxes provide an important part of the validation as they rep-
resent the combined eect of all the individual enzyme kinetics. As a means
of validating the model we simulated the glucose incubation experiments. To
reect the experimental set up, three additions were made to the model, i)
by including the total incubation (650 L) and the total trophozoite cytoso-
lic volume (6.9  0.57 L, n = 3) and ii) setting the external metabolites
to those measured at 15 min (Fig. 4.2) and iii) changing the xed external
metabolite concentrations to time dependent variables. The rst change was
incorporated to ensure the correct internal to external volume ratio and the
second change was made as it takes the cells approximately 10 min to reach a
constant uptake rate. The nal change was to allow the model to predict how
the external metabolite concentrations change over time. The total cytosolic
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Figure 4.2: Model predictions of external uxes compared to experimental results.
Saponin derivedP. falciparum trophozoites were incubated in14C glucose and exter-
nal metabolite concentrations determined over a period of 90 minutes. Data points
( and  ) represent two independent experiments, with the concentrations of A)
glucose B) lactate, C) glycerol and D) pyruvate determined in singleton for each
time point. For the predicted ux, the thickly dashed line is the model prediction
with a glucose transporter Vmax of 0.21 molmin  1 mg 1 . The two closely match-
ing nely dashed lines represent model prediction at the upper and lower boundary
of the experimentally determined glucose transportVmax values.
volume was calculated from cell counts we assumed a cytosolic volume of 28
fL per trophozoite2.
In Figure 4.2 we compare the experimental data with the prediction of the
altered model. There is an excellent correlation between the model prediction
and experimentally determined external metabolite concentrations for the pe-
riod between 15 and 100 minutes. TheV max of the glucose transporter was
previously determined to be 0.21 with a lower and upper range of 0.14 & 0.30
¼molmin  1 mg 1 . To show that the 50% error on the parameter did not in-
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fluence the model unduly we also show the flux predictions over a much larger
range (0.1, 1.0 µmol·min−1·mg−1) of the glucose transporter maximal activity
(Fig. 4.2). Even within the wide range of glucose transporter rates, the model
still predicts the experimental results accurately. We assumed the system to
be in steady state for the 15 to 50 minute period and the steady state flux
values are given in Table 4.1.
The Vmax of the glycerol-3-phosphate dehydrogenase activity was fitted to the
measured glycerol production rate, which excludes this flux as part of the
model validation. None of the other fluxes are fitted, and the good description
of experimental data by the model provides a good degree of model validation.
Table 4.1: Experimentally determined glycolytic flux in P. falciparum trophozoites.
Glycolytic fluxes for P. falciparum trophozoites were experimentally determined by
incubating the parasites in 5 mM external glucose and measuring the change in
external metabolites over time. The values represent the linear uptake or production
rate over a period of at least 30 minutes. The experimental column includes both
labelled and unlabelled incubations. The model prediction of steady state fluxes
are given for an external glucose concentration set at 5 mM, lactate 1 mM, glycerol
0.2 mM and pyruvate 0.15 mM and Vmax for the glucose transport set to 0.21
µmol·min−1·mg−1. The upper and lower limits were determined by setting the
glucose transporter Vmax to its upper and lower values and adjusting the ATPase
rate to obtain an ATP:ADP ratio of 3 in each case.
Flux Experimental Model Prediction (Lower/Upper Range)
flux ± SEM n
µmol·min−1·mg−1 µmol·min−1·mg−1
Jglucose 0.060 ± 0.0068 4 0.0486 (0.043 - 0.055)
Jlactate 0.11 ± 0.0076 5 0.0920 (0.077 - 0.098)
Jpyruvate 0.0056 ± 0.0017 2 0.00512 (0.0046 - 0.0059)
Jglycerol 0.0063± 0.0013 2 0.00512 (0.0046 - 0.0059)
In addition to the labelled glucose flux experiments, additional flux experi-
ments were performed with unlabelled glucose. In these experiments the exter-
nal metabolites were determined enzymatically (see materials and methods)
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and the fluxes were estimated from the change in concentration over time.
These fluxes compare well to those obtained during the labelled uptake exper-
iments and to those predicted by the model. In each of the flux experiments
a constant flux was reached after approximately 10 minutes. Thereafter the
respective consumption and production rates were estimated with linear re-
gression over at least a 30 min period (Table 4.1).
4.3.2 Internal metabolite concentrations
By comparing experimentally measured internal metabolite concentrations to
those predicted by the model, a second method of validation was obtained.
In the scientific literature some glycolytic metabolite data are available, such
as for the mouse infecting P. berghei 181. However, these metabolites were de-
termined in infected erythrocytes (parasitemia >75%) and the concentrations
were compared to those found in the erythrocyte (See Table 4.2). For isolated
P. falciparum trophozoites, as far as we are aware, the glycolytic metabolites
have not previously been determined, although lactate has been measured, as
well as ATP, ADP and NAD+ 204 (Table 4.2).
In this work the steady state concentrations of glucose 6-phosphate (G6P),
fructose 6-phosphate (F6P) and fructose 1,6-bisphosphate (F1,6BP) were de-
termined enzymatically (Table 4.2). The intermediate determinations were
limited to upper glycolysis due to high concentrations of extracellular pyru-
vate and lactate which prevented the enzymatic determination of metabolites
found in the lower half of glycolysis via lactate dehydrogenase. GAP and
DHAP were assayed, but the concentrations were below the limit of detection
(l.o.d) which was an intracellular concentration of approximately 100 µM. Due
to the high volume of isolated parasites required to determine the intermedi-
ates, samples of a trophozoite incubation were taken at only two time intervals
(30 and 40 min). At these intervals glucose consumption and product forma-
tion rates had reached a constant value and the system is expected to be in
steady state. The concentration difference between the two points was not
significant (P <0.05, n = 6) and the average values for the time points are
presented (mean ± SEM, n = 12) in Table 4.2.
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The model was adapted to reflect the isolated trophozoite experiments in which
the metabolite concentrations were determined. The external metabolites con-
centrations of the model were fixed (2.7 mM glucose, 12 mM lactate, 1.5 mM
pyruvate, 1.5 mM glycerol) at concentrations estimated to occur in the samples
midway between 30 and 40 minutes. The model was allowed to reach steady
state and the predicted metabolite concentrations are shown in Table 4.2 for
comparison to concentrations measured in vivo. As with the flux predictions,
the steady state metabolites were also calculated at both high (1.0) and low
(0.1) glucose transporter Vmax and these boundaries are listed in parenthesis
in Table 4.2.
4.3.3 Model Analysis
4.3.3.1 Metabolic control analysis
To quantify the importance of each of the enzyme for the steady state be-
haviour of the glycolytic pathway, we performed metabolic control analysis on
the system. The complete matrix of flux and concentration control coefficients
are presented in Appendix A in Table A.1 and A.2 respectively. Subsets of
the coefficients with relatively high values are shown in Table 4.3 and 4.4.
P. falciparum does not have a single ’rate limiting’ step, and the majority
of the flux control is divided across five reactions, namely the glucose trans-
porter (vGlcTr), hexokinase (vHK), phosphofructokinase (vPFK), glyceralde-
hyde 3-phosphate dehydrogenase (vG3PDH), and the ATP demand reaction
(vATPase) (Table 4.3). The enzymes with high flux control, as well as glyc-
erol 3-phosphate dehydrogenase (vGlrDH) and lactate dehydrogenase (vLDH)
have the highest degree of concentration control (Table 4.4).
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Table 4.3: Selected flux control coefficients. The coefficients were determined by
JWS Online and Copasi for the model of P. falciparum glycolysis during the asex-
ual trophozoite phase. The reactions with the majority of the flux control, namely
the glucose transporter (vGlcTr), hexokinase (vHK), phosphofructokinase (vPFK),
glyceraldehyde 3-phosphate dehydrogenase (vG3PDH), and the ATP demand reac-
tion (vATPase) are shown. The complete set of flux control coefficients are shown
in Appendix A.
vGlcTr vHK vPFK vG3PDH vATPase
JGlcTr 0.223 0.438 0.353 0.306 -0.448
JHK 0.223 0.438 0.353 0.306 -0.448
JPGI 0.223 0.438 0.353 0.306 -0.448
JPFK 0.223 0.438 0.353 0.306 -0.448
JALD 0.223 0.438 0.353 0.306 -0.448
JTPI 0.244 0.478 0.385 0.335 -0.489
JG3PDH 0.233 0.457 0.368 0.320 -0.467
JPGK 0.233 0.457 0.368 0.320 -0.467
JPGM 0.233 0.457 0.368 0.320 -0.467
JENO 0.233 0.457 0.368 0.320 -0.467
JPK 0.233 0.457 0.368 0.320 -0.467
JLDH 0.244 0.478 0.385 0.335 -0.489
JLacTr 0.244 0.478 0.385 0.335 -0.489
JATPase 0.244 0.478 0.385 0.335 -0.489
JGlrDH 0.050 0.098 0.079 0.063 -0.100
JPyrTr 0.050 0.098 0.079 0.063 -0.100
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Table 4.4: Summary of selected concentration control coefficients. The coeffi-
cients were determined with JWS Online and Copasi. Similar to the flux con-
trol coefficients, the majority of the concentration control is in the glucose trans-
porter (vGlcTr), hexokinase (vHK), phosphofructokinase (vPFK), glyceraldehyde
3-phosphate dehydrogenase (vG3PDH), and the ATP demand reaction (vATPase)
as well in the glycerol producing reaction (vGlrDH). The complete set of control
coefficients are shown in Appendix A.
vGlcTr vHK vPFK vG3PDH vATPase vGlrDH
ATP 0.244 0.478 0.385 0.335 -1.49 -0.110
DHAP 0.298 0.584 0.470 -0.648 -0.613 -0.155
GAP 0.297 0.581 0.468 -0.662 -0.616 -0.155
Pyr 0.009 0.017 0.014 0.011 -0.017 0.154
2PGA 0.237 0.465 0.374 0.325 -0.415 -0.052
NAD -0.004 -0.008 -0.007 -0.006 0.009 0.010
Glucose 0.511 -0.288 -0.232 -0.202 0.295 0.003
F6P 0.452 0.887 -0.390 -0.338 -0.445 -0.093
LAC 0.006 0.012 0.010 0.009 -0.013 -0.004
3PGA 0.276 0.541 0.435 0.378 -0.519 -0.062
G6P 0.464 0.909 -0.366 -0.317 -0.470 -0.093
PEP -0.055 -0.108 -0.087 -0.076 1.31 0.076
B1,3PG 1.168 2.29 1.85 1.60 -5.85 -0.457
F1,6BP 0.668 1.31 1.06 -1.07 -1.38 -0.291
NADH 0.072 0.141 0.114 0.100 -0.144 -0.168
ADP -0.740 -1.45 -1.17 -1.02 4.52 0.333
4.3.3.2 Parameter Sensitivity Analysis
We used parameter sensitivity analysis in the study as a tool to test if any
parameters were unduly influencing the model. A general parameter sensi-
tivity analysis was performed using Copasi, yielding flux response coefficients
(Appendix A, Tables A.3 & A.4) that describe the relative change in steady
state flux or metabolite concentrations due to a small change in parameter
value. An overall consideration of the flux response coefficients indicates that
no single parameter has an unusually high coefficient and in this model, the
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parameters with higher flux response coefficients are also from reactions with
high flux control (HK, PFK, G3PDH and the glucose transport). The enzyme
that has the most parameters with high response coefficients is PFK, which is
described by a MWC equation. In this equation, the parameters in particular
which have high response coefficients are the cγ and L parameters, which alter
the equilibrium ratio of the R and the T-state. These higher response coeffi-
cients are thus not considered to be unusual.
Two Michaelis constants for aldolase were obtained from the scientific litera-
ture and the response coefficients for these constants, KDHAP and KGAP , are
both below 0.045, which indicates that these parameters do not have a large
effect on steady state model behaviour.
Pyruvate and lactate are transported by the same monocarboxylate trans-
porter and this transporter is well characterised44,57. We used the kinetic
parameters from scientific literature, but the maximal specific activity was
measured at 4°C. We increased the experimental rate by assuming a Q10 of 2.
The response coefficients in themselves do not indicate if this assumption has
an influence on model output, as it looks at only a small change in parameter.
We showed (Appendix A Fig. A.4) that varying the Vmax between the original
Vmax value determined at 4°C and the 8-fold extrapolation induces almost no
change in steady state flux and only influences the concentration of lactate
and to lesser extent, pyruvate.
The Vmax of the glycerol producing enzyme was fitted to obtain the correct
glycerol flux. Increasing the rate 2-fold almost doubles the glycerol and pyru-
vate flux, has no influence on the glucose flux and little influence (5%) on the
lactate flux (Fig. A.5). G6P also decreases by 50%. These results indicate
that fitting the glycerol flux does not detract from the good model prediction
of glucose and lactate flux.
The ATP:ADP ratio was varied (by altering the ATPase activity) between and
upper and lower boundaries (6 and 1) as measured in scientific literature to
determine its effect on steady state model behaviour. At the upper boundary
the glycolytic flux increases approximately 10% and apart from increasing the
F1,6BP (+ 50%) and 1,3BPG (2-fold increase) concentrations, there was min-
imal effect on the other metabolite concentrations (Appendix A, Figs. A.1,
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A.2 & A.3).
4.4 Discussion
In Chapter 3, we presented the construction of a detailed kinetic model of P.
falciparum glycolysis. The model was composed of rate equations derived from
a thorough biochemical characterisation of each enzyme in isolation. Can our
understanding of the individual kinetics describe glycolysis in vivo? To answer
this question we measured the steady state fluxes and metabolite concentra-
tions in isolated trophozoites and compared them to the model prediction.
The glucose and lactate fluxes of several experiments (Table 4.1) compare well
to the model. The model not only predicts the linear region of uptake and
production, but also the decreasing rate of glucose uptake, as external glucose
concentration drops to below the Km value (1.8 mM) for external glucose (Fig.
4.2). It should be highlighted that this good prediction of steady state flux
and glucose run-out conditions is an important validation for the mathematical
model. It should be emphasized that apart from the glycerol branch none of
the model parameters were fitted to the flux data set. The model parameters
were determined in independent experiments on the isolated enzymes. Consid-
ering that each of the kinetic parameters contains experimental error and that
this model has over 100 parameters, it raises the question of how the model
can predict the glycolytic flux to within 15% of the experimentally determined
values. Even during early stages of model construction, the flux prediction
was comparable to measured fluxes and the glycolytic flux has been highly re-
producible experimentally. What is the reason for this flux robustness? MCA
theory shows that control of the flux can be divided across all of the reac-
tions within the system. Thus if one step had almost all of the flux control,
the accuracy of the parameters within this step would be greatly reflected
in the accuracy of the flux predictions. In this model, glycolytic flux con-
trol is divided predominantly between five reactions (Table A.1), namely the
glucose transporter (0.223), hexokinase (0.438), phosphofructokinase (0.353),
glyceraldehyde 3-phosphate dehydrogenase (0.306) and ATPase (-0.448). The
remaining enzymatic steps have minor control over the flux (<0.1),which would
mean that experimental error in the parameters of these reactions, would only
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have a small effect on flux prediction at that particular steady state. This is
confirmed when one considers the PSA results, which indicate that only the
parameter values of the flux controlling enzymes have high response coeffi-
cients (Table A.3) and that parameters of the enzymes with no flux control
have almost no effect on steady state flux. In the extreme case where a sin-
gle enzyme or reaction has almost all of the flux control, a 10% error in its
rate would be reflected in a 10% error in the flux. In this model, however,
even though the flux prediction is more sensitive to error in the controlling
enzymes, there are four enzyme reactions that divide most of the flux control.
As such, error in these reactions, has less of an impact on the steady state
flux. (e.g. an error of 10%, in say the Vmax of HK, would only equate to a
4.2% error in flux prediction). By assuming random unbiased error (e.g. 20%
over and under-predictions) across the four enzymes (excluding the ATPase
reaction, which cannot be experimentally determined), one would expect that
the total error in flux prediction would be less than 20% and may explain why
the flux predictions compare well to those measured in vivo. This concept of
robustness has been mathematically formalised in a dissertation by Quinton-
Tulloch et al.164 and concludes among others, that a wide distribution of the
flux control increases the robustness in flux.
It has been noted that the use of irreversible rate equations, such as used
for PK and PFK in this model, may skew or artificially alter the flux control
distribution no matter how high the equilibrium constant42. However, Cornish-
Bowden and Cardenas42 showed that provided there is a feedback loop that
allows communication around an irreversible step, the model behaves in an al-
most identical fashion. Although PK and PFK are modelled with irreversible
MWC equations, they do have product inhibition terms. This ensures that
the irreversible reaction does not isolate one part of the pathway and does not
influence model prediction.
The metabolite concentrations predicted by the model for F1,6BP compare
well (1.1 vs. 0.74 mM), but for G6P and F6P there is a 2-3 fold over pre-
diction of what was measured (Table 4.2). Predicted DHAP concentrations
are considerably higher than measured and this accumulation of DHAP in the
model may be due to the way in which the glycerol branch was modelled. Since
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the enzymes for the production of glycerol in asexual P. falciparum are as yet
unknown, the glycerol branch was grouped into a single equation and the Vmax
was fitted to obtain the correct flux. If an additional enzyme step is incor-
porated into the glycerol pathway, the predicted concentration of DHAP may
well be lower. Predicted GAP concentrations (0.050 mM) are in agreement
with the inability to quantify the concentration experimentally as it is below
the limit of detection in our assays. The predicted internal lactate concentra-
tion is fairly high at 13 mM, but in P. berghei infected erythrocytes it has been
measured at approximately 8 mM (Table 4.2). The 1.1 mM intracellular lac-
tate concentration measured by Teng et al. (Table. 4.2) is not in disagreement
with the model, where internal lactate concentrations are strongly dependent
on the extracellular lactate concentrations. If extracellular lactate concentra-
tion were low (e.g. 1 mM) during the determination by Teng et al (compared
to 12 mM in this work), the model would predict a very similar internal lactate
concentration.
Overall the model gives a good description of metabolic flux and the steady
state metabolite concentrations are comparable to those found in vivo. Bakker
et al.7 (T. brucei) and Teusink et al.205 (yeast) could also, on the basis of the
underlying kinetics, largely describe glycolysis. It would appear that at least
for small networks for which good enzyme assays are available, such as glycol-
ysis, the kinetics of the individual enzymes are sufficient in describing systemic
properties such as flux and metabolite concentrations.
The asexual stage of Plasmodium spp. derives most of its ATP from glycoly-
sis and as such, this pathway has been investigated as a potential drug target.
Phosphoglucoisomerase202, aldolase219, triosephosphate isomerase216,106, phos-
phoglycerate kinase148 and lactate dehydrogenase34,73,20) have been proposed
as drug targets and inhibited in vitro. The validated model provides a unique
tool to investigate each of these proposals on the basis of their metabolic con-
trol. MCA of the model highlights four steps (glucose transporter, HK, PFK
and G3PDH ) as having most of the flux and concentration control (Tables
A.1, A.2). Of these, only the glucose transporter has been proposed as a drug
target. The remaining proposed drug targets, PGI, ALD, PGK and LDH, have
low control of the glycolytic flux and in each of these a high degree of inhibi-
tion would be required before having an effect on glycolytic flux. The glucose
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transporter, PfHT1, has been proposed and investigated quite extensively as
a potential drug target155, without taking into account the metabolic control
structure of P. falciparum glycolysis. A further step would be to use differen-
tial control analysis and also take into account the metabolic control structure
of the host. MCA of the Holzhutter et al. model of erythrocyte glycolysis94
indicates that glucose transporter has negligible control of the flux and when
compared the high control of the P. falciparum transporter, MCA highlights
this step as a potential drug target. We would expect that interfering with
glycolysis, the parasite’s main ATP producing pathway will strongly inhibit
its growth rate.
An interesting question that arises from the MCA results is the high concentra-
tion control ( >1) over PEP by the GlcTr, HK, PFK, G3PDH and PK (-1.0).
The finding that PEP inhibits TPI strongly, and inhibits PK in P. falciparum
(Chapter 3) and activates PFK in P. berghei 22 identifies PEP as a key regula-
tory molecule in Plasmodium spp. and suggests that it may regulate glycerol
metabolism. Hypothetically, on the basis of the control coefficients, the reduc-
tion in PK expression would result in an increased PEP concentration. This
in turn would activate PFK (P. berghei) and would further increase the PEP
concentration, ultimately inhibiting TPI strongly. The almost complete in-
hibition of TPI, would be expected to increase the glycerol flux. Grüning et
al.77 reported a similar feedback loop in yeast, where low PK activity results
in the accumulation of PEP resulting in the inhibition of TPI and consequent
activation of the pentose phosphate pathway. The current model describes
the glycerol branch with a single rate limiting (flux control coefficient 0.78)
reaction and is thus not suitable for testing the above hypothesis that PEP
regulates the glycerol flux in P. falciparum. However, the model does highlight
the importance of PEP and upon further elucidation of the glycerol pathway
the model may improve our understanding of the regulation of the glycerol flux.
Lian et al.125 showed that asexual P. falciparum produces glycerol and our
finding of an experimental ratio of approximately 1:1 for the glycerol and pyru-
vate flux indicates that the glycerol branch is essential for maintaining redox
balance by oxidising excess NADH produced due to pyruvate excretion. The
role of glycerol during the asexual phase is unclear. It may be that since the
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monocarboxylate transporter cannot differentiate between lactate and pyru-
vate, the production of glycerol is required for redox balance. Alternatively,
glycerol itself may play a physiological role as it does in yeast, where it has
been shown to be important for osmotic regulation110,91.
P. falciparum does have a gene for glycerol kinase186, but it has been shown
that it is not expressed during the asexual stage and enzyme activity could
also not be detected (this study and186). A gene or putative gene sequence
for glycerol-3-phosphate phosphatase is also not present in the genome125.
PGM2, an isozyme of phosphoglycerate mutase, has been reported to have
phosphatase activity towards a number of substrates85 and it is possible that
it can use glycerol 3-phosphate as a substrate. These findings do raise the
question of how glycerol is produced in asexual P. falciparum and why the
parasite does not express glycerol kinase during the asexual phase.
4.5 Conclusion
We have constructed and validated a kinetic model for asexual P. falciparum
glycolysis. We have shown that the model describes the steady fluxes well
and in addition gives similar metabolites concentrations. However, these are
overestimated compared to those measured experimentally. Furthermore, as-
sumptions made during model construction have been shown to not greatly
influence the model output. Having constructed and validated the model, the
model was analysed as a whole using MCA and PSA to investigate potential
drug targets and improve our understanding of its regulation.
Several enzymes within the P. falciparum glycolysis have been proposed as
potential drug targets. In order to evaluate these proposals a kinetic model
was constructed (Chapter 3) and validated as a tool for the analysis of the
system as a whole. Independently of fitting, the model, purely as a function
of the independently determined enzyme kinetics, describes the steady state
glycolytic fluxes in isolated trophozoites and predicts the metabolite concentra-
tions in upper glycolysis within a factor of two. Model analysis showed that the
assumptions used during model construction do not have a large influence on
the system behaviour and that the validated model gives a good representation
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of P. falciparum glycolysis during the asexual phase. The validated model in-
dicates that PEP may play a role in the regulation of the glycerol flux. Model
analysis highlighted the glucose transporter, HK, PFK and G3PDH as the
enzymes with the highest flux and metabolite control, indicating that these
enzymes should be preferentially targeted over those with minimal control.
Furthermore, this work adds further support for research aimed at targeting
the glucose transporter, PfHT1 in the quest for novel antimalarials.
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Chapter 5
Differential control analysis as a tool for
drug target identification in Plasmodium
falciparum
Penkler, G.P., Rautenbach, M., Snoep, J.L.
5.1 Introduction
P. falciparum, with its dual host life cycle and numerous physiologically differ-
ent forms and stages, presents a vast array of potential drug targets. Finding
an effective drug target has proven difficult, however, and the challenges are
amplified by the parasites’ extraordinary ability to become resistant to most
antimalarials within a decade or two. Asexual Plasmodium spp. relies almost
entirely on glycolysis for ATP. As such, several glycolytic enzymes have been
proposed as potential drug targets155,219,169,20.
Previously, we biochemically characterised each of the glycolytic enzymes and
from the data constructed and validated a detailed kinetic model of asexual
P. falciparum glycolysis (Chapters 3 & 4). Metabolic control analysis of the
model indicated that the P. falciparum glycolytic pathway does not have a sin-
gle ’rate-limiting’ step, but that the hexose transporter (PfHT1), hexokinase
(HK), phosphofructokinase (PFK) and glyceraldehyde 3-phosphate dehydro-
genase (G3PDH) are the enzymes most important for controlling the flux.
Metabolic control analysis (MCA) is a method that can be used to deter-
mine the degree of flux control exerted by an enzyme and was developed in-
dependently by Kascer & Burns107 and Heinrich & Rapoport168,82 and further
developed by others (see64,87for review). MCA is a theoretical framework that
110
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defines: i) flux (J ) and concentration (c) control coefficients (CJv & Ccv), which
quantify the relative change of steady state systemic behaviour, (e.g. J and
c), due to a small change in a local reaction rate, v (Eq. 5.1.1).
CJv =
d ln J




d ln v (5.1.1)
ii) elasticity coefficients (εvp ) which quantify the relative change in the local
reaction rate, v, due to a small change in an effector, p, (e.g. substrate or
inhibitor concentration) (Eq. 5.1.2).
εvp =
∂ ln v
∂ ln p (5.1.2)
iii) response coefficients (RJp & Rcp), which describe the relative change in a
systemic property such as flux or metabolite concentration due to a change in
a local parameter, p. These response coefficients can be further described as
the product of their respective elasticity and control coefficient (Eq. 5.1.3).
For more detail on MCA and its formulation, refer to64,87.
RJp =
d ln J
d ln p = C
J
vi
· εvip & Rcp =
∂ ln c




MCA, which has been used as a tool to amongst others i) improve our under-
standing of certain diseases (see33 for review), ii) suggest novel strategies to
treat cancer138 and iii) identify drug targets in African sleeping sickness8 and
cancer147. For drug target identification, the approach has generally been to
identify an enzyme, or group of enzymes138 with a high flux or concentration
control. Inhibition of these reactions is expected to require lower concentra-
tions of inhibitor, compared to reactions with low flux control. In addition to
considering the enzymes which have high control in the pathogen, one should
also consider the host metabolic control structure8,98. Subsequently one can
identify enzyme(s) with a high flux control in the parasite, whereas the equiva-
lent reaction in the host has a low flux control. Due to this differential control,
inhibition of this enzyme to the same degree in both the parasite and host
would have a greater effect on the parasite and would reduce the side effects
of drugs that are not completely selective. This differential control approach
has been proposed as a tool for drug target identification8,98, but has yet to
be demonstrated in vivo. A measure of the degree of differential control de-
fined by Hornberg et al.98 is given by the ratio of the host and pathogen flux
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response coefficients for a drug.
In our previous work, model analysis indicated that the PfHT1 has a rela-
tively high control of the glycolytic flux and that the glucose transporter in
the host erythrocyte has almost no control (Chapter 4). This provided the
ideal opportunity to test the concept of differential control analysis as a tool
for drug target identification in vivo (i.e. on whole trophozoites and erythro-
cytes) and is the focus of this article. If the model predictions were correct,
specific inhibition of the glucose transporter in P. falciparum would lead to a
far greater decrease in flux in the parasite than in the host’s erythrocytes even
with a comparable inhibition of both glucose transporters. A compound that
has been widely utilised for inhibiting glucose transport is cytochalasin B.
Cytochalasins are fungal metabolites with similar structural and biological ac-
tivity characteristics. Cytochalasin B is perhaps best known as an inhibitor of
actin microfilament dynamics129, which would explain a number of observed
cellular effects (motility31, morphology183, adhesion56 and division changes31).
Of interest in this study, is the observation that cytochalasin B is a potent in-
hibitor of glucose transport in erythrocytes10,14,50,76 as well as in Plasmodium
spp.116,119,222,223. In erythrocytes, most studies have reported the inhibition of
glucose efflux10,14,50,76, but it has also been shown to inhibit glucose uptake
into pink erythrocyte ghosts strongly120. Bloch14 reported that glucose efflux
is nearly completely inhibited by 100 µM cytochalasin B in human erythro-
cytes. Glucose uptake via GLUT1 and PfHT1, which have been expressed in
frog oocytes is inhibited by cytochalasin B, with approximately 75% inhibi-
tion for PfHT1 with 50 µM223. Cytochalasin B is also reported to inhibit the
uptake of 2-DOG into infected erythrocytes116.
The mechanism by which cytochalasin B inhibits glucose transport is unclear,
but for erythrocytes it has been shown to bind asymmetrically to the trans-
porter in a noncompetitive manner10,14, although others have reported com-
petitive binding kinetics50. Although the mechanism is uncertain, it is clear
from the erythrocyte ghost and frog oocyte experiments that although cy-
tochalasin B induces a number of cellular changes, it does inhibit the glucose
transporters of human erythrocytes and P. falciparum. Despite the low speci-
ficity of cytochalasin B, it appears that in the central carbon metabolism the
only mode of action is on the glucose transporter.
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Our previous findings indicated that PfHT1 has a relatively high control over
glycolytic flux and that the erythrocyte glucose transporter has almost no flux
control. In this Chapter we investigate the model prediction of differential
control of the flux by the glucose transporter in Plasmodium spp. and hu-
man erythrocytes. We present experimental evidence of differential control by
showing that inhibition of the glucose transporter with cytochalasin B in in-
tact P. falciparum trophozoites and erythrocytes decreases the glycolytic flux
in the parasite, but not in the erythrocyte.
5.2 Methods
5.2.1 Culturing and isolation of P. falciparum
P. falciparum D10 was routinely cultured in A+ erythrocytes (kindly donated
by the Western Province blood bank) at 3 - 4% v/v haematocrit in culture
medium consisting of RPMI 1640, 0.5% m/v Albumax II® , 22 mM glucose,
25 mM HEPES, 3 mM hypoxanthine and 50 µg/mL gentamicin sulphate, un-
der 3% oxygen, 4% carbon dioxide and 93% nitrogen at 37 ° C as described
elsewhere (36, 146). Synchronisation of the cultures was ensured by centrifug-
ing the infected erythrocytes (750 × g, 3 min) and suspending the pellet in
5% m/v sorbitol97. Following 5 min incubation at 37 ° C and centrifugation
(750 × g, 3 min), the pellet was suspended in culture media and cultured as
described above. Sorbitol destroys all but the ring stage parasites97, ensuring
that they are kept in phase.
Isolation of trophozoites from infected erythrocytes was achieved using a saponin
lysis protocol178, which permeabilises the erythrocyte and parasitophorous
vacuolar membrane by interacting with the cholesterol found in these mem-
branes3,4. Greater than 95% of parasites isolated in this manner can maintain
a transmembrane potential and exclude 0.04% v/v trypan blue177. Saponin
(0.05% m/v and 0.005% w/w active component sapogenin) was added to in-
fected erythrocytes suspended in culture medium (typically 5% v/v haemat-
ocrit). After mixing by inversion, the suspension was centrifuged (1800 × g,
7 min). Upon removal of the supernatant, the parasites were washed twice in
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culture medium or a buffer of choice.
5.2.2 Inhibition of glycolytic flux
For the flux experiment, trophozoites were isolated, washed twice and then sus-
pended in modified Ringer incubation buffer (5 mM glucose, 50 mM HEPES,
1 mM MgCl2, 10 mM KCL, 120 mM NaCl, pH 7.1) similar to that described
by Wünsch et al.224, containing between 0 and 100 µM cytochalasin B made
up in DMSO (final concentration <0.5% m/v). In this buffer the parasites
were able to exclude 0.04% v/v trypan blue. Two aliquots were taken for cell
counting (Improved Neubauer haemocytometer). Aliquots of the incubation
suspension were taken over 60 min and following centrifugation (10 000 × g, 5
min, 4°C) the supernatant was retained for the determination of extracellular
lactate. The control contained no cytochalasin B, but an equivalent concen-
tration of DMSO.
Extracellular L-lactate was assayed by using a lactate dehydrogenase (LDH)
and NAD+ linked assay. After samples and standards were incubated for
20 min at room temperature in HEPES buffer (20 mM) containing LDH
(10 U/ml), NAD+ (0.2 mM) and hydrazine (16 µL/ml), absorbance was de-
termined at 340 nm on a spectrophotometer (VarioSkan microplate reader,
Thermo Electron Corporation). Hydrazine binds to pyruvate and thus ther-
modynamically drives the unfavourable LDH reaction (reverse) to completion.
5.2.3 Inhibition of 14C Glucose Uptake
Isolated parasites were washed twice and then suspended in glucose free modi-
fied Ringer buffer (50 mM HEPES, 1 mM MgCl2, 10 mM KCL, 120 mM NaCl,
pH 7.1) similar to that described by Wünsch et al.224. In this buffer the par-
asites were able to exclude 0.04% v/v trypan blue. Between 30 and 90 µL of
trophozoites (1× 109 trophozoites/mL final concentration) were mixed with an
equal volume of glucose (10 mM final concentration, 1:100 label to unlabelled
14C glucose) and cytochalasin B (0 - 200 µM final concentration) made up in
DMSO (final concentration <0.5% m/v). The experiment was performed at
37◦C and the reaction was quenched after 500 ms with 5 mL incubation buffer
containing 100 mM unlabelled glucose kept at −5°C on a salt-ice mixture. The
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rapid quenching was performed using a quench-flow device describe previously
(Appendix B B). The quenched trophozoites were immediately transferred to
a filter (covered with a thin layer of filter aid Celite 545, Sigma-Aldrich to
prevent clogging) and washed with a further 10 mL ice cold incubation buffer.
After washing, the filter was added to a scintillation vial containing 5 mL scin-
tillant, incubated overnight and then counted on a scintillation counter. As a
control, trophozoites were quenched prior to the addition of labelled glucose,
and subsequently following the same sample preparation procedure.
5.2.4 Effect of Cytochalasin B on glycolytic enzyme
activity
The specific activity of each glycolytic enzyme in the presence of 100 µM
cytochalasin B was determined in NAD+/NADP linked kinetics assays as de-
scribed previously (Chapter 3). As a control the enzymes were also assayed
without cytochalasin B, but the assay mixture included the same concentration
of DMSO (solvent for Cytochalasin B).
5.2.5 Model Simulations and Analysis
Most of the model simulations presented in this chapter were performed using
Wolfram Mathematica 8.0®. The kinetic model of P. falciparum glycolysis
is available on JWS Online (jjj.biochem.sun.ac.za)201,144 for interrogation or
download in various standard formats. Steady state analysis and metabolic
control analysis was performed both in Wolfram Mathematica 8.0®, JWS On-
line and Copasi96.
5.3 Results
In previous work we constructed a detailed kinetic model of P. falciparum
glycolysis, using kinetic parameters determined in vitro (Chapter 3). The
model was validated by comparing model predictions (purely based on the
measured isolated enzyme kinetics) to steady state system behaviour, i.e. flux
and metabolite concentrations in intact P. falciparum trophozoites. Previous
metabolic control analysis of the P. falciparum kinetic model and a model
of erythrocyte glycolysis95 (Chapter 4), revealed that the glucose transporter
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had high control in the parasite and low control in the host, indicative of an
effective drug target. To identify all potential drug targets in the network, we
extend this analysis to include each of the glycolytic enzymes and quantify
the effectivity (see Introduction, Eq. 5.3.1) of each reaction. Furthermore,
to demonstrate this predicted differential control of the glucose transporter in
the host and parasite we investigate i) the inhibition of 14C glucose transport
(zero trans uptake) in P. falciparum trophozoites by cytochalasin B and ii) the
inhibition of lactate flux by cytochalasin B in intact isolated trophozoites and
uninfected erythrocytes. The inhibition of glucose transport in erythrocytes
by cytochalasin B was not investigated as this has been well characterised in
the scientific literature. If model simulations are correct, it is expected that
the glucose flux would be inhibited to a far greater degree in the parasite than
the flux in the erythrocyte, even if both glucose transporters are inhibited to
the same degree.
5.3.1 Metabolic Control Analysis
Metabolic control analysis was performed on the P. falciparum model as well
as the model of erythrocyte glycolysis compiled by Holzhutter et al.95 using
JWS Online201,144. For both models, the flux control coefficients of each en-
zyme on the glycolytic flux are summarised in Table 5.1. For two other models
of erythrocyte glycolysis, the control distribution is similar to the Holzhutter et
al.95 model with the ATPase and 2,3 bisphosphoglycerate shunt having most
of the flux control53. The Holzhutter et al. model was used in this work as it
includes the glucose transporter as an explicit reaction step.
As defined before, effectivity (Eq. 5.3.1) can be quantified as the ratio of
the drug response coefficients and this can be further expressed in terms of the
elasticity and flux control coefficients (Eq. 5.3.1). This ratio was termed selec-
tivity, but it is ambiguous as it does not differentiate between drug selectivity
(i.e. degree of selective drug binding and inhibition of the parasite and host
enzyme) and the subsequent selective inhibition of the flux. To disambiguate,
we define the degree to which a drug inhibits the pathogen flux compared to
the host flux as effectivity. We maintain the definition of drug selectivity as
the degree to which the drug inhibits the pathogen enzyme compared to the
inhibition observed for the host enzyme.
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In the instance of a non-selective drug that inhibits both pathogen and host en-
zymes to the same degree, the elasticities would be equal (εv(pathogen)drug = ε
v(host)
drug )


















To determine the effectivities of each enzyme in parasite and erythrocyte gly-
colysis, we assumed that a drug would inhibit both enzymes to the same degree
(i.e. elasticity coefficients are equal) and thus the effectivity is the ratio of the
flux control coefficients. For each enzyme the effectivity is listed in Table 5.1,
with the pyruvate transporter (PyrTr) having the highest unscaled effectiv-
ity. However, despite its high effectivity, the PyrTr is not the best target as
it only has a low control in the parasite. Ideally an effectivity index should
also highlight potential drug targets and as such, favour a reaction with a high
control in the parasite and low control in the host. Consider two reactions, one
reaction with a high flux control coefficient (e.g. 0.9) and the other having a
low flux control coefficient (e.g. 0.01), each with an effectivity of 10 (i.e. where
control of the equivalent reactions in the host are a factor 10 less). Both of
these steps have the same effectivity, but intuitively it would be preferable to
target the reaction with higher control in the parasite. We propose a logarith-
micly scaled effectivity (Eq. 5.3.2), which scales the coefficients and favours
reactions with high control in the parasite. In the example above where both
reactions have an effectivity of 10, the reaction with high flux control has a
scaled effectivity of 5.5 compared to 1.5 for the reaction with low flux control.







(∣∣∣CJ(host)vi · εvi(host)drug ∣∣∣)
Log
(∣∣∣CJ(pathogen)vi · εvi(pathogen)drug ∣∣∣)
(5.3.2)
Both the standard and scaled (logarithmic) effectivity methods were applied
to the P. falciparum and the erythrocyte flux control distributions (Table 5.1)
and the enzymes are ranked in terms of their scaled effectivity.
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Table 5.1: Summary of glucose flux control coefficients in P. falciparum and human
erythrocytes. The glucose flux control coefficients for each glycolytic enzyme were
obtained by metabolic control analysis of P. falciparum and erythrocyte glycolysis
models. The effectivity of each enzyme in both the standard ratio form (Eq. 5.3.1)
and logarithmic scaled form (Eq. 5.3.2) is listed. The enzymes are ranked in terms
of the highest scaled effectivity.
CJGlucosevenzyme Standard Scaled
Enzyme P. falciparum Erythrocytes Effectivity Effectivity
G3PDH 0.306 -0.000500 608 6.41
GlcTr 0.223 0.000140 1652 5.94
PFK 0.353 0.0229 15.4 3.63
PyrTr -0.0240 -0.00000413 5811 3.32
HK 0.438 0.0681 6.43 3.25
ALD 0.0780 -0.00323 24.1 2.25
LacTr 0.00300 -0.00000747 402 2.03
LDH (NADH) 0.0500 -0.00359 13.9 1.88
TPI 0.00300 -0.0000313 95.8 1.79
PGI 0.0200 0.00452 4.42 1.38
PGM 0.00100 0.00238 0.420 0.874
ENO 0.00100 0.00439 0.228 0.786
PK 0.00100 0.0134 0.0746 0.624
ATPase -0.448 0.703 0.637 0.439
PGK 0 0.00545 0 -
GlrTr -0.00500 - - -
LDH (NADPH) - 0.0101 - -
B1,3PG shunt - 0.208 - -
The top five effectivities determined by both methods indicate glyceraldehyde
3-phosphate dehydrogenase (G3PDH), the glucose transporter (GlcTr), and
phosphofructokinase (PFK) as potential drug targets. The logarithmic scaled
method, however, provides a better ranking of the reactions as potential drug
targets as it ascribes a higher value to reactions with high control in the para-
site, even if there is a large percentage difference in the parasite and host flux
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control. These scaled effectivity rankings indicate G3PDH, GlcTr and PFK to
be the best potential drug targets in P. falciparum glycolysis.
5.3.2 Inhibiting the P. falciparum glucose transporter
The scaled effectivities (Table 5.1) indicated that G3PDH and the glucose
transporter are good potential drug targets, based on their significant control
of glycolytic flux in the parasite and low flux control in the erythrocyte. In
order to test this hypothesis, the glucose transporter was chosen for inhibition
experiments as i) it has been well characterised for the human erythrocyte
and P. falciparum and ii) cytochalasin B is a known inhibitor of the glucose
transporter in both organisms.
In erythrocytes, the inhibition of glucose transporter by cytochalasin B has
been well characterised (see Introduction) with more than 95% inhibition of
efflux achieved at 100 µM cytochalasin B14. To characterise the inhibition
of the P. falciparum glucose transport by cytochalasin B, we used a simple
quench flow device (Appendix B B) to measure the zero-trans uptake rate
of 14C glucose at different inhibitor concentrations. The rapid quench time
(0.5 s) ensured that we measured zero-trans influx and were not measuring
metabolism (Chapter 3). To kinetically characterise the inhibition we assumed
no inhibition of glucose transport by internal glucose (i.e. zero-trans influx)
as described by Eq. 5.3.3.
The uptake rate of labelled 14C glucose into isolated trophozoites was reduced
by cytochalasin B with almost complete reduction (93%) obtained at 100 µM
(Fig 5.1). The uptake rates are presented as a percentage of the uninhib-
ited rate (0.18 µmol·min−1·mg−1). These results are in good agreement with
Woodrow et al.223 who reported 75% inhibition at 50 µM cytochalasin B, com-
pared to approximately 70% determined in this work. To obtain an inhibition
constant for cytochalasin B, we assumed i) zero-influx kinetics (i.e. no inter-
nal glucose) and ii) cytochalasin B acts as a noncompetitive inhibitor. The
data were fitted (Fig. 5.1) in Wolfram Mathematica 8.0 to a Michaelis-Menten
equation with cytochalasin B acting as a noncompetitive inhibitor (Eq. 5.3.3),
where VGlcTr is the maximal enzyme rate, KGlc is the Michaelis constant for
glucose, KicytB is the inhibition constant for cytochalasin B, and glucose and
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cytB refer to the concentrations of glucose and cytochalasin B respectively.
The VGlcTr was determined previously as 0.207 µmol·min−1·mg−1 and KGlc
determined as 1.8 ± 0.9 mM (Chapter 3) and the concentration of glucose in
the assay was 5 mM. The fitted KicytB was 11 ± 3.7 µM, which is substan-
tially higher than KicytB , 0.17 ± 0.018 µM (zero-trans entry)120 and 0.50 µM









Figure 5.1: Inhibition of 14C labelled glucose transport into isolated trophozoites
by cytochalasin B. The rate of 14C glucose uptake was determined using a simple
quench ow device at a sampling time of 500 ms. The rate is expressed as a per-
centage of the uninhibited rate (0.18 molmin  1 mg 1 ). The data were tted to
Eq. 5.3.3 and an inhibition constant of 11  3.7 M was obtained for cytochalasin
B. The data are from four biological repeats with n  2 technical repeats. Error
bars represent SEM.
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5.3.3 Inhibition of lactate flux
5.3.3.1 Experimental
To investigate the response of the glycolytic flux (i.e. lactate flux) to the
inhibition of the transporter by cytochalasin B, we measured the production
of extracellular lactate by intact erythrocytes and isolated trophozoites incu-
bated in 5 mM glucose and varying concentrations of the inhibitor (Fig. 5.2).
Inhibition of glycolytic flux was not observed in erythrocytes whereas almost
complete inhibition was obtained at 100 µM cytochalasin B in trophozoites
(Fig. 5.2). A dose response curve of cytochalasin B with respect to lactate
flux in isolated trophozoites (Fig. 5.2) gives an IC50 value of 15 ± 1.1 µM and
a Hill coefficient of −1.8 ± 0.33. The IC50 is defined as the concentration of
cytochalasin B required to obtained 50% inhibition of flux.
5.3.3.2 Model Simulations
With the detailed kinetic models for P. falciparum glycolysis (Chapter 3 &
4) and erythrocyte glycolysis95 we can simulate the effect of inhibition of the
glucose transport activity on the steady state glycolytic flux.
In the Holzhutter model the glucose transporter needed to be decreased to
a very large extent before any inhibition of the glycolytic flux was observed.
To obtain a significant decrease in glycolytic flux (i.e. >5%) the transporter
needed to be inhibited by more than 90%. In the cytochalasin B inhibition
experiment we used very high cytochalasin B concentrations of up to 200
µM. We are not sure of the exact percentage inhibition of glucose transport
activity in the erythrocyte at these cytochalasin B concentrations, but we
expect higher than 90% inhibition14. As such we would have expected to
see a small decrease in the glycolytic flux in the erythrocytes at the higher
cytochalasin B concentrations.
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Figure 5.2: IΝΗΙΒΙΤΙΟΝ ΟΦ ΓΛΨΧΟΛΨΤΙΧ ×ΥΞ ΙΝ P. falciparum ΤΡΟΠΗΟΖΟΙΤΕΣ ΑΝ∆ ΥΝ-
ΙΝΦΕΧΤΕ∆ ΕΡΨΤΗΡΟΧΨΤΕΣ ΒΨ ΧΨΤΟΧΗΑΛΑΣΙΝ B ΧΟΜΠΑΡΕ∆ ΤΟ ΤΗΕ ΜΟ∆ΕΛ ΠΡΕ∆ΙΧΤΙΟΝ ΟΦ ×ΥΞ
ΙΝΗΙΒΙΤΙΟΝ. TΗΕ ΡΑΤΕ ΟΦ ΛΑΧΤΑΤΕ ΠΡΟ∆ΥΧΤΙΟΝ ΙΝ ΕΡΨΤΗΡΟΧΨΤΕΣ ΑΝ∆ ΙΣΟΛΑΤΕ∆ P. falciparum
ΩΑΣ ∆ΕΤΕΡΜΙΝΕ∆ ΟvΕΡ Α 30 ΜΙΝ ΠΕΡΙΟ∆ ΩΗΕΝ ΙΝΧΥΒΑΤΕ∆ ΙΝ 5 ΜM ΓΛΥΧΟΣΕ ΑΝ∆ vΑΡΨΙΝΓ
ΧΟΝΧΕΝΤΡΑΤΙΟΝΣ ΟΦ ΧΨΤΟΧΗΑΛΑΣΙΝ B. TΗΕ ×ΥΞ ΙΣ ΕΞΠΡΕΣΣΕ∆ ΑΣ Α ΠΕΡΧΕΝΤΑΓΕ ΟΦ ΤΗΕ ΥΝ-
ΙΝΗΙΒΙΤΕ∆ ×ΥΞ. FΟΡ P. falciparum ΤΡΟΠΗΟΖΟΙΤΕΣ ΤΗΕ ΙΝΗΙΒΙΤΙΟΝ ∆ΑΤΑ ΩΕΡΕ −ΤΤΕ∆ ΤΟ Α
∆ΟΣΕ ΡΕΣΠ ΟΝΣΕ ΕΘΥΑΤΙΟΝ ΨΙΕΛ∆ΙΝΓ ΑΝ IC 50 vΑΛΥΕ ΟΦ 15  1.1 M ΑΝ∆ Α HΙΛΛ ΧΟΕΧΙΕΝΤ
ΟΦ -1.8  0.31 (ΣΕΕ IΝΣΕΡΤ). TΗΕΡΕ ΙΣ ΝΟ ΟΒΣΕΡvΑΒΛΕ ΙΝΗΙΒΙΤΙΟΝ ΙΝ ΤΗΕ ΕΡΨΤΗΡΟΧΨΤΕ
ΓΛΨΧΟΛΨΤΙΧ ×ΥΞ. TΗΕ ∆ΑΤΑ ΑΡΕ ΤΗΕ ΧΟΜΒΙΝΑΤΙΟΝ ΟΦ ΤΩΟ ΙΝ∆ΕΠΕΝ∆ΕΝΤ ΒΙΟΛΟΓΙΧΑΛ ΡΕΠΕΑΤΣ
ΩΙΤΗ ΤΕΧΗΝΙΧΑΛ ΡΕΠΕΑΤΣ ΙΝ ΤΡΙΠΛΙΧΑΤΕ. TΗΕ ΒΟΛ∆ ∆ΑΣΗΕ∆ ΛΙΝΕ ΡΕΠΡΕΣΕΝΤΣ ΜΟ∆ΕΛ ΣΙΜΥΛΑ-
ΤΙΟΝΣ ΟΦ ΛΑΧΤΑΤΕ ×ΥΞ ΑΣ Α ΦΥΝΧΤΙΟΝ ΟΦ ΧΨΤΟΧΗΑΛΑΣΙΝ B ΧΟΝΧΕΝΤΡΑΤΙΟΝ. TΗΕ −ΝΕΛΨ ∆ΑΣΗΕ∆
ΛΙΝΕΣ ΡΕΠΡΕΣΕΝΤ ΤΗΕ ΣΑΜΕ ΣΙΜΥΛΑΤΙΟΝ, ΒΥΤ ΡΕ×ΕΧΤ ΤΗΕ ΕΞΠΕΡΙΜΕΝΤΑΛ ΕΡΡΟΡ ΟΦ ΤΗΕ −ΤΤΕ∆
ΙΝΗΙΒΙΤΙΟΝ ΧΟΝΣΤΑΝΤ ΦΟΡ ΧΨΤΟΧΗΑΛΑΣΙΝ B. EΡΡΟΡ ΒΑΡΣ ΑΡΕ SEM, Ν = 6
For the trophozoites we have measured the cytochalasin B inhibition of glucose
transport and it is therefore easy to simulate the inhibition in the detailed
kinetic model. Such a simulation can address the question; can the inhibition
of the ux be ascribed to the inhibition of the glucose transporter alone? To
simulate the inhibition of the lactate ux in P. falciparum we modied the
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model by including a new equation (Eq. 5.3.4) for glucose transport, which
included noncompetitive inhibition by cytochalasin B. For the equation, we i)
assumed symmetrical noncompetitive binding of cytochalasin B and ii) used
the inhibition constant (KicytB , 11 ± 3.7 µM) determined in this study (Fig.
5.1) and iii) assumed internal and external concentrations of cytochalasin B
were equal. The VGlcTr was determined previously as 0.21 µmol·min−1·mg−1
and KGlc determined as 1.8 ± 0.9 mM (Chapter 3). The subscripts ext and























The modified model provided a tool to investigate how the cytochalasin B
inhibition of the transporter influences glycolytic flux (i.e. lactate flux). The
inhibition experiment was simulated in the model by determining the steady
state lactate flux over a range of cytochalasin B concentrations (0 - 100 µM),
and expressing it as a percentage of the uninhibited flux (Fig. 5.2). This
was also simulated with the KicytB set to its upper and lower ranges within
the experimental error (11 ± 3.7 µM) and indicated in Figure 5.2 as finely
dashed lines. The experimental inhibition of flux is slightly underestimated
by the model, at high cytochalasin concentrations, but it describes the overall
inhibition experiment quite well (Fig. 5.2).
5.3.4 Inhibition of glycolytic enzymes
As previously mentioned, cytochalasin B inhibits the glucose transporter in
both Plasmodium spp. and erythrocytes and also influences a number of cel-
lular processes. We assume the inhibition of the flux is due to the inhibition
of the glucose transporter since none of the known effects of cytochalasin B
interfere with the central carbon metabolism. In addition, the following obser-
vations are in agreement with this assumption: i) in erythrocytes, cytochalasin
B does not influence the production rate of lactate and as such it is not ex-
pected to inhibit glycolysis at an enzyme level, and ii) glucose transport is
inhibited by cytochalasin B in pink erythrocytes, and iii) glucose uptake via
PfHT1, which was expressed in frog oocytes is inhibited by cytochalasin B.
As a further control to ensure that the inhibition of lactate flux is not due to
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the inhibition of the glycolytic enzymes, we measured the specific activity of
each glycolytic enzyme in isolated P. falciparum lysates under near saturating
substrate concentrations in the presence or absence of 100 µM cytochalasin B
(Fig. 5.3).
No significant (P <0.05 n = 6) inhibition at 100 µM cytochalasin B was ob-
served for any of the enzymes. If anything, a mild activation of the enzyme
rate (PGI, ENO, and LDH) is observed, although the reason for this is un-
clear. These results, in addition to the previously mentioned reasons, provide
further evidence that the inhibition of the flux during the short time period
of the incubation experiments, is directly due to the inhibition of the glucose
transporter.
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Figure 5.3: Specific activities for the glycolytic enzymes of P. falciparum in the
presence or absence of cytochalasin B. The specific activity of each glycolytic en-
zyme was determined at near saturating substrate concentrations, in the presence
or absence of 100 µM cytochalasin B prepared in DMSO. The control excluded
cytochalasin, but included an equivalent concentration of DMSO. No inhibition of
enzyme activity by cytochalasin B is observed, although small, but significant in-
creases in activity are observed for PGI and ENO (Paired T-test, P < 0.05) and
LDH (Paired T-test, P < 0.01). The data are from a single biological experiment,
but the enzyme activities were determined from two independent trophozoite iso-
lations. In each isolation the enzyme activity was determined in triplicate. Error
bars represent SEM, n = 6, except in the case of PFK where n = 3. HK (hexoki-
nase), PGI (phosphoglucoisomerase), PFK (phosphofructokinase), ALD (aldolase),
TPI (triosephosphate isomerase), G3PDHrev (glyceraldehyde 3-phosphate dehydro-
genase in the reverse direction), PGKrev (Phosphoglycerate kinase assayed in reverse
direction), PGM (phosphoglycerate mutase), ENO (enolase), PK (pyruvate kinase),
LDH (lactate dehydrogenase)
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5.3.5 Control coefficient of PfHT1
In this study we show that cytochalasin B directly inhibits the glucose trans-
porter (a local property) and that this inhibition of the transporter results in
a decrease in the glycolytic flux (systemic property). These local and systemic
properties can be described by elasticity and response coefficients (see intro-
duction) respectively. The elasticity of PfHT1 quantifies the degree of change
in the rate of the transporter due to a small change in the concentration of the
inhibitor (cytB) and can be mathematically described as:
εvGlcTrcytB = ∂ ln vGlcTr∂ ln cytB
The relative change in the steady state lactate flux (JLac) due to a small change
in the inhibitor concentration (cytB) can be defined mathematically as a re-
sponse coefficient:
RJLaccytB = d ln JLacd ln cytB = C
JLac
vGlcTr · εvGlcTrcytB
The response coefficient can be further described as the product of the flux
control coefficient (i.e. CJLacvGlcTr) and the elasticity. The control coefficient can











= d ln JLac
∂ ln vGlcTr
Thus a plot of the percentage change of the lactate flux as a function of the per-
centage glucose transporter activity can be used to determine the flux control
coefficient (Fig. 5.4). The slope of resulting curves at 100% transport activity
would reflect the relative change in the lactate flux (i.e. the flux control coef-
ficient). To determine the flux control coefficient we plotted the percentage of
lactate flux as a function of percentage glucose transporter activity for i) exper-
imentally measured values, ii) the equations used to describe the experimental
data (i.e. Hill equation, Insert - Fig. 5.2 and Eq. 5.3.3, a Michaelis-Menten
equation with a noncompetitive inhibitor, Fig. 5.1) and iii) model simulations
(as described for the prediction of lactate flux, Fig. 5.2) where the KicytB was
set to its upper and lower ranges within the experimental error (11 ± 3.7 µM)
.
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Figure 5.4: Determination of the control coecient for P. falciparum PFHT1. Per-
centage of lactate ux is plotted as function of the percentage of the glucose transport
activity in P. falciparum. Uninhibited transporter activity (100%) equates to 100%
lactate ux. As the transporter activity is decreased, the lactate ux decreases ac-
cordingly. The slope of the curves near 100% glucose transporter activity is equal
to the ux control coecient for the glucose transporter (see text for discussion).
The experimental data for P. falciparum shown here is the ratio of the percentage
×ux (Fig. 5.2) and percentage transporter rate at identical cytochalasin B inhibitor
concentrations. The tted curve describes the decrease in ux and glucose trans-
porter rate predicted by the equations that were used to t the experimental ux
inhibition (Hill equation, see Insert Fig. 5.2) and glucose transporter inhibition (Eq.
5.3.3, Fig. 5.1). The model simulation (bold dashed line) describes the predicted
decrease in lactate production as a function of the transporter activity. The simula-
tion was also determined at the upper and lower ranges (nely dashed lines) of the
experimentally determined K i cytB (11  3.7 M). The control coecients obtained
from the slopes near 100% transporter activity are listed in Table 5.2.
The slope of the experimental data were taken between approximately 75%
and 100% (smallest experimental perturbation) of the glucose transporter ac-
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tivity and yielded a flux control coefficient of 0.315. For the equations the
slope was taken at 100% transporter activity. The flux control coefficient for
the model simulations was determined using two methods, i) the elasticity
matrix inversion method described by87 and implemented on JWS Online and
ii) a perturbation method (Fig. 5.4 where cytochalasin B concentration was
increased (i.e. transporter activity and flux decrease). For the latter method,
the error on the cytochalasin inhibition constant KicytB , could also be incor-
porated by repeating the calculation at higher and lower values (11 ± 3.7 µM).
The glucose transporter flux control coefficients are listed in Table 5.2.
Table 5.2: Flux control coefficients for the P. falciparum glucose transporter. Flux
control coefficients were determined from the slopes of experimental and model sim-
ulation data shown in Fig. 5.4. For the experimental data, the slope was taken
between approximately 75% and 100%. For model simulation, the control coeffi-
cient was determined using a standard matrix inversion method as well as by the
perturbation method. For the latter, model simulation was determined at KicytB
set to its upper and lower ranges within the experimental error (11 ± 3.7 µM). The
resulting lower and upper flux control coefficients are indicated in parentheses.
Source CJLacvGlcTr
Experimental 0.315
Experimental Fitted Curve 0.0100
Model Simulation: Matrix Method 0.223
Model Simulation: Perturbation Method 0.228 (0.172 - 0.340)
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5.4 Discussion
Differential control analysis is a powerful tool to identify enzymes in the
pathogen with high flux control where the equivalent reaction has a low flux
control in the host. A reaction with high differential control presents a favourable
drug target as inhibition of the host and parasite enzyme to the same degree
is expected to affect the parasite to a larger degree than the host.
This work has three aims. Firstly to identify potential drug targets in P.
falciparum using differential control analysis, secondly to demonstrate via in-
hibition experiments that a differential effect in host and parasite can be ob-
tained and thirdly, to experimentally determine the flux control coefficient
(CJvGlcTr) of the glucose transporter in P. falciparum as a form of validating
the kinetic model.
Metabolic control analysis of an erythrocyte model of glycolysis95 and the P.
falciparum kinetic model (Chapter 3 & 4) indicates (Table 5.1) that the glu-
cose transporter, HK, PFK and G3PDH as well as the ATPase share most of
the flux control in asexual P. falciparum. For the erythrocyte the ATPase and
the 2,3 -bisphosphoglycerate shunt have the highest control of the glycolytic
flux53 and the glucose transporter in the erythrocyte has no flux control.
The hexose transporter, PfHT1155, aldolase219, triosephosphate isomerase169
and lactate dehydrogenase20 have been proposed as potential drug targets
in glycolysis of P. falciparum. The low flux control coefficients of aldolase,
LDH and TPI would indicate that in order to use these as drug targets, the
step would need to be inhibited to a large extent to inhibit parasite glycolysis.
When one considers the scaled effectivities (Table 5.1), Glucose transport, HK,
and G3PDH are ranked the highest and are possibly the best potential drug
targets in P. falciparum glycolysis. P. falciparum PFK is also highly ranked,
which would indicate an attractive target, but its control in the erythrocyte
is only a factor 15 less. As such, this target would require a greater degree of
drug specificity, so as to not inhibit the host.
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In contrast to the erythrocyte GLUT1, MCA of a detailed model of P. fal-
ciparum glycolysis shows that the parasite transporter, PfHT1, has significant
control (CJvPfHT1 = 0.221) of the glycolytic flux. Inhibition of the transporter
should result in a significant inhibition of the flux. To demonstrate differential
control in vivo we set out to show that the inhibition of the glucose transporter
in erythrocytes (shown by others) and P. falciparum leads to an inhibition of
glycolytic flux in P. falciparum, but not in erythrocytes.
In P. falciparum the glycolytic flux is strongly inhibited by cytochalasin B
(Fig. 5.2). The inhibition of the lactate flux is ascribed to the inhibition
of PfHT1, which was almost completely inhibited at 100 uM (Fig. 5.1) in
vivo. In stark contrast, the flux of the erythrocyte was not visibly inhibited
by 200 µM cytochalasin B (Fig. 5.2), even though at half this concentration,
the transporter has been shown to be inhibited by more than >95%14. Fur-
thermore, analysis of the Holzhutter model indicated 5% inhibition of flux at
90% inhibition of glucose transporter. Thus although the transporter in ery-
throcytes needs to be inhibited to a much larger extent than the transporter
in the parasite, we would have expected to see a small decrease in erythro-
cyte flux at the highest cytochalasin B concentrations. It has recently been
shown that unless the rate of glucose uptake rate in erythrocytes is measured
in under 30 ms, the maximal uptake rate is underestimated and does not re-
flect zero-trans influx kinetics15. Thus, if the Vmax of glucose transport in the
Holzhutter model is underestimated, it may explain why no inhibition of the
flux is observed. It has been reported that, due to the high over-capacity of
the glucose transporter (103 fold greater than glucose utilisation), more than
99% inhibition of the transporter would be required to observe inhibition of
the glycolytic flux14. This may explain our finding that 200 µM cytochalasin
B does not inhibit glycolytic flux in erythrocytes.
By including a rate equation that captured the kinetics of the noncompeti-
tive inhibition of the glucose transporter by cytochalasin B into the model, we
could give a good description of the inhibition of lactate flux in P. falciparum
trophozoites by cytochalasin B in vivo. This finding provides further evidence
that inhibition of the glucose transporter by cytochalasin B alone is sufficient
to describe the inhibition of the flux.
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These findings successfully demonstrate the differential control in vivo pre-
dicted by the model and also show that by inhibiting both transporters to
a similar degree (> 97%), only the parasite flux is influenced. This demon-
stration highlights the glucose transporter as a potential target as well as the
strength of differential control analysis. Although this study highlights the
glucose transporter as a potential drug target within malaria glycolysis, only
the parasite and erythrocyte glucose transporter control coefficients have been
compared. In reality, the human body has a number of different glucose trans-
porters within a variety of different tissues (e.g. brain, muscle, liver). In these
cases, the glucose transporter may have a high control of the glycolytic flux,
and consequently a lower effectivity and less attractive drug target. Inhibi-
tion of these targets could also, in many cases, be highly toxic to the host. It
would therefore be necessary to also evaluate the metabolic flux control of the
glucose transporter in other tissues before trying to develop glucose transport
inhibitors. Another factor to consider when developing inhibitors of glucose
transport is the fact that the glucose concentration is expected to vary be-
tween tissues. In tissues with glucose concentrations lower than found in the
blood stream, competitive inhibitors of glucose transport would potentially
exacerbate toxicity in the host by inhibiting glucose uptake to a large degree.
As such, glucose transport inhibitors should preferably be uncompetitive to
ensure efficacy regardless of the glucose concentration.
Does high scaled effectivity always present a good potential drug target? This
would not always be the case, especially in complex nonlinear systems. The
reason for this is that control coefficients typically represent a change in flux
or metabolite concentration over a small (typically 1%) change in enzyme rate.
For larger changes, as would be expected during a drug inhibition, the change
in flux or metabolite concentrations may not be linear. As the enzyme is in-
hibited, the control would be expected to increase. If the pathogen and host
control coefficients changed in a similar manner, then the pathogen would al-
ways be inhibited to a greater extent. However, one could foresee a scenario
where an enzyme with low control may reach a threshold point and suddenly
gain a great deal of control in a network, whereas in the pathogen the change
in control could be linear and result in a greater degree of inhibition in the
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host. In selecting a drug target based on model analysis, it may thus be valu-
able to consider more than just the control coefficients and also examine the
effect of large changes to enzyme rate. Furthermore, alternative pathways or
isozymes should also be considered, as inhibiting a reaction may not influence
the pathogen if it is able to utilise an alternative pathway.
For determining the effectivities, we assumed a similar degree of inhibition
to both host and pathogen enzymes, which is useful when analysing a network
for potential drug targets if drug selectivity (εvpathogendrug / ε
vhost
drug ) is unknown. The
half maximal inhibition constants for cytochalasin B, are 10 fold lower for
the erythrocyte transporter than for the parasite transporter and as such the
erythrocyte transporter it is inhibited to a greater extent at a similar concen-
tration of cytochalasin B. The strength of the effectivity definition is that it
can take both selectivity of inhibition and the differential control into account.
Thus whereas the selectivity of the cytochalasin B is poor, its effectivity for
inhibiting flux in the parasite is high due to the large percentage difference in
control coefficients.
We were able to determine a flux control coefficient (0.32) for the glucose trans-
porter from experimental data, which was approximately 1.5 times greater than
calculated by MCA (0.22). However, the experimental control is expected to
be a slight overestimation as it was determined over a large (20%) change in
transporter activity, whereas control coefficients typically are determined for
very small changes. Model simulation over the large change yielded a flux
control coefficient range (0.17 - 0.34), which is in good agreement with the
experimentally determined value. The large discrepancy between the control
coefficients determined from the experimental data (0.32) and that determined
from the fitted curve (0.01) is due to the type of equation that was used to
fit the data points. The sigmoidal nature of a Hill equation results in a low
gradient (i.e. control coefficient) at the origin (i.e. 100% PfHT1 activity, Fig.
5.4). The small number of data points biases the curve towards a more sig-
moidal shape (especially the % PfHT1 activity at 50 µM cytochalasin B, Fig.
5.4), and inevitably results in a more sigmoidal fit and reduced control coeffi-
cient. This does, however, not detract from the good comparison between the
experimentally determined control coefficient and that determined by model
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simulation.
This good comparison of experimental data and model prediction provides,
in conjunction with previous work (Chapter 4), a further validation for the
kinetic model. Not only can the model give a good prediction for the reference
criteria for which it was constructed, but it also gives a fair prediction of a per-
turbation of this reference condition (i.e. inhibition titration). It thus provides
a greater degree of confidence in using the kinetic model as a tool for drug tar-
get identification and for understanding the systemic behaviour of the network.
The other potential drug target that was highlighted in this study is G3PDH,
which has a high differential control ratio, and has a glycolytic flux control co-
efficient of 0.306 in the parasite. Poolman et al.160 demonstrated that iodoac-
etate inhibits G3PDH in Streptococcus spp. and used the compound to deter-
mine the flux control strength of the enzyme. Iodoacetate could be used to
investigate the flux control of G3PDH in the erythrocyte and P. falciparum
trophozoites, in a similar manner to which cytochalasin B was used in this
study.
This study has identified drug targets based on differential control analysis
and we have demonstrated the concept in vivo. Differential control analysis
highlighted the glucose transporter and G3PDH as potential drug targets in
P. falciparum. We were able to demonstrate the differential control inhibition
in vivo by showing that although cytochalasin B specifically inhibits both the
erythrocyte and P. falciparum glucose transporter, only the flux of the para-
site is inhibited with negligible effect on the host erythrocyte. These findings
highlight the importance of detailed kinetic models and differential control
analysis as tools for drug target identification.
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Chapter 6
General Discussion, Conclusions and
Future Work
The aim of the research reported in this thesis was threefold: Firstly, to cre-
ate a detailed kinetic model of P. falciparum glycolysis and secondly use this
model as a tool for drug target identification in the pathway. Lastly, we aimed
to demonstrate experimentally that the predicted drug target was effective in
intact P. falciparum trophozoites. During the project we also addressed ques-
tions such as i) is the bottom up approach used in this study to construct
and validate a kinetic model applicable to other pathways and organisms and
ii) whether a model constructed in this manner gives a sufficient description
of the network to use as a tool for drug target identification and iii) whether
differential control analysis of networks is a suitable approach for drug target
identification in general.
We have shown that a model of P. falciparum glycolysis constructed from the
individual enzyme kinetics measured experimentally in vitro can predict the
metabolic fluxes, metabolites concentrations in intact P. falciparum tropho-
zoites. In addition, our model was able to predict an enzyme inhibitor titration
of the glucose transporter for which a flux control coefficient could be deter-
mined. This description was achieved without fitting and raises the question
of whether any network can be well described on the basis of enzyme kinetics.
Kinetic models of yeast205,215 and T. brucei glycolysis7 have also, from the
enzyme kinetics, been able to give a good description of systemic properties.
It thus appears that, at least for smaller networks, this bottom up approach
can sufficiently describe a system and can be used for applications such as drug
target identification. Experimentally, the enzymes of glycolysis are relatively
134
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simple to characterise biochemically, with the result that the kinetic data is
fairly accurate. It would be expected that kinetic data would be more error
prone and less complete for pathways (e.g. pentose phosphate pathway, tricar-
boxylic acid cycle, purine nucleotide biosynthesis) in which the enzymes are
more difficult to characterise biochemically. However, in this study we used
some kinetic parameters from the scientific literature (e.g. Vmax for pyruvate
and lactate transport, KDHAP and KGAP ) and had a range of uncertainty in
other parameters, such as the ATP:ADP ratio. These were shown to not influ-
ence the model prediction unduly. Furthermore, PSA of the model indicated
that less than a third of the parameters had high response coefficients. These
findings indicate that having accurate kinetic data, although preferable, is not
a prerequisite for an accurate systemic description. For complex networks it
may thus be possible to still adequately describe systemic behaviour with er-
ror prone or incomplete kinetic data. Furthermore, by iteratively identifying
parameters that have a high influence on model behaviour or prediction with
MCA and PSA, it is possible to prioritise time and resources to experimen-
tally improving the accuracy of important parameters. Such an approach may
provide kinetic models at less cost in terms of time and resources and still be
sufficient as a tool for drug target identification
Differential control analysis of the host and parasite kinetic models indicated
that of the suggested P. falciparum glycolytic drug targets, glyceraldehyde 3-
phosphate dehydrogenase and the glucose transporter were the most attractive
due to their high effectivity. The finding that the glucose transporter has high
effectivity, provides further support to research currently directed at selectively
inhibiting this transporter103,101,198.
Until now, differential control analysis has only been suggested as a tool for
drug target identification and has not been demonstrated in vivo. Having pre-
sented experimental evidence of the differential flux control of the erythrocyte
and P. falciparum glucose transporter, we demonstrated that this knowledge
can be used to effectively inhibit the parasite glycolytic flux. This difference
in inhibition is achieved despite the fact that the erythrocyte transporter is
inhibited to an even greater degree than the parasite transporter. This finding
highlights differential control analysis as a tool for drug target identification;
Even though a drug may inhibit the host enzyme to a greater extent than the
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pathogen, if the effectivity of the reaction is high enough, the host would be
influenced to a lesser degree than the pathogen.
Since humans have a number of tissues, each with distinct requirements in
terms of metabolism and consequently different pathway regulation, enzyme
expression and possibly network topology, the metabolic control profile of a
network would be tissue specific. As such the effectivity of a drug compared
to the pathogen could differ in different tissues. Therefore, the glucose trans-
porter might not necessarily have such a low flux control in other human tissues
(compared to the erythrocyte). It would therefore be expedient to perform dif-
ferential control analysis on a number of different tissue specific pathways or
consider enzymes whose function or metabolic control is expected to be con-
served between tissues.
The kinetic model has already enhanced our understanding of P. falciparum
glycolysis by indicating the flux controlling enzymes and by showing that glyc-
erol production is required to maintain trophozoite redox balance. Another as-
pect that could be investigated is the role of the kinetic regulation of PFK and
PK in P. falciparum glycolysis. In particular PK, which exhibits cooperativity
with regards to ATP and inhibition by both of its substrates raises the question
of the role of this kinetic behaviour in the glycolytic pathway. Does the regu-
lation improve network robustness, have a role in the glycerol metabolism by
regulating the PEP concentration or possibly have a role in the PEPC branch?
The importance of the PPP in the detoxification of reactive oxygen species
and free ferriprotoporphyrin IX (FP) warrants that the current model be ex-
tended to include this pathway. Such a combined model would improve the
understanding of its link to glycolysis and whether GluPho, the first enzyme
in this pathway, which has been highlighted as a potential drug target plays
an important role in controlling the PPP flux.
This study has considered the isolated trophozoite and uninfected erythro-
cytes. The logical progression of the kinetic model presented in this work,
would be to integrate it into a model of erythrocyte glycolysis. This is cur-
rently being investigated in our research group. Such a model would be partic-
ularly useful for understanding host-pathogen relationships such as the change
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in intra-erythrocyte 2,3-bisphosphoglycerate (2,3BPG) concentrations, which
regulates oxygen homoeostasis within the erythrocyte. In theory, if parasite
metabolism increased the intracellular concentration of 2,3 BPG significantly,
it would promote oxygen release from the haemoglobin. This release of oxygen
may have important implications for the oxidative stress experienced by the
parasite.
6.1 Conclusion
This study has merged the disciplines of biochemistry and systems biology
to investigate and identify potential drug targets in the glucose catabolism
of P. falciparum. In the study, each of the glycolytic enzymes of asexual
P. falciparum glycolysis were biochemically characterised and described by
a mechanistic rate equation. Without the need for fitting, the kinetic ODE
model constructed with these rate equations gave a fair description of the
steady state flux, flux control coefficient of the glucose transporter and some
of the metabolic intermediate concentrations. This validated model provides a
measure of confidence in the drug targets that were identified in P. falciparum
glycolysis with differential control analysis. Furthermore, we were able to
experimentally demonstrate differential control of the glucose transport in the
parasite and host erythrocyte. This shows that even though a drug may inhibit
the host enzyme to a greater extent than in the pathogen, the pathogen’s flux
is still inhibited to a greater degree provided the effectivity is high enough.
This finding highlights the strength of kinetic models and differential control
analysis as tools for drug target identification. The detailed kinetic model
constructed in this study provides a strong foundation for future extension,
which will aim to improve our understanding of the central carbon metabolism






Supplementary Material for Chapter 4:
Model Validation and Analysis
A.1 Metabolic Control Analysis
JWS Online and Copasi were used to perform MCA on the model and de-
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A.2 Parameter Sensitivity Analysis
A.2.1 Response Coefficients
Copasi was used to determine the flux response coefficients (Table A.3).
A.2.2 ATP:ADP ratio
Figure A.1: Model predictions of steady state ux for glucose uptake and lactate,
pyruvate and glycerol production as a function of the ATP:ADP ratio. The ratio
was obtained by tting the ATPase reaction, where higher rates lead to a lower
ratio.
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FΙΓΥΡΕ A.2: Model predictions of steady state metabolite concentrations in up-
per glycolysis. The concentrations for metabolites in upper glycolysis (G6P, F6P,
F1,6BP, DHAP and GAP) and the rst metabolite in lower glycolysis 1,3-BPG are
shown across a range of ATP:ADP ratios. The ratio was obtained by tting the
ATPase reaction
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FΙΓΥΡΕ A.3: Model predictions of steady state metabolite concentrations in lower
glycolysis. The concentrations for the metabolites found in lower glycolysis (3-PG,
2-PG, PEP, Pyruvate, Lactate and NAD) of P. falciparum are shown across a range
of ATP:ADP ratios. In each instance the desired ratio was obtained by tting the
ATPase reaction.
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A.2.3 Pyruvate and Lactate Transport Rate
A1 A2
B 1 B 2
Figure A.4: Broad range parameter sensitivity analysis of the monocarboxylate
transporter. Lactate and pyruvate are transported out of the parasite via a mono-
carboxylate transporter that has been characterised inP. falciparum at 4°C. The
rate of transport at 37°C is expected to be up to 8 fold greater, based on the assump-
tion of a Q10 of 2. The response of the model to A) Lactate transporterVmax and
(B) Pyruvate transporter Vmax was investigated over a range covering the indicated
published value and hypothesised rate at 37°C. The eects on both ux (A1 & B1)
as well as steady state metabolite concentrations of all metabolites (A2 & B2) are
shown. For simplicity, all metabolites are shown together as for the lactate trans-
porter rate (A2) only lactate vary and for the pyruvate transporter (B2), pyruvate
is not visibly aected. Overall, the MCT transporter rate has minimal eect on the
overall model prediction and the assumption of an 8 fold increase in reaction rate,
plausible or not, only impacts model output to a small degree.
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A.2.4 Glycerol Transport Rate
A B
FΙΓΥΡΕ A.5: Eect of the glyceraldehyde 3-phosphate dehydrogenase on model pre-
diction. The Vmax for the glyceraldehyde 3-phosphate dehydrogenase was tted to
obtain an experimentally determined glycerol ux. The inuence on this behaviour
is shown for all the external uxes (A) and on the steady state metabolite concen-
trations (B) is indicated. For B, the largest change is the G6P concentration, while
others are largely unaected.
A.3 Resp onse Co ecients
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Development of a Simple Quench Flow
Device
B.1 Introduction
Glucose uptake in P. falciparum trophozoites has been shown to be rapid.
Manual uptake assays, which are limited in speed and accuracy were not suf-
ficient to capture zero-trans uptake rates. Commercial quench-flow devices
have the advantage that they are extremely rapid with sampling times less
than 10 ms, but they are expensive and require large volumes of sample. The
latter point in particular is relevant, as obtaining large volumes of isolated P.
falciparum trophozoites is difficult due to the culture volume required. The
availability of programmable logic boards prompted the idea of creating a
solenoid valve based quench-flow device. The main criteria for the device were
low sample volume ( <50 µL), minimal wastage and a quench time of approx-
imately 100 ms.
B.2 Materials
The Arduino Uno Logic Board with an ATmega328 microcontroller was pur-
chased from RS Components (South Africa). A standard 24V relay board
to open the solenoid valves (8 mm 2/3 way Universal X-Valve, 24 VDC, 100
PSI, Parker Hannifin Corporation, USA) when triggered by a 5 VDC signal
from the Arduino logic board was bought on Ebay.com. An LCD and keypad
model for the Arduino Logic board was bought from Ebay.com. Standard 12
149
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VDC and 24 VDC power sources were obtained from RS Components (South
Africa). PTFE (Teflon) tubing (2 mm) was used throughout. Samples were
mixed through a 4 way HPLC mixer. One way valves (Fourmost Auto Plug-
one way valve) were obtained from Phil’s Hobby Shop (Illinois, USA).
B.3 Machine Design
B.3.1 Design Overview
A quench-flow reaction device typically involves mixing two or more reagents
and halting the reaction with a quench buffer after a short pre-set time. The
quench-flow device presented here (Fig. B.1), has two sample ports and a
quench buffer injection port. Samples are manually pipetted into the sample
ports and closed. The samples are mixed through the mixing chamber, when
then high pressure (200 kPa) sample lines are opened by the solenoid S1. S1
is kept open and after a set time (programmable quench time), the S2 valve
is opened and this drives quench buffer from the buffer reservoir through the
mixing chamber and onto the sample held in the collection vial. This effectively
quenches the reaction and the contents of the collection vial can be further
analysed (e.g. spectrophotometer). Two non-return valves were incorporated
into the design to ensure correct sample and quench buffer directionality and
also ensure that the solenoid valves could not be flooded.
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Figure B.1: Schematic description of the quench-flow device. Samples (e.g. cells
and glucose, or substrate and enzymes) are manually inserted into the sample ports
1 and 2 respectively, which are subsequently closed. Initiating the quench-flow
device from the controller opens solenoid valve S1, which opens the pressure line
and injects the samples through the mixing chamber into the collection vial. After
the set quench time (e.g. 500 ms), solenoid valve S2 is triggered, and the pressure
line drives quench buffer through the mixing device and into the collection chamber,
quenching the reaction. Although not indicated on the diagram, each of the sample
and quench-flow lines are temperature regulated and the quench buffer reservoir is
kept in an salt ice bath (see text for description).
B.3.1.1 Sample Ports
Most quench-flow devices that are commercially available require a fairly large
volume of sample, as a lot of sample remains in the tubing. Obtaining high
volumes (up to 1 mL) of isolated P. falciparum trophozoites is expensive and
very labour intensive. To minimise wastage, two in-line sample ports were
inserted near the mixing chamber. To insert the sample, these ports are opened
and the required sample volume (30 - 200 µL) is manually pipetted into the
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port. This method has the advantage that the accuracy of the sample volume
is determined by the pipette rather than the quench device. Furthermore, the
close proximity of the sample to the mixing chamber reduces the dead time,
and minimises the loss of sample that remains in the tubing.
B.3.1.2 Quenching
The quench buffer reservoir was typically a 500 mL shot bottle kept in a salt-ice
bath at -20 °C. Opening of the S2 solenoid valve would increase the pressure in
the reservoir and drive buffer through the quench line and through the mixing
chamber. The advantage of quenching through the mixing chamber is that any
residual mixed sample in the chamber and line is flushed into the collection
vial, thus minimising sample loss. This is particularly relevant when using
cells (i.e. yeast or P. falciparum trophozoites), that are fairly viscous and do
not entirely flush through during the mixing cycle.
B.3.1.3 Mixing
A simple 4-channel HPLC mixer was incorporated into the device. In simple T-
mixers, it has been shown that the distance that the mixed sample travels after
the T-section greatly determined the extent of mixing30. In this device, the
distance was approximately 7 cm, and the sample was injected into a collection
vial providing additional mixing. For the quench times (>150 ms) required
for our assays this mixing was deemed sufficient. Specialised mixing micro-
volume devices are commercial available and could easily be incorporated into
the device if more complete mixing were required.
B.3.1.4 Controller
Two solenoid valves (closed by default) were controlled by a self-programmed
Arduino Uno logic board. The logic board is linked to an LCD screen and
keypad. When triggered by the user a 24 VDC relay was activated, which in
turn opened the solenoid valves. The time between opening the first (S1, Fig.
B.1) and second (S2, Fig. B.1) solenoid valve determined the quench time of
the reaction. From the menu, a user can set with the keypad i) the Quench
Time, which is defined as the time between mixing samples and quenching, ii)
the Mix Delay which is the time the quench valve is open (i.e. the longer the
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mix time, the greater the volume of quench buffer is injected) and iii) The air
flush time, which after manual flushing of the system is used to dry the area
before another sample run.
B.3.1.5 Temperature Regulation
We required an assay temperature of 37 °C. To regulate this temperature 1.5
mm silicon piping was coiled over the sample ports and mixing chamber. This
pipe was connected to a water bath and warm water circulated through the
heating coil using a peristaltic pump. Temperature of the mixing chamber was
checked with a thermometer. A separate piping coil was placed on the quench
line and a peristaltic pump circulated a salt-water mixture at 0 °C.
B.3.1.6 Flushing
After each assay run, sample ports and mixing chamber were flushed by man-
ually injecting assay buffer through the sample ports with a 100 mL syringe.
After sufficient rinsing ( >20 mL), an Air Flush option on the controller was
activated which was used to remove residual buffer and dry the chambers.
B.3.1.7 Pressure
The pressure line was linked to a nitrogen gas canister (Afrox, South Africa).
Pressure was regulated to 200 kPa.
B.4 Calibration
Calibration of the quench-flow device is required to determine the dead-time.
When the first solenoid valve opens at T0, it takes time before the samples are
mixed. Furthermore, when the quench solenoid valve is opened it takes time
for the reaction to be completely quenched.
The rapid oxidation of NADH by 70% m/v perchloric acid (PCA) was used for
device calibration. 100 µL of 20 mM NADH was mixed with 100 µL 70% m/v
PCA and the reaction was quenched with approximately 1.5 mL 1 N NaOH
between 0.1 and 5 s (Fig. B.2). After quenching, to account for small varia-
tions in quench volume, the volume of all the quenched samples was adjusted
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to 2 mL. Aliquots of each sample were diluted between 10 and 50 time and to
quantify the remaining NADH, the absorbance at 340 nm was measured on a
spectrophotometer (Biotek PowerWave™ 340). As a control (A0), the NADH
was added to the quench buffer prior to the addition of PCA.
From these data, the dead time can be calculated from Eq. B.4.1157, where At
describes the absorbance measured at a specific time, A0 refers to the control
absorbance with no reaction occurring, k refers to the first order rate constant,
t refers to time and td refers to the dead time. The data were fitted to this
equation in Wolfram Mathematica 8.0, which yielded a dead time of 151 ±
62.0 ms.
At = A0e−k(t+td) (B.4.1)
Figure B.2: Determination of the quench-ow device dead time. The dead time of
the quench-ow device was determined by measuring the rapid oxidation of NADH
by 70% m/v PCA. To obtain the dead time, td, the data between 0 and 500 ms were
tted to Eq. B.4.1. A dead time of 151  62.0 ms was calculated. The data is the
combination of two independent experiments and error bars are SEM, n = 4.
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B.5 Discussion
We required a simple and cost effective quench-flow device that could operate
with very low sample volumes (30 µL) with minimal wastage at quench speeds
of approximately 100 ms.
The air pressured system presented here meets these requirements fairly well.
In particular it is able to utilise very low sample volumes with minimal wastage.
The dead time is a bit higher than initially wanted, but still suitable for our
assay requirement. This dead time could be improved by increasing the pres-
sure of the gas line, but would require different solenoid valves. Another option
would be to pressurise the buffer reservoir, but this raises safety concerns and
would require a specialised reservoir for the pressure. This method would also
require the buffer to move through the solenoid valve and thus the solenoid
specification should cater for required quench buffers (e.g. corrosive quench
buffers)
Further development of the device is possible, but at present it is suitable
for our requirements and promises to be an important tool for investigating
the glucose uptake in P. falciparum trophozoites.
Stellenbosch University http://scholar.sun.ac.za
List of References
1. Agbenyega, T., Angus, B. J., Bedu-Addo, G., Baffoe-Bonnie, B., Guyton, T.,
Stacpoole, P. W., and Krishna, S. (2000). Glucose and lactate kinetics in children
with severe malaria. J. Clin. Endocrinol. Metab., 85(4):1569–1576.
2. Allen, R. and Kirk, K. (2004). Cell volume control in the Plasmodium-infected
erythrocyte. Trends Parasitol.., 20(1):7–10.
3. Ansorge, I., Benting, J., Bhakdi, S., and Lingelbach, K. (1996). Protein sorting
in Plasmodium falciparum-infected red blood cells permeabilized with the pore-
forming protein streptolysin O. Biochem. J., 315:307–314.
4. Ansorge, I., Paprotka, K., Bhakdi, S., and Lingelbach, K. (1997). Permeabiliza-
tion of the erythrocyte membrane with streptolysin O allows access to the vacuolar
membrane of Plasmodium falciparum and a molecular analysis of membrane topol-
ogy. Mol. Biochem. Parasitol., 84(2):259–261.
5. Antonio, C., Larson, T., Gilday, A., Graham, I., Bergström, E., and Thomas-
Oates, J. (2008). Hydrophilic interaction chromatography/electrospray mass spec-
trometry analysis of carbohydrate-related metabolites from Arabidopsis thaliana
leaf tissue. Rapid Commun. Mass Spectrom., 22(9):1399 –1407.
6. Atamna, H., Pescarmona, G., and Ginsburg, H. (1994). Hexose-monophosphate
shunt activity in intact Plasmodium falciparum infected erythrocytes and in free
parasites. Mol. Biochem. Parasitol., 67:79–89.
7. Bakker, B. M., Michels, P. A., Opperdoes, F. R., and Westerhoff, H. V. (1997).
Glycolysis in bloodstream form Trypanosoma brucei can be understood in terms
of the kinetics of the glycolytic enzymes. J. Biol. Chem., 272(6):3207–3215.
8. Bakker, B. M., Westerhoff, H. V., Opperdoes, F. R., and Michels, P. A. (2000).
Metabolic control analysis of glycolysis in trypanosomes as an approach to improve
selectivity and effectiveness of drugs. Mol. Biochem. Parasitol., 106(1):1–10.
156
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 157
9. Barrett, M. P. (1997). The pentose phosphate pathway and parasitic protozoa.
Parasitol. Today, 13(1):11–16.
10. Basketter, D. A. and Widdas, W. F. (1978). Asymmetry of the hexose trans-
fer system in human erythrocytes. comparison of the effects of cytochalasin B,
phloretin and maltose as competitive inhibitors. J. Physiol., 278:389–401.
11. Becker, K., Tilley, L., Vennerstrom, J. L., Roberts, D., Rogerson, S., and Gins-
burg, H. (2004). Oxidative stress in malaria parasite-infected erythrocytes: host-
parasite interactions. Int. J. Parasitol., 34(2):163–189.
12. Bisson, L. F. and Fraenkel, D. G. (1983). Involvement of kinases in glucose
and fructose uptake by Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A.,
80(6):1730 –1734.
13. Blacklow, S. C., Raines, R. T., Lim, W. A., Zamore, P. D., and Knowles,
J. R. (1988). Triosephosphate isomerase catalysis is diffusion controlled. appendix:
Analysis of triose phosphate equilibria in aqueous solution by 31P NMR. Biochem-
istry, 27(4):1158–1167.
14. Bloch, R. (1973). Inhibition of glucose transport in the human erythrocyte by
cytochalasin B. Biochemistry, 12(23):4799–4801.
15. Blodgett, D. M. and Carruthers, A. (2004). Conventional transport assays
underestimate sugar transport rates in human red cells. Blood Cells Mol. Dis.,
32(3):401–407.
16. Bosia, A., Ghigo, D., Turrini, F., Nissani, E., Pescarmona, G. P., and Ginsburg,
H. (1993). Kinetic characterization of Na+/H+ antiport of Plasmodium falciparum
membrane. J. Cell. Physiol., 154(3):527–534.
17. Boyer, P. D. and Robbins, E. A. (1957). Determination of the equilibrium of the
hexokinase reaction and the free energy of hydrolysis of adenosine triphosphate.
J.Biol. Chem., 224(1):121–135.
18. Bozdech, Z. and Ginsburg, H. (2005). Data mining of the transcriptome of
Plasmodium falciparum: the pentose phosphate pathway and ancillary processes.
Malar. J., 4(1):17–29.
19. Bradford, M. (1976). A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding. Anal.
Biochem., 72:248–254.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 158
20. Brady, R. L. and Cameron, A. (2004). Structure-based approaches to the de-
velopment of novel anti-malarials. Curr. Drug Targets, 5(2):137–149.
21. Brown, W. M., Yowell, C. A., Hoard, A., Vander Jagt, T. A., Hunsaker, L. A.,
Deck, L. M., Royer, R. E., Piper, R. C., Dame, J. B., Makler, M. T., and
Vander Jagt, D. L. (2004). Comparative structural analysis and kinetic prop-
erties of lactate dehydrogenases from the four species of human malarial parasites.
Biochem., 43(20):6219–6229.
22. Buckwitz, D., Jacobasch, G., and Gerth, C. (1990a). Phosphofructokinase from
Plasmodium berghei: a kinetic model of allosteric regulation. Mol. Biochem. Par-
asitol., 40(2):225–232.
23. Buckwitz, D., Jacobasch, G., and Gerth, C. (1990b). Phosphofructokinase from
Plasmodium berghei. influence of Mg2+, ATP and Mg2+-complexed ATP. Biochem.
J., 267(2):353–357.
24. Buckwitz, D., Jacobasch, G., Gerth, C., Holzhutter, H. G., and Thamm, R.
(1988). A kinetic model of phosphofructokinase from Plasmodium berghei. influ-
ence of ATP and fructose-6-phosphate. Mol. Biochem. Parasitol., 27(2-3):225–232.
25. Buckwitz, D., Jacobasch, G., Kuckelkorn, U., Plonka, A., and Gerth, C. (1990c).
Glucose-6-phosphate dehydrogenase from Plasmodium berghei: kinetic and elec-
trophoretic characterization. Exp. Parasitol., 70(3):264–275.
26. Buehner, M., Ford, G. C., Moras, D., Olsen, K. W., and Rossman, M. G.
(1973). D-glyceraldehyde-3-phosphate dehydrogenase: three-dimensional struc-
ture and evolutionary significance. Proc. Natl. Acad. Sci. U.S.A., 70(11):3052–
3054.
27. Byrant, C., Voller, A., and Smith, M. (1964). The incorporation of radioactivity
from (14c) glucose into soluble metabolic intermediates of malarial parasites. Am.
J. Trop. Med. Hyg., 13:515–519.
28. Bzik, D. J., Fox, B. A., and Gonyer, K. (1993). Expression of Plasmodium
falciparum lactate dehydrogenase in Escherichia coli. Mol. Biochem. Parasitol.,
59(1):155–166.
29. Campanale, N., Nickel, C., Daubenberger, C., Wehlan, D., Gorman, J., Klonis,
N., Becker, K., and Tilley, L. (2003). Identification and characterization of heme-
interacting proteins in the malaria parasite, Plasmodium falciparum. J. Biol.
Chem., 278(30):27354–27361.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 159
30. Capretto, L., Cheng, W., Hill, M., and Zhang, X. (2011). Micromixing within
microfluidic devices. Top. Curr. Chem., 304:27–68.
31. Carter, S. B. (1967). Effects of cytochalasins on mammalian cells. Nature,
213(5073):261–264.
32. Caruthers, J., Bosch, J., Buckner, F., Van Voorhis, W., Myler, P., Worthey,
E., Mehlin, C., Boni, E., DeTitta, G., Luft, J., Lauricella, A., Kalyuzhniy, O.,
Anderson, L., Zucker, F., Soltis, M., and Hol, W. G. (2006). Structure of a ribulose
5-phosphate 3-epimerase from Plasmodium falciparum. Proteins, 62(2):338–342.
33. Cascante, M., Boros, L. G., Comin-Anduix, B., de Atauri, P., Centelles, J. J.,
and Lee, P. W.-N. (2002). Metabolic control analysis in drug discovery and disease.
Nat Biotechnol, 20(3):243–249.
34. Chaikuad, A., Fairweather, V., Conners, R., Joseph-Horne, T., Turgut-Balik,
D., and Brady, R. L. (2005). Structure of lactate dehydrogenase from Plasmodium
vivax: complexes with NADH and APADH. Biochem., 44(49):16221–16228.
35. Chan, M. and Sim, T. (2005). Functional analysis, overexpression and kinetic
characterisation of pyruvate kinase from Plasmodium falciparum. Biochem. Bio-
phys. Res. Comm., 326:188–196.
36. Chan, M., Tan, D. H., and Sim, T. S. (2007). Plasmodium falciparum pyruvate
kinase as a novel target for antimalarial drug-screening. Travel Med. Infect. Dis.,
5(2):125–131.
37. Choi, I. and Mikkelsen, R. (1990). Plasmodium falciparum: ATP/ADP trans-
port across the parasitophorous vacuolar and plasma membranes. Exp. Parasitol.,
71(4):452–462.
38. Clarke, J. L., Scopes, D. A., Sodeinde, O., and Mason, P. J. (2001). Glucose-6-
phosphate dehydrogenase-6-phosphogluconolactonase. a novel bifunctional enzyme
in malaria parasites. Eur. J. Biochem., 268(7):2013–2019.
39. Cloonan, N., Fischer, K., Cheng, Q., and Saul, A. (2001). Aldolase genes of
Plasmodium species. Mol. Biochem. Parasitol., 113(2):327–330.
40. Collard, F., Collet, J. F., Gerin, I., Veiga-da Cunha, M., and Van Schaftingen,
E. (1999). Identification of the cDNA encoding human 6-phosphogluconolactonase,
the enzyme catalyzing the second step of the pentose phosphate pathway. FEBS
Lett., 459(2):223–226.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 160
41. Cornish-Bowden, A. and J.H.S., H. (2005). Kinetic characterization of enzymes
for systems biology. The Biochemist, 27:11–14.
42. Cornish-Bowden, A. and L., C. M. (2000). Animating the Cellular Map, chapter
10. Irreversible Reactions in Metabolic Simulations: how reversible is irreversible?,
pages 65 – 71. Stellenbosch University Press.
43. Cox-Singh, J., Davis, T., Lee, K.-S., Shamsul, S., Matusop, A., Ratnam, S.,
Rahman, H., Conway, D., and Singh, B. (2008). Plasmodium knowlesi malaria in
humans is widely distributed and potentially life threatening. Clin. Infect. Dis.,
46(2):165–171.
44. Cranmer, S., Conant, A. R., Gutteridge, W. E., and Halestrap, A. P. (1995).
Characterization of the enhanced transport of L- and D-lactate into human red
blood cells infected with Plasmodium falciparum suggests the presence of a novel
saturable lactate proton cotransporter. J. Biol. Chem., 270(25):15045–15052.
45. Cranmer, S., Magowan, C., Liang, J., Coppel, R., and Cooke, B. (1997). An
alternative to serum for cultivation of Plasmodium falciparum in vitro. Trans. R.
Soc. Trop. Med. Hyg., 91(3):363–365.
46. Crooke, A., Diez, A., Mason, P., and Bautista, J. (2006). Transient silenc-
ing of Plasmodium falciparum bifunctional glucose-6-phosphate dehydrogenase-
6-phosphogluconolactonase. FEBS J., 273(7):1537–1546.
47. Daubenberger, C. A., Poltl-Frank, F., Jiang, G., Lipp, J., Certa, U., and
Pluschke, G. (2000). Identification and recombinant expression of glyceraldehyde-
3-phosphate dehydrogenase of Plasmodium falciparum. Gene, 246(1-2):255–264.
48. Dawkins, P. and Dickens, F. (1965). The oxidation of d- and l-glycerate by rat
liver. Biochem. J., 94:353–367.
49. Desai, S. A., Krogstad, D. J., and McCleskey, E. W. (1993). A
nutrient-permeable channel on the intraerythrocytic malaria parasite. Nature,
362(6421):643–646.
50. Devés, R. and Krupka, R. M. (1978). Cytochalasin B and the kinetics of inhi-
bition of biological transport: a case of asymmetric binding to the glucose carrier.
Biochim. Biophys. Acta., 510(2):339–348.
51. Döbeli, H., Trzeciak, A., Gillessen, D., Matile, H., Srivastava, I. K., Perrin,
L. H., Jakob, P. E., and Certa, U. (1990a). Expression, purification, biochemical
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 161
characterization and inhibition of recombinant Plasmodium falciparum aldolase.
Mol. Biochem. Parasitol., 41(2):259–268.
52. Döbeli, H., Trzeciak, A., Gillessen, D., Matile, H., Srivastava, I. K., Perrin,
L. H., Jakob, P. E., and Certa, U. (1990b). Expression, purification, biochemical
characterization and inhibition of recombinant Plasmodium falciparum aldolase.
Mol. Biochem. Parasitol., 41(2):259–268.
53. du Preez, F., Conradie, R., Penkler, G., Holm, K., van Dooren, F., and Snoep,
J. (2007). A comparative analysis of kinetic models of erythrocyte glycolysis. J.
Theor. Biol.
54. Dunn, C. R., Banfield, M. J., Barker, J. J., Higham, C. W., Moreton, K. M.,
Turgut-Balik, D., Brady, R. L., and Holbrook, J. J. (1996). The structure of lactate
dehydrogenase from Plasmodium falciparum reveals a new target for anti-malarial
design. Nat. Struct. Biol., 3:912–915.
55. Eggstein, M. and Kuhlmann, E. (1974). Methods of Enzyme Analysis. Academic
Press Inc., 2nd edition.
56. El-Kady, I. and Mostafa, M. (1995). Production of cytochalasins C, D
& E from dematiaceous hyphomycetes. Folia Microbiologica, 40:301–303.
10.1007/BF02814213.
57. Elliott, J. L., Saliba, K. J., and Kirk, K. (2001). Transport of lactate and pyru-
vate in the intraerythrocytic malaria parasite, Plasmodium falciparum. Biochem.
J., 355:733–739.
58. Ernest, I., Callens, M., Opperdoes, F., and Michels, P. (1994). Pyruvate kinase
of Leishmania mexicana. cloning and analysis of the gene, overexpression in Es-
cherichia coli and characterization of the enzyme. Mol. Biochem. Parasitol., pages
43–54.
59. Ernest, I., Callens, M., Uttaro, A., Chevalier, N., Opperdoes, F., Muirhead, H.,
and Michels, P. (1998). Pyruvate kinase of Trypanosoma brucei: overexpression,
purification, and functional characterization of wild-type and mutated enzyme.
Protein Expr. Purif., 13:373–382.
60. Evans, M. L., Matyka, K., Lomas, J., Pernet, A., Cranston, I. C., Macdonald,
I., and Amiel, S. A. (1998). Reduced counterregulation during hypoglycemia with
raised circulating nonglucose lipid substrates: evidence for regional differences in
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 162
metabolic capacity in the human brain? J. Clin. Endocrinol. Metab., 83(8):2952–
2959.
61. Eyschen, J., Vitoux, B., Marraud, M., Cung, M. T., and Branlant, G. (1999).
Engineered glycolytic glyceraldehyde-3-phosphate dehydrogenase binds the anti
conformation of NAD+ nicotinamide but does not experience A-specific hydride
transfer. Arch. Biochem. Biophys., 364(2):219–227.
62. Faller, L., Baroudy, B., Jonson, A., and Ewall, R. (1977). Magnesium ion
requirements for yeast enolase activity. Biochem., 16:3864–3869.
63. Famin, O. and Ginsburg, H. (2003). The treatment of Plasmodium falciparum-
infected erythrocytes with chloroquine leads to accumulation of ferriprotopor-
phyrin ix bound to particular parasite proteins and to the inhibition of the para-
site’s 6-phosphogluconate dehydrogenase. Parasite, 10(1):39–50.
64. Fell, D. A. (1992). Metabolic control analysis: a survey of its theoretical and
experimental development. Biochem. J., 286 ( Pt 2):313–330.
65. Fjeld, C. C., Birdsong, W. T., and Goodman, R. H. (2003). Differential bind-
ing of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal
binding protein to serve as a metabolic sensor. Proc. Natl. Acad. Sci. U. S. A.,
100(16):9202–9207.
66. Fletcher, K., Canning, M., and Theakston, R. (1977). Electrophoresis of
glucose-6-phosphate and 6-phosphogluconate dehydrogenases in erythrocytes from
malaria-infected animals. Ann. Trop. Med. Parasitol., 71:125–130.
67. Foth, B. J., Stimmler, L. M., Handman, E., Crabb, B. S., Hodder, A. N., and
McFadden, G. I. (2005). The malaria parasite Plasmodium falciparum has only
one pyruvate dehydrogenase complex, which is located in the apicoplast. Mol.
Microbiol., 55(1):39–53.
68. Fry, M., Webb, E., and Pudney, M. (1990). Effect of mitochondrial inhibitors on
adenosinetriphosphate levels in Plasmodium falciparum. Comp. Biochem. Physiol.
B, 96(4):775–782.
69. Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W.,
Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., Paulsen, I. T., James, K.,
Eisen, J. A., Rutherford, K., Salzberg, S. L., Craig, A., Kyes, S., Chan, M. S.,
Nene, V., Shallom, S. J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J.,
Selengut, J., Haft, D., Mather, M. W., Vaidya, A. B., Martin, D. M., Fairlamb,
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 163
A. H., Fraunholz, M. J., Roos, D. S., Ralph, S. A., McFadden, G. I., Cummings,
L. M., Subramanian, G. M., Mungall, C., Venter, J. C., Carucci, D. J., Hoff-
man, S. L., Newbold, C., Davis, R. W., Fraser, C. M., and Barrell, B. (2002).
Genome sequence of the human malaria parasite Plasmodium falciparum. Nature,
419(6906):498–511.
70. Gayathri, P., Banerjee, M., Vijayalakshmi, A., Balaram, H., Balaram, P., and
Murthy, M. R. N. (2009). Biochemical and structural characterization of residue
96 mutants of Plasmodium falciparum triosephosphate isomerase: active-site loop
conformation, hydration and identification of a dimer-interface ligand-binding site.
Acta Crystallogr. D Biol. Crystallogr., 65(Pt 8):847–857.
71. Geenen, S., Taylor, P., Snoep, J., Wilson, I., Kenna, J., and Westerhoff, H.
(2012). Systems biology tools for toxicology. Arch. Toxicol., 86(8):1251–1271.
72. Goldberg, R., Tewari, Y., and Bhat, T. (2004). Thermodynamics of enzyme-
catalyzed reactions-a database for quantitative biochemistry. Bioinformatics,
20(16):2874–2877.
73. Gomez, M. S., Piper, R. C., Hunsaker, L. A., Royer, R. E., Deck, L. M., Makler,
M. T., and Vander Jagt, D. L. (1997). Substrate and cofactor specificity and selec-
tive inhibition of lactate dehydrogenase from the malarial parasite P. falciparum.
Mol. Biochem. Parasitol., 90(1):235–246.
74. Goodyer, I. D., Hayes, D. J., and Eisenthal, R. (1997). Efflux of 6-deoxy-
D-glucose from Plasmodium falciparum-infected erythrocytes via two saturable
carriers. Mol. Biochem. Parasitol., 84(2):229–239.
75. Grall, M., Srivastava, I., Schmidt, M., Garcia, A.-M., Mauel, J., and Perrin, L.
(1992). Plasmodium falciparum: Identification and purification of the phospho-
glycerate kinase of the malaria parasite. Exp. Parasitol., 75(1):10–18.
76. Griffin, J. F., Rampal, A. L., and Jung, C. Y. (1982). Inhibition of glucose
transport in human erythrocytes by cytochalasins: A model based on diffraction
studies. Proc. Natl. Acad. Sci. U. S. A., 79(12):3759–3763.
77. Grüning, N.-M., Rinnerthaler, M., Bluemlein, K., Mülleder, M., Wamelink, M.
M. C., Lehrach, H., Jakobs, C., Breitenbach, M., and Ralser, M. (2011). Pyru-
vate kinase triggers a metabolic feedback loop that controls redox metabolism in
respiring cells. Cell Metab., 14(3):415–427.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 164
78. Hansen, M., Kun, J., Schultz, J., and Beitz, E. (2002). A single, bi-functional
aquaglyceroporin in blood-stage Plasmodium falciparum malaria parasites. J. Biol.
Chem., 277(7):4874–4882.
79. Hanson, R. L., Rudolph, F. B., and Lardy, H. A. (1973). Rabbit muscle phos-
phofructokinase. the kinetic mechanism of action and the equilibrium constant. J.
Biol. Chem., 248(22):7852–7859.
80. Hayashi, M., Yamada, H., Mitamura, T., Horii, T., Yamamoto, A., and
Moriyama, Y. (2000). Vacuolar H(+)-ATPase localized in plasma membranes of
malaria parasite cells, Plasmodium falciparum, is involved in regional acidification
of parasitized erythrocytes. J. Biol. Chem., 275(44):34353–34358.
81. Hayward, R. (2000). Plasmodium falciparum phosphoenolpyruvate carboxyk-
inase is developmentally regulated in gametocytes. Mol. Biochem. Parasitol.,
107(2):227–240.
82. Heinrich, R. and Rapoport, T. (1974). A linear steady-state treatment of enzy-
matic chains. general properties, control and effector strength. Eur. J. Biochem.,
42(1):89–95.
83. Helfert, S., Estevez, A., Bakker, B., Michels, P., and Clayton, C. (2001). Roles
of triosephosphate isomerase and aerobic metabolism in Trypanosoma brucei.
Biochem J., 357(Pt 1):117–125.
84. Hess, B. and Plesser, T. (1979). Temporal and spatial order in biochemical
systems. Ann. N. Y. Acad. Sci., 316:203–213.
85. Hills, T., Srivastava, A., Ayi, K., Wernimont, A., Kain, K., Waters, A., Hui, R.,
and Pizarro, J. (2011). Characterization of a new phosphatase from plasmodium.
Mol. Biochem. Parasitol., 179(2):69–79.
86. Hoefnagel, M., Starrenburg, M., Martens, D., Hugenholtz, J., Kleerebezem,
M., van Swam, I., Bongers, R., Westerhoff, H., and Snoep, J. (2002). Metabolic
engineering of lactic acid bacteria, the combined approach: kinetic modelling,
metabolic control and experimental analysis. Microbiology, 148(Pt 4):1003–1013.
87. Hofmeyr, J. (2000). Metabolic control analysis in a nutshell. Proc. ICSB,
Pasadena, California,, pages 291–300.
88. Hofmeyr, J. and Cornish-Bowden, A. (1991). Quantitative assessment of regu-
lation in metabolic systems. Eur. J. Biochem., 200(1):223–236.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 165
89. Hofmeyr, J. and Cornish-Bowden, A. (2000). Regulating the cellular economy
of supply and demand. FEBS Lett., 476(1-2):47–51.
90. Hofmeyr, J. H. S. and Cornish-Bowden, A. (1997). The reversible hill equation:
how to incorporate cooperative enzymes into metabolic models. Comput. Appl.
Biosci., 13(4):377–385.
91. Hohmann, S. (2002). Osmotic stress signaling and osmoadaptation in yeasts.
Microbiol.Mol. Biol. Rev., 66(2):300–372.
92. Holmes, M. A., Buckner, F. S., Van Voorhis, W. C., Verlinde, C. L., Mehlin,
C., Boni, E., DeTitta, G., Luft, J., Lauricella, A., Anderson, L., Kalyuzhniy, O.,
Zucker, F., Schoenfeld, L. W., Earnest, T. N., Hol, W. G., and Merritt, E. A.
(2006). Structure of ribose 5-phosphate isomerase from Plasmodium falciparum.
Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun., 62(5):427–431.
93. Holzhutter, H. (2004). The principle of flux minimization and its application to
estimate stationary fluxes in metabolic networks. Eur. J. Biochem., 271(14):2905–
2922.
94. Holzhutter, H., Jacobasch, G., and Bisdorff, A. (1985a). Mathematical mod-
elling of metabolic pathways affected by an enzyme deficiency. a mathematical
model of glycolysis in normal and pyruvate-kinase-deficient red blood cells. Eur.
J. Biochem., 149(1):101–111.
95. Holzhutter, H. G., Jacobasch, G., and Bisdorff, A. (1985b). Mathematical mod-
elling of metabolic pathways affected by an enzyme deficiency. a mathematical
model of glycolysis in normal and pyruvate-kinase-deficient red blood cells. Eur.
J. Biochem., 149(1):101–111.
96. Hoops, S., Sahle, S., Gauges, R., Lee, C., Pahle, J., Simus, N., Singhal, M., Xu,
L., Mendes, P., and Kummer, U. (2006). COPASI- COmplex PAthway SImulator.
Bioinformatics, 22(24):3067–3074.
97. Hoppe, H., Verschoor, J., and Louw, A. (1991). Plasmodium falciparum: a
comparison of synchronisation methods for in vitro cultures. Exp. Parasitol.,
72(4):464–467.
98. Hornberg, J., Bruggeman, F., Bakker, B., and Westerhoff, H. (2007). Metabolic
control analysis to identify optimal drug targets. Prog. Drug. Res., 64:171, 173–89.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 166
99. Itin, C., Burki, Y., Certa, U., and Döbeli, H. (1993). Selective inhibition of
Plasmodium falciparum aldolase by a tubulin derived peptide and identification of
the binding site. Mol. Biochem. Parasitol., 58(1):135–143.
100. Joët, T., Chotivanich, K., Silamut, K., Patel, A., Morin, C., and Krishna,
S. (2004). Analysis of Plasmodium vivax hexose transporters and effects of a
parasitocidal inhibitor. Biochem. J., 381(3):905–909.
101. Joët, T., Eckstein-Ludwig, U., Morin, C., and Krishna, S. (2003). Validation
of the hexose transporter of Plasmodium falciparum as a novel drug target. Proc.
Natl. Acad. Sci. U. S. A., 100(13):7476–7479.
102. Joët, T., Holterman, L., Stedman, T. T., Kocken, C. H., Van Der Wel, A.,
Thomas, A. W., and Krishna, S. (2002). Comparative characterization of hexose
transporters of Plasmodium knowlesi, Plasmodium yoelii and Toxoplasma gondii
highlights functional differences within the apicomplexan family. Biochem. J.,
368:923–929.
103. Joët, T. and Krishna, S. (2004). The hexose transporter of Plasmodium falci-
parum is a worthy drug target. Acta Trop., 89(3):371–374.
104. Jortzik, E., Mailu, B., Preuss, J., Fischer, M., Bode, L., Rahlfs, S., and Becker,
K. (2011). Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase: a
unique bifunctional enzyme from Plasmodium falciparum. Biochem. J.,
436(3):641–650.
105. Joshi, S., Singh, A., Kumar, A., Misra, P., Siddiqi, M., and Saxena, J. (2008).
Molecular cloning and characterization of Plasmodium falciparum transketolase.
Mol. Biochem. Parasitol., 160(1):32–41.
106. Joubert, F., Neitz, A. W., and Louw, A. I. (2001). Structure-based inhibitor
screening: a family of sulfonated dye inhibitors for malaria parasite triosephos-
phate isomerase. Proteins, 45(2):136–143.
107. Kacser, H. and Burns, J. A. (1973a). The control of flux. Symp. Soc. Exp.
Biol., 27:65–104.
108. Kacser, H. and Burns, J. A. (1973b). The control of flux. Symp. Soc. Exp.
Biol., 27:65–104.
109. Kanaani, J. and Ginsburg, H. (1991). Transport of lactate in Plasmodium
falciparum-infected human erythrocytes. J. Cell. Physiol., 149(3):469–476.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 167
110. Karlgren, S., Pettersson, N., Nordlander, B., Mathai, J., Brodsky, J. L., Zeidel,
M., Bill, R., and Hohmann, S. (2005). Conditional osmotic stress in yeast: a system
to study transport through aquaglyceroporins and osmostress signaling. J. Biol.
Chem., 280(8):7186–7193.
111. Kaslow, D. and Hill, S. (1990). Cloning metabolic pathways by complementa-
tion in Escherichia coli. J. Biol. Chem., 265:12337–12341.
112. Khan, S. and Waters, A. (2004). Malaria parasite transmission stages: an
update. Trends Parasitol.., 20(12):575–580.
113. Kim, H., Certa, U., Döbeli, H., Jakob, P., and Hol, W. G. (1998). Crystal
structure of fructose-1,6-bisphosphate aldolase from the human malaria parasite
Plasmodium falciparum. Biochem., 37(13):4388–9436.
114. Kim, J.-Y., Kim, H.-H., Shin, H.-L., Sohn, Y., Kim, H., Lee, S.-W., Lee, W.-
J., and Lee, H.-W. (2012). Genetic variation of aldolase from korean isolates of
Plasmodium vivax and its usefulness in serodiagnosis. Malar. J., 11:159.
115. Kirk, K. (2001). Membrane transport in the malaria-infected erythrocyte.
Physiol. Rev., 81(2):495–537.
116. Kirk, K., Horner, H., and Kirk, J. (1996). Glucose uptake in Plasmodium
falciparum-infected erythrocytes is an equilibrative not an active process. Mol.
Biochem. Parasitol., 82(2):195–205.
117. Knapp, B., Hundt, E., and Küpper, H. A. (1990). Plasmodium falciparum
aldolase: gene structure and localization. Mol. Biochem. Parasitol., 40(1):1–12.
118. Krishna, S., Waller, D. W., ter Kuile, F., Kwiatkowski, D., Crawley, J., Crad-
dock, C. F., Nosten, F., Chapman, D., Brewster, D., and Holloway, P. A. (1994).
Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysio-
logical and prognostic significance. Trans. R. Soc. Trop. Med. Hyg., 88(1):67–73.
119. Krishna, S., Woodrow, C. J., Burchmore, R. J. S., Saliba, K. J., and Kirk,
K. (2000). Hexose transport in asexual stages of Plasmodium falciparum and
Kinetoplastidae. Parasitol. Today, 16(12):516–521.
120. Krupka, R. M. (1985). Asymmetrical binding of phloretin to the glucose trans-
port system of human erythrocytes. J. Membr. Biol., 83(1-2):71–80.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 168
121. Kumar, S. and Banyal, H. S. (1997). Purification and characterisation of the
hexokinase of Plasmodium berghei, a murine malaria parasite. Acta Vet. Hung.,
45(2):119–126.
122. Kurdi-Heidar, B. and Luzzato, L. (1990). Expression and characterization
of glucose-6-phosphate dehydrogenase of Plasmodium falciparum. Mol. Biochem.
Parasitol., 41:83–92.
123. Lang-Unnasch, N. and Murphy, A. D. (1998). Metabolic changes of the malaria
parasite during the transition from the human to the mosquito host. Annu. Rev.
Microbiol., 52:561–590.
124. Leskovac, V. (2004). Comprehensive Enzyme Kinetics. Kluwer academic pub-
lishers.
125. Lian, L.-Y., Al-Helal, M., Roslaini, A., Fisher, N., Bray, P., Ward, S., and Bi-
agini, G. (2009). Glycerol: an unexpected major metabolite of energy metabolism
by the human malaria parasite. Malar. J., 8:38.
126. Liebermeister, W. and Klipp, E. (2006). Bringing metabolic networks to life:
convenience rate law and thermodynamic constraints. Theor. Biol. Med. Model.,
3:41.
127. Ling, I. and Wilson, R. (1988). Glucose-6-phosphate dehydrogenase activity of
the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol., 31:47–56.
128. Lowry, O. and Passonneau, J. (1964). The relationship between substrates and
enzymes of glycolysis in brain. J. Biol. Chem., 239:31–42.
129. MacLean-Fletcher, S. and Pollard, T. D. (1980). Mechanism of action of cy-
tochalasin b on actin. Cell, 20(2):329–341.
130. Maeda, T., Saito, T., Harb, O., Roos, D., Takeo, S., Suzuki, H., Tsuboi, T.,
Takeuchi, T., and Asai, T. (2009). Pyruvate kinase type-ii isozyme in Plasmodium
falciparum localizes to the apicoplast. Parasitol. Int., 58(1):101–105.
131. Maeda, T., Saito, T., Oguchi, Y., Nakazawa, M., Takeuchi, T., and Asai,
T. (2003). Expression and characterization of recombinant pyruvate kinase from
Toxoplasma gondii tachyzoites. Parasitol. Res., 89(4):259–265.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 169
132. Maithal, K., Ravindra, G., Nagaraj, G., Singh, S., Balaram, H., and Balaram,
P. (2002). Subunit interface mutation disrupting an aromatic cluster in Plasmod-
ium falciparum triosephosphate isomerase: effect on dimer stability. Protein Eng.,
15(7):575–584.
133. Manning, S., Woodrow, C., Zuniga, F., Iserovich, P., Fischbarg, J., Louw,
A., and Krishna, S. (2002). Mutational analysis of the hexose transporter of
Plasmodium falciparum and development of a three-dimensional model. J. Biol.
Chem., 277(34):30942–30949.
134. McDaniel, H. and Siu, P. (1972). Purification and characterization of phospho-
enolpyruvate carboxylase from Plasmodium berghei. J. Bacteriol., 109:385–390.
135. Mehlin, C. (2005). Structure-based drug discovery for Plasmodium falciparum.
Comb. Chem. High Throughput Screen., 8(1):5–14.
136. Meier, B., Döbeli, H., and Certa, U. (1992). Stage specific expression of aldolase
isozymes in the rodent malaria parasite P. berghei. Mol. Biochem. Parasitol.,
52:15–28.
137. Mony, B., Mehta, M., Jarori, G., and Sharma, S. (2009). Plant-like phospho-
fructokinase from Plasmodium falciparum belongs to a novel class of atp-dependent
enzymes. Int. J. Parasitol., 39(13):1441–1453.
138. Moreno-Sánchez, R., Saavedra, E., Rodríguez-Enríquez, S., Gallardo-Pérez, J.,
Quezada, H., and Westerhoff, H. (2010). Metabolic control analysis indicates a
change of strategy in the treatment of cancer. Mitochondrion, 10(6):626–639.
139. Nagarajan, K. (1968). Metabolism of Plasmodium berghei. 3. carbon dioxide
fixation and role of pyruvate and dicarboxylic acids. Exp. Parasitol., 22(1):33–42.
140. O’ Brian, E., Kurdi-Haidar, B., Wanachiwanawin, W., Carvajal, J., Vulliamy,
T., Cappadoro, V., Mason, P., and Luzzatto, L. (1994). Cloning of the glucose-6-
phosphate dehydrogenase from Plasmodium falciparum. Mol. Biochem. Parasitol.,
64:313–326.
141. O’Donnell, R. and Blackman, M. (2005). The role of malaria merozoite pro-
teases in red blood cell invasion. Curr.Opin. Microbiol., 8(4):422–427.
142. Olafsson, P. and Certa, U. (1994). Expression and cellular localisation of
hexokinase during the bloodstage development of Plasmodium falciparum. Mol.
Biochem. Parasitol., 63(1):171–174.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 170
143. Olafsson, P., Matile, H., and Certa, U. (1992). Molecular analysis of Plasmod-
ium falciparum hexokinase. Mol. Biochem. Parasitol., 56(1):89–101.
144. Olivier, B. and Snoep, J. (2004). Web-based kinetic modelling using JWS
Online. Bioinformatics, 20(13):2143–2144.
145. Olszewski, K., Mather, M., Morrisey, J., Garcia, B., Vaidya, A., Rabinowitz,
J., and Llinás, M. (2010). Branched tricarboxylic acid metabolism in Plasmodium
falciparum. Nature, 466(7307):774–778.
146. Olszewski, K. L. and Llinás, M. (2011). Central carbon metabolism of Plas-
modium parasites. Mol. Biochem. Parasitol., 175(2):95–103.
147. Ozbayraktar, F. and Ulgen, K. (2010). Drug target identification in sphin-
golipid metabolism by computational systems biology tools: metabolic control
analysis and metabolic pathway analysis. J. Biomed. Inform., 43(4):537–549.
148. Pal, B., Pybus, B., Muccio, D. D., and Chattopadhyay, D. (2004). Biochemical
characterization and crystallization of recombinant 3-phosphoglycerate kinase of
Plasmodium falciparum. Biochim. Biophys. Acta, 1699(1-2):277–280.
149. Pal-Bhowmick, I., Krishnan, S., and Jarori, G. (2007a). Differential susceptibil-
ity of Plasmodium falciparum versus yeast and mammalian enolases to dissociation
into active monomers. FEBS J., 274(8):1932–1945.
150. Pal-Bhowmick, I., Mehta, M., Coppens, I., Sharma, S., and Jarori, G. (2007b).
Protective properties and surface localization of Plasmodium falciparum enolase.
Infect. Immun., 75(11):5500–5508.
151. Pal-Bhowmick, I., Sadagopan, K., Vora, H., Sehgal, A., Sharma, S., and Jarori,
G. (2004). Cloning, over-expression, purification and characterization of Plasmod-
ium falciparum enolase. Eur. J. Biochem., 271:4845–4854.
152. Pal-Bhowmick, I., Vora, H., and Jarori, G. (2007c). Sub-cellular localiza-
tion and post-translational modifications of the Plasmodium yoelii enolase suggest
moonlighting functions. Malar. J., 6:45.
153. Pancholi, V. (2001). Multifunctional alpha-enolase: its role in diseases. Cell.
Mol. Life Sci., 58(7):902–920.
154. Parthasarathy, S., Eaazhisai, K., Balaram, H., Balaram, P., and Murthy,
M. (2003). Structure of Plasmodium falciparum triose-phosphate isomerase-2-
phosphoglycerate complex at 1.1 å resolution. J. Biol. Chem., 278(52):52461–70.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 171
155. Patel, A., Staines, H., and Krishna, S. (2008). New antimalarial targets: the
example of glucose transport. Travel Med. Infect. Dis., 6(1-2):58–66.
156. Pattanaik, P., Raman, J., and Balaram, H. (2002). Perspectives in drug design
against malaria. Curr. Top. Med. Chem., 2(5):483–505.
157. Peintler, G., Nagy, A., Horvath, A., Kortvelyesi, T., and Nagypal, I. (2000).
Improved calibration and use of stopped-flow instruments. Phys. Chem. Chem.
Phys., 2:2575–2586.
158. Penkler, G. (2009). Construction and validation of a detailed kinetic model for
Plasmodium falciparum during the asexual phase: A feasibility study. Master’s
thesis, University of Stellenbosch.
159. Penna-Coutinho, J., Cortopassi, W., Oliveira, A., Franca, T., and Krettli,
A. (2011). Antimalarial activity of potential inhibitors of Plasmodium falciparum
lactate dehydrogenase enzyme selected by docking studies. PLoS One, 6(7):e21237.
160. Poolman, B., Bosman, B., Kiers, J., and Konings, W. N. (1987). Control of
glycolysis by glyceraldehyde-3-phosphate dehydrogenase in Streptococcus cremoris
and Streptococcus lactis. J. Bacteriol., 169(12):5887–5890.
161. Preuss, J., Hedrick, M., Sergienko, E., Pinkerton, A., Mangravita-Novo, A.,
Smith, L., Marx, C., Fischer, E., Jortzik, E., Rahlfs, S., Becker, K., and Bode,
L. (2012a). High-throughput screening for small-molecule inhibitors of plasmod-
ium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase. J.
Biomol. Screen., 17(6):738–751.
162. Preuss, J.and Maloney, P. P. S., Hedrick, M., Hershberger, P., Gosalia, P.,
Milewski, M.and Li, Y., Sugarman, E., Hood, B.and Suyama, E., Nguyen,
K.and Vasile, S., Sergienko, E., Mangravita-Novo, A., Vicchiarelli, M., McAnally,
D., Smith, L., Roth, G., Diwan, J., Chung, T., Jortzik, E., Rahlfs, S.,
Becker, K., Pinkerton, A., and Bode, L. (2012b). Discovery of a Plasmod-
ium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase in-
hibitor (r,z)-n-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-
dihydro-2h-benzo[b][1,4]thiazine-6-carboxamide (ml276) that reduces parasite
growth in vitro. J. Med. Chem.
163. Pukrittayakamee, S., White, N. J., Davis, T. M., Supanaranond, W., Crawley,
J., Nagachinta, B., and Williamson, D. H. (1994). Glycerol metabolism in severe
falciparum malaria. Metabolism, 43(7):887–892.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 172
164. Quinton-Tulloch, M. (2011). Fragile robustness: Principles and practice. PhD
thesis, University of Manchester.
165. Racker, E. (1950). Crystalline alcohol dehydrogenase from baker’s yeast. J.
Biol. Chem., 184(1):313–319.
166. Rahlfs, S. and Becker, K. (2006). Interference with redox-active enzymes as a
basis for the design of antimalarial drugs. Mini Rev. Med.Chem., 6(2):163–176.
167. Ranie, J., Kumar, V. P., and Balaram, H. (1993). Cloning of the triosephos-
phate isomerase gene of Plasmodium falciparum and expression in Escherichia coli.
Mol. Biochem. Parasitol., 61(2):159–169.
168. Rapoport, T., Heinrich, R., Jacobasch, G., and Rapoport, S. (1974). A linear
steady-state treatment of enzymatic chains. a mathematical model of glycolysis of
human erythrocytes. Eur. J. Biochem., 42(1):107–120.
169. Ravindra, G. and Balaram, P. (2005). Plasmodium falciparum triosephosphate
isomerase: New insights into an old enzyme. Pure Appl. Chem., 77(1):281–289.
170. Read, M., Hicks, K. E., Sims, P. F., and Hyde, J. E. (1994). Molecular char-
acterisation of the enolase gene from the human malaria parasite Plasmodium fal-
ciparum. evidence for ancestry within a photosynthetic lineage. Eur. J. Biochem.,
220(2):513–520.
171. Robien, M., Bosch, J., Buckner, F., van Voorhis, W., Worthey, E., Myler, P.,
Mehlin, C., Boni, E., Kalyuzhniy, O., Anderson, L., Lauricella, A., Gulde, S.,
Luft, J., DeTitta, G., Caruthers, J., Hodgson, K., Soltis, M., Zucker, F., Verlinde,
C. M. J., Merritt, E., Schoenfeld, L., and Hol, W. (2006). Crystal structure of
glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25
å resolution reveals intriguing extra electron density in the active site. Proteins,
62(3):570–577.
172. Rohwer, J., Hanekom, A., Crous, C., Snoep, J., and Hofmeyr, J. (2006). Eval-
uation of a simplified generic bi-substrate rate equation for computational systems
biology. Syst. Biol. (Stevenage), 153(5):338–341.
173. Roth, E., Calvin, M., Max-Audit, J., Rosa, J., and Rosa, R. (1988a). The
enzymes of the glycolytic pathway in erythrocytes infected with Plasmodium fal-
ciparum malaria parasites. Blood, 72:1922–1925.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 173
174. Roth, E., Joulin, V., Miwa, S., Yoshida, A., Akatsuka, J., Cohen-Solal, M.,
and Rosa, R. (1988b). The use of enzymopathic human red cells in the study of
malarial parasite glucose metabolism. Blood, 71(5):1408–1413.
175. Roth, E. F. and Jr. (1987). Malarial parasite hexokinase and hexokinase-
dependent glutathione reduction in the Plasmodium falciparum-infected human
erythrocyte. J. Biol. Chem., 262(32):15678–15682.
176. Royer, R., Deck, L., Campos, N. M., Hunsaker, L. A., and Vander Jagt, D. L.
(1986). Biologically active derivatives of gossypol: synthesis and antimalarial
activities of periacylated gossylic nitriles. J. Med. Chem., 29:1799–1801.
177. Saliba, K., Horner, H., and Kirk, K. (1998). Transport and metabolism of
the essential vitamin pantothenic acid in human erythrocytes infected with the
malaria parasite Plasmodium falciparum. J. Biol. Chem., 273(17):10190–10195.
178. Saliba, K. and Kirk, K. (1999). pH regulation in the intracellular malaria
parasite, Plasmodium falciparum. H+ extrusion via a v-type H+-ATPase. J. Biol.
Chem., 274(47):33213–33219.
179. Saliba, K., Krishna, S., and Kirk, K. (2004). Inhibition of hexose transport
and abrogation of pH homeostasis in the intraerythrocytic malaria parasite by an
O-3-hexose derivative. FEBS Lett., 570(1-3):93–96.
180. Saltelli, A., Ratto, M., Tarantola, S., and Campolongo, F. (2005). Sensitivity
analysis for chemical models. Chem. Rev., 105(7):2811–2828.
181. Sander, B. J. and Kruckeberg, W. C. (1981). Plasmodium berghei: glycolytic
intermediate concentrations of the infected mouse erythrocyte. Exp. Parasitol.,
52(1):1–8.
182. Sander, B. J., Lowery, M. S., and Kruckeberg, W. C. (1982). Plasmodium
berghei: acid-insensitive phosphofructokinase in infected mouse erythrocytes. Exp.
Parasitol., 53(1):11–16.
183. Sanger, J. W. and Holtzer, H. (1972). Cytochalasin B: effects on cell morphol-
ogy, cell adhesion, and mucopolysaccharide synthesis (cultured cells-contractile
microfilaments-glycoproteins-embryonic cells-sorting-out). Proc. Natl. Acad. Sci.
U.S.A., 69(1):253–257.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 174
184. Satchell, J., Malby, R., Luo, C., Adisa, A., Alpyurek, A., Klonis, N., Smith,
B., Tilley, L., and Colman, P. (2005). Structure of glyceraldehyde-3-phosphate de-
hydrogenase from Plasmodium falciparum. Acta Crystallogr. D Biol. Crystallogr.,
61(Pt 9):1213–1221.
185. Scheer, M., Grote, A., Chang, A., Schomburg, I., Munaretto, C., Rother, M.,
Söhngen, C., Stelzer, M., Thiele, J., and Schomburg, D. (2011). BRENDA, the
enzyme information system in 2011. Nucleic Acids Res., 39(Database issue):D670–
D676.
186. Schnick, C., Polley, S., Fivelman, Q., Ranford-Cartwright, L., Wilkinson, S.,
Brannigan, J., Wilkinson, A., and Baker, D. (2009). Structure and non-essential
function of glycerol kinase in Plasmodium falciparum blood stages. Mol. Micro-
biol., 71(2):533–545.
187. Scopes, D., Bautista, J., Vulliamy, T., and Mason, P. (1997). Plasmodium
falciparum Glc6PD ± the N-terminal portion is homologous to a predicted protein
encoded near to Glc6PD in Haemophilus Influenzae. Mol. Microbiol., 23:847–848.
188. Sein, K. K. and Aikawa, M. (1998). The pivotal role of carbonic anhydrase in
malaria infection. Med. Hypotheses, 50(1):19–23.
189. Shahabuddin, M., Rawlings, D., and Kaslow, D. (1994). A novel glucose-6-
phosphate dehydrogenase in Plasmodium falciparum: cDNA and primary protein
structure. Biochim. Biophys. Acta., 1219:191–194.
190. Sherman, I. (1998). Carbohydrate metabolism of asexual stages. In Sherman,
I., editor, Malaria: Parasite biology, pathogenesis and protection, pages 135–143.
ASM Press, Washington, D.C.
191. Sherman, I. and I.P., T. (1966). Carbon dioxide fixation in malaria (Plasmod-
ium lopurae). Nature, 24:639–642.
192. Sherman, I. and I.P., T. (1968). Carbon dioxide fixation in malaria-ii. Plas-
modium knowlesi (monkey malaria). Comp. Biochem. Physiol., 24:639–642.
193. Sherman, I. W. (1979). Biochemistry of Plasmodium (malarial parasites). Mi-
crobiol. Rev., 43(4):453–495.
194. Shoemark, D., Cliff, M., Sessions, R., and Clarke, A. (2007). Enzymatic prop-
erties of the lactate dehydrogenase enzyme from Plasmodium falciparum. FEBS
J., 274(11):2738–2748.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 175
195. Singh, A., Joshi, S., Arya, R., Kayastha, A., Srivastava, K., Tripathi, L.,
and Saxena, J. (2008). Molecular cloning and characterization of Brugia malayi
hexokinase. Parasitol. Int., 57(3):354–361.
196. Singh, S. K., Maithal, K., Balaram, H., and Balaram, P. (2001). Synthetic pep-
tides as inactivators of multimeric enzymes: inhibition of Plasmodium falciparum
triosephosphate isomerase by interface peptides. FEBS Lett., 501(1):19–23.
197. Siu, P. (1967). Carbon dioxide fixation in plasmodia and the effect of some
antimalarials on the enzyme. Comp. Biochem. Physiol., 23:785–795.
198. Slavic, K., Delves, M., Prudencio, M., Talman, A., Straschil, U., Derbyshire,
E., Xu, Z., Sinden, R., Mota, M., Morin, C., Tewari, R., Krishna, S., and Staines,
H. (2011). Use of a selective inhibitor to define the chemotherapeutic potential
of the plasmodial hexose transporter in different stages of the parasite’s life cycle.
Antimicrob. Agents Chemother., 55(6):2824–2830.
199. Smith, C., Chattopadhyay, D., and Pal, B. (2011). Crystal structure of Plas-
modium falciparum phosphoglycerate kinase: evidence for anion binding in the
basic patch. Biochem. Biophys. Res. Commun., 412(2):203–206.
200. Snoep, J., Bruggeman, F., Olivier, B., and Westerhoff, H. (2006). Towards
building the silicon cell: a modular approach. Biosystems, 83(2-3):207–216.
201. Snoep, J. L. and Olivier, B. G. (2003). JWS Online cellular systems modelling
and microbiology. Microbiol., 149(Pt 11):3045 –3047.
202. Srivastava, I. K., Schmidt, M., Grall, M., Certa, U., Garcia, A. M., and Perrin,
L. H. (1992). Identification and purification of glucose phosphate isomerase of
Plasmodium falciparum. Mol. Biochem. Parasitol., 54(2):153–64.
203. Staples, J. and Suarez, R. (1997). Honeybee flight muscle phosphoglucose
isomerase: matching enzyme capacities to flux requirements at a near-equilibrium
reaction. J. Exp. Biol., 200(Pt 8):1247–1254.
204. Teng, R., Junankar, P., Bubb, W., Rae, C., Mercier, P., and Kirk, K. (2008).
Metabolite profiling of the intraerythrocytic malaria parasite Plasmodium falci-
parum by 1H NMR spectroscopy. NMR Biomed.
205. Teusink, B., Passarge, J., Reijenga, C., Esgalhado, E., van der Weijden, C.,
Schepper, M., Walsh, M., Bakker, B., van Dam, K., Westerhoff, H., and Snoep,
J. (2000). Can yeast glycolysis be understood in terms of in vitro kinetics of the
constituent enzymes? testing biochemistry. Eur. J. Biochem., 267(17):5313–5329.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 176
206. Theakston, R. and Fletcher, K. (1973). An electron cytochemical study of 6-
phosphogluconate dehydrogenase activity in infected erythrocytes during malaria.
Life Sci., pages 405–410.
207. Thevelein, J. and Hohmann, S. (1995). Trehalose synthase: guard to the gate
of glycolysis in yeast? Trends Biochem. Sci., 20(1):3–10.
208. Ting, I. and Sherman, I. (1966). Carbon dioxide fixation in malaria-i. kinetic
studies in Plasmodium lophurae. Comp. Biochem. Physiol., 19:855–869.
209. Trager, W. and Jensen, J. (1976). Human malaria parasits in continuous cul-
ture. Science, 193:673–675.
210. Travis, S., Morrison, A., Clements, R. J., Winegrad, A., and Oski, F. (1971).
Metabolic alterations in the human erythrocyte produced by increases in glucose
concentration. the role of the polyol pathway. J. Clin. Invest., 50(10):2104–2112.
211. Uyeda, K. (1979). Phosphofructokinases. Adv. Enzymol., 48:193–244.
212. Valentini, G., Chiarelli, L., Fortin, R., Speranza, M. L., Galizzi, A., and Mat-
tevi, A. (2000). The allosteric regulation of pyruvate kinase. J. Biol. Chem.,
275(24):18145–18152.
213. van Dooren, G. G., Marti, M., Tonkin, C. J., Stimmler, L. M., Cowman, A. F.,
and McFadden, G. I. (2005). Development of the endoplasmic reticulum, mito-
chondrion and apicoplast during the asexual life cycle of Plasmodium falciparum.
Mol. Microbiol., 57(2):405–419.
214. van Dooren, G. G., Stimmler, L. M., and McFadden, G. I. (2006). Metabolic
maps and functions of the Plasmodium mitochondrion. FEMS Microbiol. Rev.,
30(4):596–630.
215. van Eunen, K., Bouwman, J., Daran-Lapujade, P., Postmus, J., Canelas, A.,
Mensonides, F., Orij, R., Tuzun, I., van den Brink, J., Smits, G., van Gulik,
W., Brul, S., Heijnen, J., de Winde, J., de Mattos, M., Kettner, C., Nielsen,
J., Westerhoff, H., and Bakker, B. (2010). Measuring enzyme activities under
standardized in vivo-like conditions for systems biology. FEBS J., 277(3):749 –
760.
216. Velanker, S. S., Ray, S. S., Gokhale, R. S., Suma, S., Balaram, H., Balaram,
P., and Murthy, M. R. (1997). Triosephosphate isomerase from Plasmodium fal-
ciparum: the crystal structure provides insights into antimalarial drug design.
Structure, 5(6):751–761.
Stellenbosch University http://scholar.sun.ac.za
LIST OF REFERENCES 177
217. Walsh, M. C., Smits, H. P., Scholte, M., Smits, G., and van Dam, K. (1994a).
Rapid kinetics of glucose uptake in Saccharomyces cerevisiae. Folia Microbiol
(Praha), 39(6):557–559.
218. Walsh, M. C., Smits, H. P., Scholte, M., and van Dam, K. (1994b). Affinity
of glucose transport in Saccharomyces cerevisiae is modulated during growth on
glucose. J. Bacteriol., 176(4):953–958.
219. Wanidworanun, C., Nagel, R. L., and Shear, H. L. (1999). Antisense oligonu-
cleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plas-
modium falciparum. Mol. Biochem. Parasitol., 102(1):91–101.
220. Williamson, D. H., Lund, P., and Krebs, H. A. (1967). The redox state of free
nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver.
Biochem. J., 103(2):514–527.
221. Winter, V. J., Cameron, A., Tranter, R., Sessions, R. B., and Brady, R. L.
(2003). Crystal structure of Plasmodium berghei lactate dehydrogenase indicates
the unique structural differences of these enzymes are shared across the plasmod-
ium genus. Mol. Biochem. Parasitol., 131(1):1–10.
222. Woodrow, C. J., Burchmore, R. J., and Krishna, S. (2000). Hexose permeation
pathways in Plasmodium falciparum-infected erythrocytes. Proc. Natl. Acad. Sci.
U. S. A., 97(18):9931–9936.
223. Woodrow, C. J., Penny, J. I., and Krishna, S. (1999). Intraerythrocytic Plas-
modium falciparum expresses a high affinity facilitative hexose transporter. J.
Biol. Chem., 274(11):7272–7277.
224. Wünsch, S., Sanchez, C., Gekle, M., Grosse-Wortmann, L., Wiesner, J., and
Lanzer, M. (1998). Differential stimulation of the Na+/H+ exchanger determines
chloroquine uptake in Plasmodium falciparum. J. Cell. Biol., 140(2):335–345.
225. Wünsch, S., Sanchez, C., Gekle, M., Kersting, U., Fischer, K., Horrocks, P.,
and Lanzer, M. (1997). A method to measure the cytoplasmic pH of single, living
Plasmodium falciparum parasites. Behring Inst. Mitt., 99(99):44 –50.
226. Yoshida, A. and Roth, Jr, E. (1987). Glucose-6-phosphate dehydrogenase of
malaria parasite Plasmodium falciparum. Blood, 69(5):1528–1530.
227. Young, H. and Pace, N. (1958). Some physical and chemical properties of crys-
talline alpha-glycerophosphate dehydrogenase. Arch. Biochem. Biophys., 75(1):125
–141.
Stellenbosch University http://scholar.sun.ac.za
